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 Somatic cells in the human body contained roughly six feet of DNA. This genomic information 
needs to be condensed to fit within a microscopic nucleus, as well as properly interpreted by cellular 
machinery. The specific and controlled condensing of the genome allows for discrete cell types with 
unique functions ranging from blood cells that carry oxygen through the body, pancreatic cells that 
release hormones, and neural cells that send electric signals. Chromatin refers to the DNA sequence 
wrapped around histone protein octamers. Differing levels of chromatin compaction throughout the 
genome contribute to cell specificity and function. Loosely compact chromatin is associated with high 
levels of gene expression, whereas tightly compact chromatin is associated with inactive genes. While 
there are several layers of control that regulate chromatin compaction, two of the most widely studied 
mechanisms are DNA and histone tail modifications. These modifications are controlled and interpreted 
by a series of proteins that deposit, remove, or recognize and respond to the modification. The 
complexity of these modifications increases when you take into account all the types of modifications, 
residues, and downstream proteins that are involved. The importance of studying these complex 
processes is highlighted by the frequency of chromatin dysregulation in human diseases. Over the past 
few decades, it has become increasingly clear that the chromatin environment is irregular in many 
disease contexts, leading to the development of chromatin-based therapies in the clinic. To study and 
control the regulation of the chromatin environment in normal and disease contexts, we designed a 
novel chemical-based system to redirect specific chromatin modifying machinery in a targeted and 
reversible manner. By maintaining temporal and gene-specific control, we can begin to understand how 
these writer, reader, and eraser proteins function, as a means to develop personalized and targeted 
therapeutics.   
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CHAPTER 1: INTRODUCTION TO WRITING, READING & ERASING THE HUMAN EPIGENOME: 
IN NATURE & SYNTHETICALLY 
 
Section 1.1: Chromatin Biology 
Somatic cells in humans contain 46 chromosomes composed of both DNA and histone 
proteins. If assembled in a single linear strand together these three billion base pairs of DNA would be 
roughly six feet long1. Specific segments of base pairs code for genes that are “read” by the cellular 
machinery to create something functional (protein, micro RNA, long non-coding RNA, etc.). Expression 
of distinct sets of genes allows variety of cell types with specific functions to be constructed from a 
single DNA blueprint2. For example, in mammals the red blood cells that transport oxygen throughout 
the circulatory system are functionally and phenotypically different from neuronal cells that reside in the 
brain. For the entirety of the three billion base pairs to fit into a 10 µM nucleus, while still allowing for 
certain genes to be expressed, DNA needs to be folded in a very organized and specific manner.  
One aspect of cells with distinct gene expression profiles is altered levels of chromatin 
compaction. Chromatin is composed of DNA and eight histone protein cores (dimers of H2A, H2B, H3 
and H4). Epigenetics is the study of how heritable changes in the chromatin and gene expression occur 
in the absence of DNA sequence changes3. The building block of chromatin is called the nucleosome 
and is made up of 146 base pairs (bp) of DNA, wrapped around a histone octamer4. Chromatin is found 
in a spectrum between two broad states, heterochromatin and euchromatin. Heterochromatin is the 
tightly compacted portion of chromatin associated with transcriptional repression5. Euchromatin is a 
more open form of chromatin, typically containing genes that are being actively transcribed6. The cell 
regulates chromatin compaction through ATP-dependent nucleosome remodeling, deposition of 
histone protein variants, DNA methylation, and posttranslational modifications of the N-terminus of 
histone tails7. In addition to allowing for proper gene expression, these processes appear to work in 
concert to properly regulate DNA replication, DNA damage repair, and nuclear organization6,8–10.    
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ATP-dependent chromatin remodeling enzymes, often referred to as SWI/SNF-related or Snf2-
related enzymes, are able to physically alter the structure of chromatin at specific genomic regions. In 
eukaryotes, Snf2 proteins contain a Walker box, a conserved sequence of seven of amino acid motifs11. 
The Snf2-related proteins are then divided into one of 24 subfamilies (20 present in humans)12. These 
protein complexes catalyze small-scale chromatin transformations including (1) physically sliding 
nucleosome units along the DNA to change nucleosome density (2) altering the nucleosome DNA 
wrapped around the histone octamer (3) exchanging or removing the octamer subunits13–15. To 
accomplish this, the remodeling enzymes need to bind the structurally complex nucleosome, disturb 
histone-DNA interactions, and physically restructure the nucleosome13. In humans, the proteins that 
have the greatest sequence homology to Snf2 and participate in nucleosome positioning are 
SMARCA4/BRG1, SMARCA2/BRM, SMARCA5/hSNFR2H, SMARCA1/ hSNF2L, CHD1, CHD2, 
CHD3, CHD4, CHD5, CHD6, CHD7, CHD7, CHD8, CHD9, LSH, PASG, SMARCA6, ALC1/CHD1L. 
Based on work done in Drosophila, it is likely that nucleosome repositioning occurs in sequential steps 
of 1 bp per ATP molecule hydrolyzed16. The proteins that are involved in exchanging the histone dimers 
are DOMO1, SWR1, EP400, INO80, ETL1/SMARCAD1. Other chromatin remodeling members, whose 
functions are not well characterized, include RAD54L, RAD54B, ATRX, RAD54L2, SMARCA3, 
SNF2L3, TTF2, SHPRH, TAF172/BTAF1, CSB, RAD26, PICH, RAD26L, ERCC6L2, 
SMARCAL1/HARP, and ZRANB313. ATPase remodeling enzymes, often in association with accessory 
proteins, form chromatin remodeling complexes. These complexes fall into the SWI/SNF (BAF and 
PBAF), ISWI (NURF, CHRAC, ACF, NORC, RSF, WICH), CHD (CHD1, NuRD), or INO80 (ION80, 
SRCAP, Tip6) family of complexes17. Often these complexes are able to perform tradition “remodeling” 
functions as well as control histone tail post-translational modifications. For example, the NuRD 
complex (a member of the CHD family) includes HDAC1 and HDAC2, which are able deacetylate the 
histone tails and contribute to the compaction of the nucleosomes14. Because of the diversity and 
complexity of several of these complexes, research is still undergoing to understand how these 
complexes form and function in different genomic contexts. Two additional processes that regulate 
chromatin compaction are DNA and posttranslational histone tail modifications. Protruding out of the 
nucleosomes are the N-terminal histone tails that are subjected to post- translational chemical 
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modifications, whereas DNA bases (cytosine and adenine) can be directly modified with chemical 
groups18–21. The combination of histone and DNA modifications constitute the epigenetic code, with 
some highly studied modifications being associated with high or low levels of gene expression22.  
Currently, four different cytosine modifications have been observed: methylation, hydroxy-methylation, 
formylation, and carboxylation23. For histone tail modifications, there have been over ten modifications 
identified, with even more currently being validated and characterized24,25. To orchestrate the histone 
code throughout the genome, there are a series of proteins involved. The “writer” enzymes are capable 
of modifying the nucleotide base or histone tail residues, whereas the “eraser” enzymes remove the 
modifications. “Reader” proteins comprise domains able to recognize specific DNA or histone 
modifications, and are able to directly or indirectly initiate downstream changes like recruitment of 
transcription factors, co-repressors, co-activators, and RNA polymerase7. While there are several 
possible modifications (phosphorylation, ubiquitination, arginine methylation, etc.), two of the most 
widely studied are methylation (of DNA and lysine residues on histone tails) and acetylation (of multiple 
lysines on histone tails)26.     
The term DNA methylation is most often associated with the formation of 5-methylcytosine in 
the context of a cytosine-guanine (CpG) dinucleotide. DNA methylation is strongly associated with gene 
repression27,28. The mark is deposited by DNA methyltransferases (DNMTs), enzymes that initiate the 
transfer of a methyl group from S-adenosyl-1-methionine (SAM) to cytosine at the 5’ position29. The 
mammalian DNMT family includes DNMT1, DNMT2, DNMT3A, DNMT3B, and DNMT3L26. DNMT1 is 
considered the maintenance methyltransferase, as it propagates the methylation pattern from the 
parental to daughter strand after DNA replication30,31. Importantly, DNA methylation has been shown to 
propagate through cell replication32. The main function of DNMT2 is catalyzing the methylation of 
tRNAs, which increases tRNA stability33. The de novo methyltransferases are DNMT3A and DNMT3B, 
as they are able to methylate both hemi-methylated and un-methylated DNA. They are critical for 
introduction of DNA methylation throughout gametogenesis and the early stages of embryogenesis27,34. 
Lastly, DNMT3L lacks the C-terminal domain needed for methyltransferase activity, but rather functions 
as a regulatory factor for de novo methylation, working in concert with DNMT3A and DNMT3B to 
increase activity35,36. The proteins that recognize DNA methylation, the methyl CpG binding proteins 
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(MBPs), include zinc finger (ZnF) proteins, SRA domain proteins, and methyl CpG binding domain 
(MBD) proteins37. Upon recognition of DNA methylation, gene silencing is initiated in part through 
recruitment of chromatin remodeling complexes. For example, MBD2 (one of 11 MBD members) has 
a MBD domain and a transcription repression domain (TRD). It functions as a member of the 
nucleosome remodeling and deacetylase (NuRD) complex to silence genes26,38. Other proteins, like 
SETDB1 and 2, contain a MBD domain but are unable to bind to 5-methylcytosine. Specifically, 
SETDB1 and 2 do serve other functions that contribute to heterochromatin formation, including 
methylating histones39. UHRF1, a SRA family member, recognizes specifically hemimethylated CpG 
sites and functions with DNMT1 in the maintenance of DNA methylation2,40–42. DNA demethylation can 
occur either passively or actively. If DNMT1 activity is lacking, successive rounds of replication will 
passively cause a reduction in DNA methylation43. For active demethylation, the ten-eleven 
translocation (TET) family of proteins is required. Much remains to be discovered about this family of 
enzymes, but it has been shown that they are able to catalyze the oxidation steps of methylated 
cytosine, ultimately removing the methylation23. Though there are exceptions, DNA methylation is 
strongly associated with transcriptionally silenced genes.  
Histone tail mono-, di-, and tri-methylation of the lysine amino acid has been highly studied, 
and unlike DNA methylation, its influence on transcriptional activity is strongly context dependent44. For 
example, histone 3 lysine 36 trimethylation (H3K36me3) is found in the gene body of transcriptionally 
active genes, whereas histone 3 lysine 27 trimethylation (H3K27me3) is associated with gene 
repression and found near the transcriptional start sites (TSS)44,45. The writers of mono-, di-, and tri-
methylation of the histone tails are generically called histone lysine methyltransferases (KMTs). They 
transfer methyl groups from the methyl donor, adenosyl-methionine. More specifically, KMTs are split 
into two families based on the presence (or lack) of SET domain26. The mammalian SET-containing 
enzymes include the H3K4 methyltransferases (SMYD1, SMYD1, MLL1-5, SET1A, SET1B, ASH1L, 
ASH2L, PRDM9, SET7)46,47, the H3K9 methyltransferases (EHMT1/GLP, EHMT2/G9a, SETDB1, 
SETDB2, SUV39H1, SUV39H2, PRDM2, PRDM3, PRDM8, PRDM16)8,48–50, the H3K27 
methyltransferases (EZH1, EZH2, NSD2, NSD3)51–53, H3K36 methyltransferases (NSD1, SMYD2, 
SETD2)54, and the H4K20 methyltransferases (SET8, SUV4-20H1, SUV4-20H2)55. While there are 
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other methyltransferases in this broad SET-containing family, these are some of the more characteristic 
enzymes. The only highly studied KMT that lacks the SET domain is the H3K79 methyltransferase, 
DOT156–58. The proteins that recognize lysine methylation contain one or multiple of the highly 
characterized reader domains: chromodomain59, chromobarrel domain60, double chromodomain61, 
PWWP domain62, plant homeodomain63, WD40 domain64, malignant brain tumor domain65, and tudor 
domain26,66. Some of these reader domains have been discovered in proteins alongside other reader 
domains (i.e. UHRF1 recognizes hemimethylated DNA and H3K9me3)67 or alongside catalytic domains 
(i.e. WDR5 recognizes H3K4me2 and initiates H3K4me3)64. Histone tail demethylation is performed by 
one of two ways. Lysine specific demethylase (LSD) members, LSD1/KDM1A and LSD2/KDM1B, 
contain an amine oxidase (AOD) domain responsible for demethylase activity in a flavin adenine 
dinucleotide (FAD)-dependent manner68. The second family of demethylation enzymes is the Jumonji 
C (JmjC) domain containing enzymes69. This larger family is further split into seven subfamilies (called 
KDM2-8) and all members function by using the co-substrate 2-oxoglutarate (2OG) and dioxygen with 
cofactor Fe(II)70–74. In the past few decades, a lot of research has elucidated the various histone 
demethylases and the substrates upon which they act75.  
High levels of histone acetylation are associated with euchromatin and active transcription76,77. 
The lysine residues of histone tails are prone to acetylation, causing a buffering of the positively charged 
lysine. This overall reduction in charge, ultimately leads to a decreased association between the 
negatively charged DNA and the histone subunits25,78–80. In addition, downstream recruitment effects 
occur because of the presence of the acetylation mark. Lysine acetylation marks are deposited from 
acetyl co-A by histone acetyl transferases (HATs). The two HAT families are classified based on cellular 
location. Type A HATs act on chromatin in the nucleus, whereas Type B HATS act on newly translated 
histones in the cytoplasm. The Type A HATs are further classified into five subtypes based on their 
structural and functional characteristics: GNAT, MYST, p300/CREB, TAF250, SRC/NCoA26. The main 
Type B HAT is HAT1, which forms a complex with histone chaperones and is responsible for depositing 
H4K5ac and H4K12ac81. The GNAT (General Control Non-Repressible 5 (GCN5) related N-
acetyltransferase) family contains a P300/CBP-associated factor (PCAF) domain, an adenosine 
deaminase 2 (ADA2) domain, and a bromodomain and its members are KAT2a/Gcn5L and KAT2B 
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(PCAF)82. The MYST (Moz, YBF2/SAS3, SAS2, TIP60) family is characterized by an acetyl CoA binding 
site and a zinc finger motif and includes KAT5/TIP60, KAT6A/MOZ/MYST3, KAT6B/MORF/MYST4, 
KAT7/HBO1/MYST2, and KAT8/hMOF/MYST183.  The p300/CBP family of HATs, KAT3A/CBP and 
KAT3B/p300, has been associated with all four histone subunits and contains several domains 
including the KIX domain, a bromodomain, cysteine-histidine rich domains, and a HAT domain84. The 
TAF250 HATs associate with general transcription factors and stabilize transcriptional machinery85. 
Lastly, the SRC/NCoA family of HATs recruit coactivators with histone methyltransferase and 
acetyltransferase activity86. 
To date, three domains have been identified to bind acetylated histones, the bromodomains 
(BRD), double PHD finger, and Yeats domain26. Bromodomain containing proteins are the most 
abundant acetyl lysine mark readers, and are classified into 8 families based on similarities in structure 
and sequence26,87,88. All bromodomains have a conserved motif of four helices and interhelical ZA and 
BC loops89,90. The bromodomains of BRD family I are found in PCAF, GCN5L2, FALZ, and CECR2. 
These domains recognize H3K14ac, H4K8ac, and H4K16ac26. BRD family II are found in the family 
members of the Bromodomain and Extra-Terminal Domain (BET) proteins BRD2, BRD3, BRD4 and 
BRDT. The BET proteins bind H4K12ac, H3K14 ac, H4K5ac, and H4K8ac. Several ubiquitously 
expressed proteins contain BRD family III including EP300, CREBBP, WDR9, PHIP, BRD8B, BAZ1B, 
BRWD3. BRD family IV is found in ATAD2, BRD1, BRD7, BRD9, BRPF1A, BRPF1B, BRPF3, and 
KIAA1240. BRD family V includes BAZ2A, BAZ2B, LOC93349, SP100, SP110, SP140, TIF1a, and 
TRIM33, and is characterized by a tandem PHD/BRD. BRD family VI includes MLL and TRIM28. BRD 
family VII contains ZMYND11, TAF1, TAF1L, WDR9, BRWD3, and PHIP. Lastly, BRD family VIII 
contains ASHIL, SMARCA2, SMARCA4, and PB126. To date, there are five proteins shown to contain 
a double PHD finger domain involved in acetyl-lysine recognition, MOZ/KAT6A, MORF/KAT6B, DPF1, 
DPF2, and DPF391. The YEATS domain is a relatively new domain currently being further 
characterized. It has recently been shown that the YEATS domain-containing protein, AF9, binds 
histone lysine acetylation and crotonylation92. The enzymes that carry out the removal of lysine 
acetylation, ultimately increasing chromatin compaction and gene repression are called histone 
deacetylases (HDACs), and are subdivided into class I, IIa, IIb, III, and IV26,93,94. HDAC Class I, IIa, IIb, 
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and IV function in a zinc-dependent manner, whereas class III, or sirtuin, HDACs function through a 
NAD+ dependent manner26,93,95. Class I consists of HDAC1, 2, 3, and 8, all of which reside 
predominantly in the nucleus and are found in most tissue types. All but HDAC8 function in conjunction 
with a repressive complex. For example, HDAC1 and HDAC2 are part of the Sin3, NuRD, CoREST, 
and PRC2 complexes, and HDAC3 functions as part of the NCoR or SMRT complex96. Class II HDACs 
are capable of shuttling in and out of the nucleus. HDAC4, 5, 7 and 9 are the members of Class IIa and 
are responsive to cellular signaling pathways due to their longer N-terminal region26. HDAC6 and 
HDAC10 are the members of Class IIb. Uniquely, HDAC6 contains two catalytic deacetylation domains 
and functions as a tubulin deacetylase97. Not much is known about HDAC10, but it has been suggested 
that it functions in cell cycle regulation93. The sole member of HDAC Class IV is HDAC11, about which 
not much is currently known aside from its sequence similarity to Class I HDACs but absence from 
repressive complexes like Sin3 and CoREST26,93. Class III HDACs, or the SIRTs, include SIRT1-
SIRT726,95. SIRT1 deacetylases both histones (at H1K16 and H4K26) and other proteins, and so it 
moves between the cytoplasm and nucleus98–100. SIRT2 is predominantly localized to the cytoplasm 
but can shuttle into the nucleus and deacetylate H4K16 and H3K5698,101. Similarly, SIRT3 is 
predominately localized to the mitochondria, but can shuttle to the nucleus to deacetylate the same 
residues26,98. SIRT4 and SIRT5 do not currently have any known histone substrates98. SIRT6 is found 
in the nucleus and acts on H3K9ac and H3K56ac. Lastly, SIRT7 acts on H3K18ac in the nucleus26. 
While the presence of histone tail acetylation has been known for decades, the complexity of its 
regulation and influence on the cell is still being actively studied.  
The close relationship and interplay between chromatin biology and transcriptional regulation 
stems from two processes, physical accessibility of the DNA based on the level of compaction and the 
addition or removal of chromatin modifications by transcriptional machinery. At the eukaryotic promoter, 
RNA polymerase II (Pol II) binds and, along with other general transcription factors, forms the 
preinitiation complex (PIC)102. Importantly, the chromatin environment is important for all these steps, 
from Pol II binding and PIC formation, to elongation and termination. It has been shown that changes 
in nucleosome net charge, influenced by acetylation levels, controls how easily DNA can be displaced 
by the transcriptional machinery103. In addition, H4K16ac prevents 30 nm fiber formation, a compact 
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form of chromatin, thereby allowing for increased overall accessibility of the DNA to the transcriptional 
machinery104. Within 30 bp of transcription Pol II is phosphorylated at the carboxy-terminal domain 
(CTD). This is an important step for the recruitment of chromatin modifying machinery and proper 
elongation105. The phosphorylated CTD recruits histone tail modifying writers and erasers. For example, 
Pol II-mediated Set2 occurs during elongation to deposit H3K36me3, followed by hypoacetylation of the 
gene body106. While this process is more complex than what has been described, these examples 
illustrate how transcriptional regulation and the chromatin environment are linked. Because of this 
interaction, changes in the function, recruitment, or expression of chromatin modifying proteins can 
have a major impact on the expression of essential genes107.  
 
Section 1.2: Disease Relevance 
 A flood of discoveries over the past decade have cemented the driving role of disruption to 
chromatin regulatory pathways leading to many human diseases. Advances in technology and cleaver 
new approaches have paved the way for understanding how these regulatory processes are 
dysregulated in diseased settings, what the downstream consequences are, and how compounds can 
be developed to exploit or correct these changes. Many clinical trials using epigenetic-based therapies 
are ongoing and a handful of epigenetic based drugs have been approved, yet more targeted and less 
toxic approaches are needed. 
Over the past several decades, both expression changes and sequence mutations have been 
found for chromatin regulatory machinery, however much work remains on detailing the early epigenetic 
mechanisms driving these diseases. In addition, global and gene-specific changes in histone or DNA 
modifications have been associated with multiple diseases, but the specific driver orchestrating these 
epigenetic changes is not clear. It is also not always certain whether a cancer-specific change is a 
clinically-irrelevant downstream effect, a potential biomarker for evaluating disease progression, or a 
central driver or addiction of the disease that might be worth targeting therapeutically. To answer this 
question, the mechanisms of action and the direct consequences of the dysregulation need to be 
elucidated. In order to study these disease and develop targeted, epigenetic-based therapies, it is 
important to understand what disease have epigenetic changes that can be potentially exploited.  
	 9	
A wide range of diseases have been identified to have mis-expression of a chromatin regulatory 
enzyme with potential clinical relevancy.  For example, multiple groups implicated overexpression of a 
polycomb group family member, BMI-1, in the initiation and progression of certain types of 
lymphoma108–110. It was shown that the zinc finger motif (specifically the RING finger) is required for 
BMI-1’s oncogenic effects110. Additionally, BMI-1 has been more recently implicated in the tumor 
initiation of hepatocellular carcinoma (HCC)111 and the cell proliferation and migration of pancreatic 
duct adenocarcinoma (PDAC)112. While the complete mechanism of action is not known, it is evident 
that BMI-1 overexpression, alone, is not enough to cause tumor formation. In the PDAC study, for 
instance, a mutant KRAS (G12D) is required for malignant transformation in vitro112. These works 
implicate BMI-1 as a potential therapeutic target for a combinatory drug approach. Other chromatin 
regulatory proteins found to be mutated or mis-expressed in pre-clinical or clinical models of disease 


















Table 1: Histone and DNA writers, readers, and modified in diseases. 
Mutated writers, 
readers, and erasers Alteration Disease (s) 
DNMT3A Missense, Frameshift, Nonsense, Splice site AML
113, MDS114 
TET1 Translocation AML115 
TET2 Missense, Nonsense, Frameshift  MPN116, AML117, MDS118, CMML119 
CBP/KAT3A Translocation, Nonsense, Missense, Frameshift 
AML120121, DLBCL122, MDS123, 
RTS124 
P300/KAT3B Translocation, Nonsense, Missense, Frameshift 
CML125, Pancreatic126, 
Colorectal126, Breast126, DLBCL122, 
AML127 
MOZ/KAT6A Translocations AML127,128 
MORF/KAT6B/MYST4 Translocations AML120, Uterine Leiomyomata129  
BRD2 Unknown ALL130 
BRD3 Translocation, Missense Midline Carcinoma131, Lung132 
BRD4 Translocation Midline Carcinoma133 
TRIM33 Translocation Lung134 
KMT2A/MLL1 Partial Tandem Duplication, Translocation AML
135, ALL136 
KMT2B/MLL2 Nonsense, Frameshift, Missense 
Medulloblastoma137, Breast138, 
Renal139, DLBCL140, Prostate141, 
FL140, Lung142  
KMT2X/MLL3 Nonsense Medulloblastoma137, Breast138 
KMT3A/SETD2 Nonsense, Frameshift, Missense Renal139, Breast138 
KMT3B/NSD1 Translocation AML143 
NSD2 Translocation, Missense Multiple Myeloma144, ALL145 
NSD3 Translocation AML146 
KMT6/EZH2 Missense DLBCL147, MPN148, MDS149 
KDM5A/JARID1A Translocation AML150 
KDM5C/JARID1C Nonsense, Frameshift, Splice site Renal139 
KDM6A/UTX Deletion, Nonsense, Frameshift, Splice site 
AML151, Renal151, Oesophageal151, 
MM151, CML151 
PHF6 Deletion, Missense  T-ALL152, AML153 
BRD8 Missense, Nonsense Liver154 
DNMT1 Nonsense, Missense Colon155 
HDAC2 Frameshift   Colon156 
HDAC9 Missense  Prostate157 
PRDM9 Nonsense, Missense  Head and Neck158 
SETD2 Frameshift, Nonsense, Splicing site Glioblastoma159, Renal160 





In most cases, when a chromatin regulatory protein has altered gene expression, localization, 
and/or functionality (caused by a mutation, modified chromatin environment, chromosomal translation, 
etc.) the chromatin environment and expression levels of dozens to thousands of genes can be 
transformed. The downstream gene expression changes are often what causes the direct disease 
etiology, rather than the specific chromatin modifying machinery directing the changes. For example, 
CpG island hyper-methylation occurs in subtypes of breast and ovarian cancer at the BRCA1 
locus161,162. BRCA1 is a tumor-suppressor gene (TSG) involved in DNA damage repair, the silencing of 
which can cause an increased mutation rate and genomic instability in the cancer163.  While hyper-
methylation of the promoter of TSGs is a common cancer-related phenomenon164–166, the mechanism 
of action is still not completely understood. DNMTs have been implicated in the inactivation of TSGs in 
several tumor types35,167,168, however it is not likely that the overexpression of DNMTs, alone, is enough. 
It has been suggested that recruitment of the DNMTs (by transcription factors, co-repressors, 
H3K9me3, lncRNAs etc) is also required165,169,170. Other disease-relevant genes that have identified with 
















Table 2: Genes with modified chromatin environments in a diseased context.  
Gene Chromatin change Disease (s) Reference 
TP53 Promoter hypermethylation Glioblastoma 171 
CDKN2A Promoter hypermethylation Burkitt’s lymphoma 172 
 Increased H3K9me2 Liver cancer 173 
TSSC3 Promoter hypermethylation Osteosarcoma  174 
FSHD Decreased CpG methylation FSHD 175 
miR-181c Promoter hypermethylation Glioblastoma 176 
Sat2 Loss of H3K4me3 Leukemia  177 
p21 Decreased H3ac and H4ac Bladder cancer 178 
IL6 H3K9me2 Type 1 Diabetes 179 
TAL1 Decreased H3K27me
3 / 
Increased H3K27ac T-ALL 180 
TMPRSS4 Decreased DNA methylation Lung Cancer 181 
RASSF1A De Novo DNA methylation Breast Cancer 170 



















 In some cases, it may be advantageous to pharmacologically target downstream gene activity 
with altered chromatin environments, rather than the mutated chromatin regulatory machinery that is 
causes the gene expression changes. Unfortunately, when chromatin regulatory machinery is 
dysregulated in some manner, there are likely changes in the expression of multiple genes contributing 
to disease progression. In addition, many overexpressed proteins are not able to be targeted due to a 
lack of specific and potent inhibitors. There are also cases where a gene is repressed (i.e. promoter 
hyper-methylation of TSG) and needs to be re-expressed. In cases of multiple gene targets, inadequate 
inhibitors, or gene repression, controlling the chromatin regulatory machinery in a global manner may 
be the best approach currently available.    
With the understanding that epigenetic changes can contribute to disease initiation, growth, 
and/or therapeutic resistance, small molecules have been developed to study epigenetic machinery 
and to regulate its activity. The idea of using epigenetic agents in combination with the standard-of-
care therapy regiment has been around for over 40 years183. Though epigenetic inhibitors and chemical 
probes have been used this, the mechanism of interaction was not able to be determined directly until 
very recently. In part due to novel techniques in structural biology and mass spectrometry, more direct 
questions can be answered so that potent, target-specific inhibitors can be synthesized.    
DNA methylation changes are a hallmark of cancer cells and present as a very desirable target. 
DNMT inhibitors (DNMTi) are divided into “nucleoside” and “non-nucleoside” inhibitors, and were first 
synthesized in the 1960’s. The first two inhibitors synthesized, Azacytidine (5-azacyidine) and 
Decitabine (5-aza-2’-deoxycytidine) fall into the nucleoside category because they mimic the structure 
of cytidine, incorporate into the DNA strands and form irreversible interactions with DNMTs, causing 
DNMT degradation184. Both drugs were FDA approved to treat patients with acute myeloid leukemia 
(AML), and Azacytidine is also approved to treat patients with myelodysplastic syndrome (MDS)185. 
Since then, other nucleoside inhibitors (cytidine and cytosine analogues) have been synthesized 
(Guadecitabine, SGI-110, CP-4200, 4’-Thio-2’-deoxycytidine, RX-3117), and are at the clinical stage 
for treatment of HCC, MDS, AML, metastatic pancreatic cancer, and advanced solid tumors. Other 
inhibitors that are in the non-nucleoside category exist and function by a different mechanism. For 
example, procainamide (used to treat cardiac arrhythmias) binds to the CpG regions of DNA to block 
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DNMT activity186. SGI-1027, another non-nucleoside inhibitor, was found to inhibit DNMT activity in 
colon cancer cells and reactivate the previously hyper-methylated MLH1 and P16187. Currently, there 
aren’t any published inhibitors of DNA methylation readers or DNA-demethylation, though inhibitors of 
these kind would potentially have a strong clinical relevance.  
Changes in the lysine methylation at specific genes has an important role in affecting the 
expression of many genes important in tumorigenesis. For this reason, inhibitors of histone lysine 
methyltransferases, demethylases, and reader proteins are currently being synthesized and tested in 
pre-clinical and clinical models. The first G9a selective inhibitor synthesized was BIX-01294, with the 
goal of affecting levels of methylation at H3K9188. To improve upon BIX-01294, UNC0638 was 
developed and was shown to hypersensitize cancers to lower doses of chemotherapies189,190. Another 
G9a inhibitor, A-366 was shown to be effective against leukemia191. Several inhibitors of EZH1 and 
EZH2 (subunits of PRC2 that catalyze H3K27 methylation) exist and are classified based on structure 
into pyridine-indazole scaffolds (EPZ005687, UNC1999, GSK343), pyridine-phenyl scaffolds 
(EPZ006088, EPZ6438), and pyridine-indole scaffolds (GSK126, CP1-1205, EI1). Several of these 
inhibitors are active in clinical trials. For example, EPZ6438 (aka Tazemetostat) is currently being tested 
in patients with B-cell lymphoma192. To achieve the opposite effect, lysine demethylase inhibitors 
targeting LSD1 and the JmjC domain have been synthesized and are at the clinical or preclinical stage. 
To target LSD1, a reversible inhibitor, HCI-2509, was developed and found to be effective against a 
subtype of neuroblastoma cells193. Additionally, a Tranylcypromine analogue inhibitor of LSD is 
currently in a clinical trial to treat AML26. Several MBT family genes (readers of lysine methylation) have 
reportedly been over-expressed in cancers, suggesting a therapeutic need for inhibitors. UNC926, a 
L3MBTL1 inhibitor, and UNC1215, a L3MBTL3, inhibitor have been synthesized and validated194,195. 
Because methylation of lysine residues on histone tails can have contrasting effects on gene 
expression, the need for target-specific inhibitors is especially important.   
Inhibitors of lysine acetylation writers, erasers, and readers have the largest presence in 
preclinical and clinical trials26,89,93,95,98,183,196–212. To target histone acetyltransferases, HAT inhibitors are 
being identified and characterized. TH1834 is a novel Tip60 inhibitor that has shown pro-apoptotic 
effects in breast cancer cell lines213. Recently, Lasko et al. discovered a potent and selective p300/CBP 
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inhibitor, designated A-485. With high resolution, crystallography, A-485 was shown to bind the catalytic 
active site of p300, and compete with acetyl-CoA. It was further shown to inhibit the androgen receptor 
transcriptional program in prostate cancer, thereby decreasing tumor growth197.  Currently, five HDAC 
inhibitors (HDACi) have already been FDA approved, with several more in clinical trials. The first HDACi 
discovered was Trichostatin A (TSA), a naturally occurring inhibitor of zinc-dependent HDACs, though 
it has yet to be used clinically214. Since then, several more hydroxamic acid derivatives were discovered 
that function as pan-HDACi and have been approved for clinical use including Vorinostat for cutaneous 
T-cell lymphoma, Belinostat for peripheral T-cell lymphoma, and Panobinostat for multiple myeloma215–
217. Other chemical classes of HDACi have also been synthesized and tested in disease settings, 
including the benzamide, romidepsin, and short chain fatty acid classes209. Some HDACi have found 
to be class specific, which offers the advantage over pan inhibitors of being able to cause a more 
specific effect or ask more directed questions. For example, entinostat is selective for class 1 HDACs, 
and has been shown to be effective at treating Hodgkin’s lymphoma198,199. For targeting readers of 
histone tail acetylation, interactors of the bromodomain represent the largest category of compounds 
currently in preclinical or clinical trials. Perhaps the most widely used are JQ1 and I-Bet762, the first 
potent and selective BET bromodomain inhibitors (BRDi)204,218,219. I-Bet762 is currently being tested in 
a clinical trial for NUT midline carcinoma. More recently, OTX015 is another BRDi currently being tested 
in patients with hematologic malignanies26. In all, these inhibitors represent useful tools for understand 
chromatin regulatory pathways as well as potentially life-saving therapeutics.  
One disadvantage of using epigenetic based therapies is that many inhibitors target multiple 
chromatin regulatory proteins. Secondly, targeting chromatin regulatory machinery in a cell-wide 
manner can affect expression of dozens, if not hundreds of other genes. During the first few decades 
of clinical trials, high levels of toxicity were observed when patients were treated with HDACi220. This 
was likely due to poor bioavailability and/or off-target binding effects183,221. For example, the 
degradation rate of butyrate and phenylbutyrate required doses greater than 400 mg/kg/day220, but it 
was also shown that these compounds also inhibited phosphorylation and methylation of non-histone 
substrates222. VPA has been previously shown to cause birth defects, like neural tube closure defects, 
in recently pregnant patients223. More recently, clinical trials with prostate cancer patients using HDAC 
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and DNMT3 inhibitors have shown high levels of toxicity. For example, Vorinostat in combination with 
a chemotherapy (docetaxel) was terminated due to toxicities including neutropenia, peripheral 
neuropathy, and gastrointestinal bleeding224. Other documented toxicities in prostate cancer patients 
included fatigue, nausea, vomiting, thrombocytopenia, and weight loss225. DNMT and HDAC inhibitors 
have been shown to induce expression at cryptic transcriptional start sites and upregulate endogenous 
retroviruses. This presents previously unexpected, and likely unpredictable off-target side effects226. 
While improvements in creating potent drugs to reduce off-target toxicities have been made, being able 
to affect the chromatin environment of specific genes or limit drug exposure to cancer cells over healthy 
cells are areas being actively pursued in research. Table 3 displays previously synthesized inhibitors 
of DNA and histone readers, writers, and erasers.  For more examples of epigenetic-based dyregulation 
in disease and therapeutic strategies please review Biswas et al.26, Jones et al.227, Feinberg et al.228, 



















Table 3: Inhibitors of chromatin writers, readers, and erasers for translational studies. 
Inhibitors of writers, 
readers, erasers Chromatin target  Status of compound Reference 
UNC926 MBT domain Preclinical  195 
UNC1215 MBT domain Preclinical  194 
MS37452 CBX7 Preclinical for prostate cancer 230 
CF16 Pygo 2 Preclinical 231 
I-BET762 BET bromodomain Clinical for NMC (Phase 1) NCT01587703 
JQ1 BET bromodomain Pre-clinical for squamous carcinoma 204 
MK-8628 BET bromodomain AML and DLBCL (Phase 1) NCT02698189 
Bizine LSD1 Preclinical for lung and prostate  232 
Namoline LSD1 Preclinical for prostate  233 
Vorinostat HDAC Approved for CTCL 215 
Belinostat HDAC Approved for PTCL 234 
Panobinostat HDAC Approved for multiple myeloma 235 
Quisinostat HDAC Clinical for ovarian cancer (Phase 2) NCT02948075  
Entinostat HDAC Clinical for NE tumor (Phase 2) NCT03211988 
Mocetinostat HDAC Clinical for Lymphoma (Phase 2) NCT02282358 
Azacytidine DNMT Approved for MDS 236 
Tazemetostat EZH2 Clinical for rhabdoid tumors, INI1-negative tumors (Phase 1) NCT02601937 
EPZ6438 EZH2 Clinical for lymphoma 192 
UNC0638 G9a Preclinical for breast cancer 189 
AZ-505 SMYD2 Preclinical for polycystic kidney 237 














Section 1.3: Synthetic Control of Chromatin 
 One way that researches learn the more about the function of any given RNA or protein is by 
changing expression levels by synthetic technique. Prior to recent advances in genome and epigenome 
editing in the mammalian genome, an early technique that evolved to study gene functionality is RNA 
interference (RNAi). Here, a biological process has been repurposed for silencing mRNA in a relatively 
quick and efficient manner. Unfortunately, RNAi is a does not reduce protein levels to that achieved 
with a gene knock-out. In addition, the RNAi is generally transient in its effectiveness, inconsistent 
between sequences, cell types, and labs, and can occur at off-target sites238,239.  Since the development 
of custom zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and 
clustered regulatory interspaced short palindromic repeats (CRISPR)/ CRISPR-associated (Cas) 
systems, gene editing has been possible. These transformative technologies enable modification of the 
genome directly by deleted genes (through nonhomologous end joining (NHEJ) creating insertion 
deletion (Indel) events or by modifying/inserting specific sequences or genes (through inducing 
homology-directed repair (HDR) and supplying a homology-containing donor template). NHEJ and 
HDR are two pathways in the DSB repair process, with NHEJ involving the ligation of broken DNA 
ends, typically leading to a small insertion/deletion and/or knock-inducing frame-shirt, whereas HDR 
involves the incorporation of the donor molecule to insert a transgene or nucleotide substitution240. To 
edit the genome, these DSB and repair pathways are initiated by fusing sequence-specific DNA-binding 
domains (ZFN or TALEN) to the Fok1restriction endonuclease, or by designing a sequence-specific 
single guide RNA (sgRNA) to recruit a Cas endonuclease241–245. These techniques have paved the way 
for genome editing and advanced the fields of basic science and translational research.  
 ZFNs were the first of these technologies to be developed for editing the mammalian genome, 
with the most commonly used type being the Cys2-His2 zinc-finger domain. Each zinc-finger consists 
of roughly 30 amino acids that form a bba conformation, with the a-helix capable of binding 3 base 
pairs of DNA. The optimized system uses six zinc fingers targeting 18 bases, theoretically providing a 
specific within 68 million bases of DNA246.  Zinc finger domains have been optimized to recognize most 
of the possible nucleotide triplets, such that pre-designed zinc finger modules can be linked together 
	 19	
through cloning techniques and used target a desired sequence. Once linked to the Fok1 
endonuclease, the zinc fingers are able to induce a DSB in a gene-specific manner. The major 
disadvantage of this technique is that it is a time consuming and labor-insensitive process. The 
alternative way to use this technology is by purchasing pre-made constructs to target your gene-of-
interest, though they are typically expensive. TALE proteins are naturally occurring in bacteria and 
contain a series of 33-35 amino acid repeat domains that recognize a single DNA base pair. Similar to 
zinc fingers, TALE repeats are strung together to recognize specific DNA sequences247. While this 
single-base-pair approach allows for more design flexibility than the triple nucleotide binding of the zinc 
fingers, the cloning process is more arduous and expensive. The most recent technique adapted for 
mammalian genome editing is the CRISPR-Cas system, which was discovered and adapted from 
bacteria and archaea. Serving as their native immune system from foreign phages and plasmid DNA, 
the CRISPR system includes a Cas nuclease. The most commonly used CRISPR system uses a Cas9 
protein that is recruited to a specific DNA sequence by way of a DNA-binding RNA. For Cas9-
recruitment to a complementary sequence fragment, a CRISPR RNA (crRNA) and trans-activating 
crRNA (tracrRNA) are required. A stemloop portion interacts with the Cas9 enzyme, and a 
complementary sequence hybridizes with the DNA of interest. Recently, a chimeric crRNA-tracrRNA 
can been created, termed sgRNA. A sequence complementary to the region of interest, typically 20 
base pairs in length, is ligated into a sgRNA-expressing plasmid. To design the 20 base pair sequence, 
the only essential targeting component is the presence of the protospacer-adjacent motif (PAM) at the 
3’ end of the DNA complementary region248 With these modified sgRNA, gene editing can be performed 
with merely the Cas9 enzyme and the sgRNA in an quick and inexpensive manner249. The ZFN, TALEN, 
and CRISPR systems have all been modified for use in several model systems, including human, 
zebrafish, mouse, worm, plant, and fly241,244,248,250–258. While these gene-editing technologies have been 
valuable for studying genotypic functions, there remains issues with low-efficient gene editing and 
irreversible off-target effects.  
 To induce the recruitment of various effectors and domains in a controlled and specific manner, 
a nuclease deficient Cas9 has been made. By creating a point mutation in each of the nuclease 
domains, RuvC1 (D10A) and HNH (H841A), the endonuclease activity is abolished. The deactivated 
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Cas9 (dCas9) is still recruited to the genomic region of interest by the sgRNA , but it will not induce a 
DSB253. Dozens of labs have added adapter proteins or domains to dCas9 for a wide range of purposes.  
 Shortly after the creation of the optimized dCas9, several labs began fusing activating domains 
to the dCas9 protein with the aim of activating endogenous gene expression. Rather than inferring the 
activity of a gene product by exogenously expressing the gene, these techniques allow for a more 
biologically relevant means of directly increasing gene expression. Maeder et al. began by using a 
dCas9-VP64 fusion to over-express human NTF3 and VEGFA with a dCas9-VP64 construct. VP64 is 
a string of four VP16 fusions (well-characterized transcriptional activators). They also showed that co-
expressing multiple gRNAs to target the same gene at different locations can increase gene activation 
in a synergistic manner259. Other groups quickly began testing other mammalian genes using dCas9 
directly fused to activatong machinery, including VP64244,260,261, VP160 (VP16x10)262, VP192263, p65 
AD (activation domain)260, VPR (VP64-Rta-p65)264,265, Tet1 CD (catalytic domain)266–268, and the p300 
core domain269. 
 In addition to testing activating fusions of dCas9, labs began demonstrating the ability to 
efficiently decrease expression with dCas9 fused to proteins and domains associated with gene 
repression260,261,265. Piloting work by Gilbert et al. used a dCas9 fused to KRAB (a strongly repressive 
domain),270 decreased expression of a fluorescent reporter 15-fold, and demonstrated the gene-
specificity  of the repression with RNA-sequencing. They next applied this system to target endogenous 
genes (CXCR4 and CD71) in cell lines stably expressing dCas9 or dCas9-KRAB260. To re-write the 
DNA methylation landscape at a specific gene, labs have used dCas9-DNMT fusions. Vojta et al. used 
a dCas9 fused to DNMT3A and demonstrated the ability to regulate the CpG methylation status in a 
roughly 35 base pair window from the sgRNA-binding sequence. In addition, they showed the expected 
decreased in expression of the endogenous genes in a specific manner271.  
 Not only can the genes of interest be regulated through targeting of the promoter, but dCas9 
has also been shown to effectively control expression through targeting of non-promoter regulatory 
elements. The Gershbach lab and colleagues targeted core enhancers (CE), distal regulatory regions 
(DRR), proximal enhancers (PE), and distal enhancers (DE) with dCas9 direct fusions (dCas9-VP64 
and dCas9-p300). For activating MYOD with sgRNAs targeting the CE, the DDR, or promoter, dCas9-
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p300 core was more effective than dCas9-VP64. In addition, when gRNAs were used targeting the 
hypersensitive site 2 (HS2) enhancer region of the human b-globin locus dCas9-p300 was able to 
significantly overexpress multiple downstream hemoglobin genes simultaneously272. This group also 
published work targeting the same HS2 enhancer with a dCas9-KRAB and demonstrated the ability to 
significantly decrease expression of multiple globin genes. Lastly, they also showed that dCas9-KRAB 
recruitment induced induce H3K9me3 (at the enhancer region to which the dCas9 was recruited) and 
decreased chromatin accessibility (at the enhancer and promoter region)273. Kearns et al. also 
demonstrated that cell type-specific regulatory elements can be controlled through recruitment of 
histone demethylase activity with dCas9-LSD1274. Lastly, a dCsa9-based high-throughput screen was 
recently performed with dCas9-p300 (for activation) and dCas9-KRAB (for repression) to study 
regulatory elements in their native context. By targeting the dCas9 fusions to DNase I hypersensitive 
sites (or regions of open chromatin) surrounding a gene of interest, gain- and loss-of-function screens 
were performed. Not only were previously identified regulatory elements validated for the b-globin 
locus, but previously unappreciated regulatory elements of HER2 were identified275.  
 The next advancement to occur with dCas9-based editing is the incorporation of indirect 
effector recruitment. For example, the “dCas9-SunTag” system has greatly increased the number of 
epigenetic modulators that can be tethered to a dCas9. The SunTag component is a repeating peptide 
array that can recruit antibody-fusion (termed single chain variable fragment (scFv) fusions)276. Suntag 
adapters capable of recruited 4, 5, 10 or 24 scFv-fusions have been created as a way to increase the 
effector efficiency (i.e. with scFv-VP64276, scFv-TET1267, scFv-DNMT3A277). A second indirect 
recruitment technique that increases the recruitment power of dCas9 is the use of scaffolding sgRNAs 
(scRNAs) in place of the tradition sgRNAs. The scRNAs provide extra recruitment power by the addition 
of extra stem loops, while maintaining the dCas9-recruitment function. Three scRNA varieties were 
made and compared with MS2 stemloops (to recruit MCP proteins), PP7 stemloops (to recruit PCP 
proteins), and com stemloops (to recruit Com proteins). By creating MCP-, PCP-, and Com- VP64 
fusions, it was shown that activation through scRNAs was more effective than the dCas9-VP64 direct 
fusions. Having two stemloops of identical or differing stem loops was also found to increase 
recruitment power278.  By taking into account the crystal structure of the interaction between dCas9 and 
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sgRNA, the MS2 system was further optimized. It was shown that incorporating the MS2 stemloops 
within the dCas9-recruiting stem loops, rather than tacking the additional loops downstream of the 
original stemloops, the recruitment power with MCP fused to VP64 was 14-fold more efficient (for 
ASCL1 targeting). The authors hypothesized that this could be the result of improved MS2 positioning 
or degradation protection of the integrated MS2 stem loops by dCas9. It was also shown that engaging 
multiple activators, for example through dCas9-VP64 and MCP-P65, was more effective than when the 
dCas9 and MCP are fused to the same effector279. Gene activation with MCP-TETcd was also found to 
be effective, through active DNA demethylation280. Chavez et al. conducted a side-by-side comparison 
of several commonly used dCas9-direct fusion, scRNA, and SunTag activation strategies in several 
human, mouse, and fly cell lines. Unsurprisingly, the relative effectiveness between the different modes 
of recruitment appeared to be dependent on effector, cell line, and sgRNA location281.   
To control the expression and activity of dCas9, several labs began designing and optimizing 
dCas9 constructs that are chemically responsive. To control the expression level of the full dCas9 
construct, Conklin and collogues used a Dox-inducible promoter to control dCas9 expression. They 
showed that dCas9-KRAB expression was highly dependent on Dox, as well as reversible within two 
days282. Conversely, Adli and colleagues demonstrated the ability to turn off dCas9 expression by the 
addition of a chemical. By repurposing a plant-based technology called auxin-induced degradation 
(AID), dCas9 proteins fused to a specific degron are rapidly and reversibly degraded in the presence 
of auxin. Within 6 hours of auxin treatment, roughly 90% of the dCas9-p300 expression was reduced283.  
 Groups have demonstrated the ability to control the epigenome-wide programming of 
mammalian cells. For example, Chakraborty et al. used the dCas9 system to stably overexpress 
endogenous MYOD1 in mouse embryonic fibroblasts, successfully reprogramming the cells into 
skeletal myocytes284. Another group activated several gene simultaneously and was able to induce 
differentiate of human induced pluripotent stem cells (iPSC) into neuronal cells 264. To control 
differentiation in a tunable and reversible manner, a group used a doxycylin (Dox)-inducible dCas9 
fusion to repress pluripotent-related genes (SOX2, OCT4, NANOG) in iPSCs. They further 
demonstrated that knockdown of pluripotent genes with dCas9-KRAB-expressing-cells resulted in 
greater than 99% of gene expression (in a uniform and consistent manner among the cell population), 
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whereas gene knockout with cells expressing Cas9 resulted in 30-40% of the cell maintaining gene 
expression and induced a less uniform population of differentiating cells282. Lastly, Balboa et al.  and 
Liu et al. used strong activators and targeted genes like OCT4, SOX2, NANOG, and LIN28A to 
reprogram mouse embryonic fibroblasts263 and human skin firboblasts285 into iPSCs.  
To study the organization and dynamics of chromatin within the mammalian nucleus, a group 
used an enhanced GFP (eGFP)- tagged dCas9 to label and image telomeres and individual coding 
genes in live cells. The florescent intensity levels and localization (indicative of dCas9 and telomere or 
gene presence) were validated with fluorescence in situ hybridization (FISH).  In addition, they 
demonstrated the ability to track the movement of telomeres and the spatial organization of individual 
gene loci in real time286.  
Combining the dCas9 technology with engineered DNA-binding molecule-mediated chromatin 
immunoprecipitation (enChIP) has been shown to be an effective tool to study DNA-protein and DNA-
RNA interactions at a given gene of interest. In addition, the specificity of dCas9-DNA binding can be 
assessed in an unbiased manner. First, a flag-tagged dCas9 was targeted an endogenous gene with 
co-expression of a sgRNA, crosslinked the cells, sonicated, and performed immunoprecipitation (IP) 
with an anti-Flag antibody to isolate DNA that formed an interaction with dCas9. Once the DNA is 
purified, downstream DNA sequencing, RNA sequencing, or mass spectrometry can be performed to 
determine interaction specificity and potential RNA and protein interactions at a given gene287.  This 
type of tool was recently optimized and further characterized by Liu et al. using a Biotinylated-dCas9 in 
vivo. The group aggressively investigated the human b-globin locus and studied 3D chromosomal 
interactions, chromatin modifications, interactions with regulatory proteins, as well as how these 
characteristics are affected by cellular state and differentiation. With this highly sensitive method, 
previously unidentified regulatory elements of the b-globin locus were identified and fully 
characterized288. For further reading of dCas9-based chromatin regulation please read Brocken et al.289 
and Thakore et al290. 
While the dCas9 and other CRISPR-related systems are continuously being improved and 
functionally expanded, one major disadvantage of the current systems is that for effective activation or 
repression, fusions to exogenous effectors must be used. The over expression of these constructs, 
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especially the chromatin regulator-based fusions could be causing currently undetected off-target 
effects. In addition, the presence of the dCas9 at the targeted sequence could be creating non-
biologically relevant interactions.  Lastly, the effect that these fusions have on gene expression are 
unidirectional, activation or repression. The ability to redirect endogenous chromatin regulatory 
machinery in a specific and reversible manner would reduce exogenous-based off-target effects, 
potential steric hindrance from fusion proteins, and allow for investigation of naturally occurring 
chromatin regulatory processes.  
    
Section 1.4: Bifunctional Molecules and CIPs  
 The fields of synthetic biology and synthetic chemistry have created new tools that are now 
being applied to the study and control of chromatin biology. Some chemical inducers of proximity (CIP), 
are a class of bifunctional molecules that bring two proteins, or activity domains, in physical proximity 
of each other in order to initiate a new biological response. CIPs have paved the way for scientist to 
control complex processes in a chemically dependent manner.  
 The first CIP to be synthesized was a homodimer of FK506 (FK1012), which brings together 
two FK506-binding-protein (FKBP12) molecules291. FK506, alone, can also bind FKBP from one side 
and calcineurin on the other. Another FKBP-interacting molecule is rapamycin capable of bringing 
together FKBP12 and the FKBP12-rapamycin-binding (FRB) domain of the TOR kinase. Three other 
commonly used CIPs are plant-based molecules that have been repurposed in mammalian system for 
CIP and have been shown to be non-toxic. Abscisic acid functions with the Pyl receptor and 
phosphatase ABI1, gibberellin induces proximity of GID1 and GA1, and indole-3-acetic acid (auxin, 
which has been previously discussion for dCas9 proteosomal degradation) can recruit the Cul1 
complex to proteins with an auxin-inducible degron292. Since the discovery and characterization of these 
CIPs, groups from multiple fields have repurposed them in diverse ways.  
 One way labs have repurposed CIPs, is through the redirection of chromatin regulatory 
machinery in order to ask mechanistic questions in a direct manner. The pilot study for this type of 
investigation resulted in the development of the chromatin in vivo assay (CiA). To study chromatin 
regulatory machinery, one of the murine Oct4 loci was engineering to contain a Gal4 DNA binding array. 
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By exogenously expressing Gal4-FKBP (to serve as the DNA anchor) and FRB fused to a protein-of-
interest (i.e. heterochromatin protein 1a, HP1a) recruitment to Oct4 can be temporally controlled by 
rapamycin treatment293.  
 With the development of CRISPR/Cas9, labs have incorporated CIPs to control the recruitment 
of dCas9 fusions. Expanding upon the original CiA system, a dCas9-based FKBP and FRB system was 
optimized and tested with rapamycin. Using ms2-FKBP and FRB- fusions (i.e. FRB-HP1, FRB-BAF), 
reversible control of the chromatin environment of endogenous mammalian genes was demonstrated. 
For example, upon recruitment of HP1 to the CXCR4 locus with the dCas9 system, H3K9me3 was 
enriched and mRNA levels were decreased294. In Zetsche et al., the authors split a dCas9-VP64 fusion 
into two different constructs, each with their own promoter, and added a FRB domain to the N-terminus 
side and FKBP to the C-terminus side. Upon treatment with 200 nM of rapamycin, the level of activation 
of the target gene (ASCL), was comparable to the full-length dCas9-VP64, and 57-fold more effective 
than the untreated cells with the split dCas9295.  The Qi lab and colleagues incorporated CIP systems 
in a very intricate way. By creating dCas9-AB1 and dCas9-GAI fusions, there were able to recruit 
activating (VPR, SunTag-VP64) or repressing (KRAB) machinery in a chemically dependent manner 
with PYL1 and GID1 fusions. The ABA- and GA- inducible recruitment strategies were mutually 
exclusive and the effects were reversible296. Lastly, a split SunTag system was created whereby the 
scFv was fused to FKBP12. VP64 was fused to a mutated FRB domain (T3089L), such that rapamycin 
analogue AP21967 could bind the FRB mutant but not the endogenous TOR protein. Activation of their 
BFP reporter was found to be roughly 140-fold upon treatment with AP21967297. Corson et al.298 and 
Stanton et al.292 describe some of the other diverse ways labs have used CIP systems in chemical 
biology research.  
 
Section 1.5: Conclusions and Future Perspectives  
 The study of chromatin biology represents a very complex relationship with many levels of 
regulation. While this overview focuses on DNA and histone tail modifications, there are several other 
components involved in chromatin compaction and gene expression, including histone variants, 
nucleosome occupancy, long non-coding RNAs, transcription factor recruitment, localization within the 
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nucleus, and chromatin looping with distal regulatory elements. With the work presented in this thesis, 
we are studying the contribution that DNA and histone tail modifications have on the chromatin 
environment and gene expression in a specific and biologically relevant way, so as to not exclude these 
other pathways. In addition to studying how these modifications and their regulator proteins function in 
a healthy system, we are also interested in how this process goes array in a disease context. It has 
become increasingly clear that dysregulation of the global chromatin environment can confer a growth 
advantage for disease, such as cancer. Thus, by redirecting chromatin regulatory machinery to control 
the expression of disease-relevant genes we can study the consequences of and reverse the effects 
of these mis-expressed genes. To redirect endogenous chromatin modifying machinery,  we have 
designed, tested, and optimized bifunctional molecules, called chemical epigenetic modifiers 
(CEMs)299,300.  
 CEMs are synthesized using FK506, a linker region of varying lengths, and an inhibitor or 
chemical probes that binds to chromatin regulatory machinery. One advantage of using FK506 is that 
it has an exocyclic alkene group capable of functioning as a chemical handle. Guo et al. described a 
thiol-ene ‘click’ reaction that opens the doors for the synthesis of several FK506 derivatives including 
bifunctional molecules that also recruit endogenous histone modifying enzymes301. To recruit histone-
modifying proteins, we have used inhibitors, including FDA-approved HDAC and HAT inhibitors. At low 
nanomolar concentrations CEMs recruit either HDACs or HATs to the targeted gene locus and 
releasing the proteins, creating a cloud of the enzymes with full, uninhibited activity. Recruiting 
endogenous proteins in this small-molecule approach, rather than exogenously over-expressing 
fusions of chromatin regulatory machinery, allows us to manipulate and investigate the physiological 
epigenetic environment, and swap bifunctional molecules to exert different effects. This system also 
allows the proteins to freely move proximal to the locus, rather than being held to the DNA and sterically 
hindered. The series of CEMs that recruit repressive machinery is called CEMr, whereas the activating 
series is called CEMa. Using these molecules, we study the complex dynamics and interplay of specific 
histone modifications and chromatin environments in a reversible, biologically relevant manner.   
 One of the ways that we study the effect induced by recruitment of specific chromatin regulatory 
machinery, is by performing chromatin immunoprecipitation (ChIP). The technique allows us to 
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determine the relative enrichments of other chromatin regulatory machinery, transcriptional machinery, 
or histone tail modifications. Briefly, the steps of ChIP include formaldehyde fixing cells, shearing the 
chromatin into small fragments, incubating with an antibody specific for the protein or modification of 
interest, reverse crosslinking, followed by a downstream quantitative analysis (i.e. next generation 
sequencing or quantitative real time PCR). A major bottleneck of this protocol is the chromatin 
sonication, which is one of the most sensitive, time consuming, and variable steps. To improve the 
consistency and efficiency of this step, we have developed and tested a sonication enhancing 
technique based on sonically active nanodroplets. With this optimized method, we have optimized 
efficiency by 16-fold and reduced variation 2.7-fold302.  
 To study chromatin biology and its relevant to human disease, we have incorporated synthetic 
biology and chemical biology to design and optimize novel platforms of investigation. With our CEMa 
and CEMr technology, we can precisely control the recruitment of chromatin regulatory machinery, 
which in turn influences the chromatin environment and level of gene expression. By repurposing 
cavitation reagents, we have also created a new ChIP protocol and demonstrated its increased 
effectiveness. With our optimized ChIP protocol, we have begun testing the CEM-mediated effects on 
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CHAPTER 2: TARGETED GENE REPRESSION USING NOVEL BIFUNCTIONAL MOLECULES TO 





Specific control of gene expression programs is critical for proper mammalian development 
and allows for the creation of differentiated tissues from a pluripotent starting state. Much of this control 
comes from regulation at the level of chromatin, where the presence or absence of chemical marks on 
DNA and histone tails regulate expression of the associated gene by directing the binding of 
transcription factors, corepressors, coactivators, and other biomolecules.1,2 These epigenetic pathways 
are commonly disrupted in many human diseases including cancer.3 Thus, both to understand human 
biology and to develop new therapeutic strategies for treating diseases driven by epigenetic 
dysregulation, it is important to develop new technologies capable of synthetically modulating 
epigenetic processes at individual genes or sets of genes. Site-specific editing of these epigenetic 
marks can be accomplished with dCas9 or TALE mediated recruitment of epigenetic enzymes.4–6 In 
one example, a small guide RNA (sgRNA) is capable of recruiting a dCas9-p300 fusion protein to target 
genes, causing histone acetylation and transcription activation.7 These new approaches have proved 
to be extremely useful opening up new avenues for the study of epigenetics and could turn out to be  a 
whole new class of therapeutic for personalized medicine. One major drawback of using a genetic 
editing technology as a therapeutic or an in vivo tool, is off target or continuous recruitment resulting  in 
permanent genetic mutation at undesirable loci.8 As an alternative, we considered a small molecule
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platform for epigenome editing. Small molecules have   some advantages over genetic methods as a 
therapeutic and a research tool: treating cells with small molecules is technically easy and requires little 
optimization, they are typically easy to synthesize, they can be active in vivo, effects are often dose 
sensitive, and most importantly their effects are reversible. Disadvantages also exist for small 
molecules: their functions are typically more difficult to engineer, their cellular effects may be less 
profound, and they may have more off-target effects than genetic methods.  
 
Using bivalent small molecules to direct proteins to DNA has been investigated.9 “Small 
molecule transcription factors” featuring hairpin polyamide DNA binding motifs linked to histone 
deacetylase inhibitors were used to activate transcription of DNA.10 Because polyamides are difficult to 
synthesize and the effects likely result from a combination of on-target and off-target effects, this 
approach is not ideal. Similar examples have been reported that use polyamides or transcription factor 
ligands as the DNA binding ligand and coactivator-binding molecules as a transcriptional activation 
domain.9 In another example, glucocorticoid receptor (GR) ligands tethered to FK506 were used to 
recruit a histone deacetylase (HDAC) 1 – FKBP fusion protein to DNA, causing down-regulation of GR-
controlled genes.11 Recently, Liszczak et al. used native chemical ligation to attach small molecules to 
dCas9, allowing CRISPR guided targeting of the molecules to DNA.12 This system did not cause any 
changes in gene expression unless the cells were co-transfected with a VP64-Brd4 fusion protein. Thus 
far, none of these methods have been shown to specifically change both the epigenetic state and the 
expression of a target gene. 
 
Controlling chemically induced proximity between corepressor complexes and DNA-bound 
transcription factors requires a bivalent ligand capable of strong interactions with both the transcription 
factor and a corepressor complex. Components of corepressor complexes with high-affinity ligands 
include the histone deacetylase (HDAC) enzymes and EZH2.13,14 We chose HDAC inhibitors as the 
ligands for many reasons: they are potent, easy to synthesize, and tolerate the attachment of long linker 
groups while still being cell-permeable.15 Also, the isoform selectivity and residence time can be tuned 
by modifying the ligand.16,17 HDAC enzymes reverse the histone acetyl marks associated with open 
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chromatin and active transcription.18,19 It may seem counterintuitive to use enzyme inhibitors to recruit 
a complex that enzymatically modifies histones, but HDACs exist in complexes that contain proteins 
capable of silencing genes through many different mechanisms, and some HDACs are catalytically 
inactive pseudoenzymes that still bind inhibitors.20,21 Furthermore, HDAC enzymes can exist in 
complexes with other HDAC isoforms that would not be inhibited by the small molecule.22 HDAC 
inhibitors bind to corepressor complexes such as CoREST, NuRD, and Sin3 with unique selectivity 
profiles, depending on the chemical structure and HDAC isoform bound.15,23 By tuning the inhibitor 
structure, it may be possible to recruit specific corepressor complexes to the target gene.  
 
Additionally, these bifunctional molecules are derived from FDA-approved HDAC inhibitors that 
have been well studied and characterized. Suberanilohydroxamic acid (SAHA) and several other 
epigenetic inhibitors are widely used in the clinic.24,25 Though these drugs are effective modulators of 
certain cellular pathways, their cell-wide effects cause high toxicity and modulate the expression of 
many genes.26 We describe a targeted, gene-specific application of these molecules. This technology 
can control gene expression in a dose sensitive and reversible manner, allowing us to gain exquisite 




Design of chemical epigenetic modifiers: 
 
We used the previously described Chromatin in vivo assay (CiA) cell line to develop bivalent 
ligands capable of epigenome editing, which we call chemical epigenetic modifiers (CEMs).27 This cell 
line is derived from mouse embryonic stem cells (mESC). One copy of the Pou5F locus is modified to 
include a Gal4 DNA-binding array upstream of the transcriptional start site, and the downstream Oct4 
gene is replaced with enhanced GFP (eGFP). Because the eGFP gene is highly expressed, this system 
is sensitive to the recruitment of gene silencing complexes, and the change in gene expression can be 
monitored by flow cytometry.  
	 49 
 
The mESCs were lentivirally infected with a plasmid expressing an FKBP-Gal4 fusion protein, 
which serves as our DNA-anchor to recruit the CEMs (Figure 1a). This was ideal for development of 
the CEM system because FK506, a natural product that forms a high affinity interaction with FKBP, can 
serve as the transcription factor ligand.28 Our control cell line expresses the unmodified Gal4 protein, 
removing the ability to bind and recruit FK506.  
 
The CEMs were constructed by attaching FK506 to an HDAC inhibitor through a short linker 
using click chemistry, so as not to disturb the stereocenters of FK506 (Figure 1b).28,29 HDAC inhibitors 
can be attached to linkers or solid supports through the solvent-exposed aryl region with little impact 
on potency. Kozikowski et al. reported click-chemistry compatible, triazole HDAC inhibitors with low-
nM potency at HDACs 1, 2, 3, 6, and 10.30 We used this template to create CEM42 and CEM23. Both 
CEMs have the same HDAC-recruiting moiety, but we wanted to investigate if the linker would have an 
impact on CEM-efficiency. CEM42 contains a relatively long 3X PEG linker and CEM23 contains a 
propyl linker (Figure 1b).  
 
Recruitment of HDAC activity can efficiently repress the CiA:Oct4 locus: 
 
To serve as a positive control for HDAC-mediated repression, we developed fusion proteins 
between Gal4 and 8 different HDAC isozymes. HDAC3-Gal4 caused repression in 38.8% of the cells 
(Figure 2a), while the other fusions did not have any repressive effects. 
 
Dose response experiments identified the optimal concentration of CEM23. We observed 
repressive activity with 10nM of CEM23. The level of repression peaked around 100nM. Doses went 
as high as 10µM, after which significant cell death occurred and an accurate level of repression was 
not obtainable (Supplementary Figure S1a). We followed FKBP-Gal4 cells treated with 100nM 
CEM23 for 72 hours. The cell population reached a maximum of 48% GFP(-) after 48 hours, and 
sustained this level through 72 hours (Figure 2c). In cells transfected with Gal4, which cannot recruit 
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the CEMs, 100nM of CEM23 did not cause a significant increase in the GFP(-) population (Figure 2b). 
The Gal4 control experiment proves that any changes in gene expression are not due to the general 
gene-silencing effect of the HDAC inhibitors, but are only possible when the inhibitor is localized at the 
target gene. It also shows that the gene silencing is not caused by Gal4 blocking progression of RNA 
polymerase. We next exposed the cells to CEM23 with and without an excess of FK506 (the component 
of CEM23 that binds to FKBP).  
 
To demonstrate the stability and reversibility of CEM23 effects, we sorted CEM23-treated cells 
using fluorescence activated cell sorting (FACS) (Supplementary Figure S2). After 48 hours of 100nM 
CEM23 treatment, the cells were separated into positive and negative populations. The GFP(-) was 
plated with or without continuous CEM23 exposure and maintained for evaluation. The negatively 
sorted cells were assessed with flow cytometry 3 days after FACS. The cells that were not treated with 
CEM23 regained almost full GFP expression (92.3% GFP+) and 71.8% of the CEM23 treated populated 
remained GFP(-) (Figure 2d).  
 
To investigate the ability of the CEMs to be washed out and dosed back into the cells, we re-
exposed a portion of the negatively sorted cells that were not given post-sort CEM-treatment and had 
regained GFP-expression. After 48 hours post reintroduction of 100nM CEM23, 78% of the population 
repressed GFP (Figure 2e). These results demonstrate the specificity and reversibility of our system 
to tune gene expression in a chemically-depend manner through endogenous HDAC recruitment. 
CEM42, featuring a longer linker region, behaved similarly to CEM23 in the FKBP-Gal4 cells. At 100nM, 
after 48 hours, CEM42 causing 41.1% of the cells to reside in the GFP(-) state, with no significant 
effects on transcription for the Gal4 control cells (Supplementary Figure S1b). 
 
Knowing that recruitment of HDAC3 was likely to be responsible for gene repression, we 
synthesized CEM36, based on a different chemotype reported to be selective for HDAC1/331 (Figure 
1b). CEM36 features a benzamide zinc chelating group that is known to have a very long residence 
time at the enzyme relative to the hydroxamic acid zinc chelating groups of CEM23 and CEM42, but is 
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less potent. After treatment of FKBP-Gal4 cells with 100nM CEM36 for 2 days, 29.9% of cells were 
GFP(-), with no effect in Gal4 control cells (Supplementary Figure S1c). 
 
To confirm that the bifunctional CEMs repress GFP, rather than one of the components alone, 
we tested the CEMs with FK506. Our results show that with a 10X excess of FK506, the repressive 
effects of CEM23 are removed, so FK506 is competing with CEM23 for the same FKBP binding site 
(Supplementary Figure S1d). We also tested the effect that the individual components have on GFP 
expression. FK506 alone did not alter expression at 100nM and 1000nM concentrations. SAHA did 
have a slightly repressive effect at 1000nM, but no repression was observed at 100nM (Supplementary 
Figure S1e).  
 
CEM-mediated repression of eGFP occurs in a variegated and whole-colony fashion:  
 
mESCs are an adherent, colony-forming cell line, thus we hypothesized that these 
characteristics were influencing the ability of cells to uptake the CEMs and thereby limited the level of 
overall gene repression. To characterize the mode of the repression, we took fluorescent microscopy 
images of the HDAC3-Gal4 and CEM-treated cell line. In an unbiased, blinded manner we counted 
~200 mESC colonies for each line and classified them into three categories: GFP-Off, GFP-On, and 
GFP-Variegated. Colonies were labeled as “GFP Off” if all cells within the colony were off or expressing 
background-level GFP expression. Colonies in which all the observable cells were expressing GFP 
relatively brightly were categories as “GFP-On”. “GFP-Variegated” colonies had cells within the 
colonies that maintained high GFP expression, in an otherwise GFP(-) colony. Examples of cells in 
these categories are shown in Supplementary Figure S3a. Cell lines were grown and counted in 
duplicate, then averaged (Supplementary Figure S3b).  
 
The Gal4-expressing and FKBP-Gal4 expressing cell lines were treated with 100nM of CEM23, 
CEM36, or CEM42 for 48 hours. Images were taken throughout areas of the wells using a High Content 
Fluorescent Microscope (Figure 3a,b). HDAC3-Gal4 cell lines served as a positive control for HDAC3-
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recruitment. In the HDAC3-Gal4 cells, an average of 43% of cells were GFP-On, 25% were GFP Off 
and 32% were variegated. As expected, the GFP expression of the Gal4-infected colonies was not 
significantly affected by CEM treatment. Of the FKBP-Gal4 cells treated with CEM23, 43% of the 
colonies were GFP-On, 32% were GFP-Off, and 25% were variegated, similar to the HDAC3-Gal4 cell 
line. The standard deviation between replicates was low when comparing the percentage of GFP-off 
colonies, whereas the percentages varied more between GFP-On and GFP-Variegated. This could be 
due to differences in what was determined to be fully on versus a variegated phenotype. Nevertheless, 
some colonies are remaining fully on or fully off, which does not support the hypothesis that CEM-to-
cell accessibility is limited by colony formation, resulting in an incomplete suppression of GFP 
expression. To validate cell morphology, representative images of the cell lines and treatment condition 
representative images are shown with a fluorescent microscope, which allowed phase microscopy of 
the colonies (Figure 3c and Supplementary Figure S3c).  
 
 
H3K27ac levels decrease upon CEM-recruitment: 
 
 To examine the effects of CEM-mediated HDAC recruitment on chromatin environment, we 
performed chromatin immunoprecipitation (ChIP) followed by quantitative RT-PCR (qPCR). H3K27ac 
is a histone mark associated with active promoters and is regulated in part by HDAC3 activity.32 We 
tested for differences in H3K27ac at the Oct4 locus of the HDAC3-Gal4 cell line, the Gal4 cell line, and 
the FKBP-Gal4 cell line with and without 48 hours of 100nM CEM23 exposure (Figure 4a).  
 
 The normalized level of H3K27ac enrichment was significantly higher in the Gal4 cell line 
compared to the HDAC3-Gal4 cell line when tested at regions 489 base pairs (bp) and 738 bp 
downstream from the transcriptional start site (TSS) (* = p<0.05, n=4) (Figure 4b). We next tested the 
H3K27ac levels at the same location in the FKBP-Gal4 cell lines with and without CEM23 treatment. 
Our results show that CEM23 decreased H3K27ac levels at 489, 738, and 1199 bp downstream of the 
TSS (Figure 4c, * = p<0.05, ** = p<0.005, n=5). The primer set at 169 bp upstream of the TSS did not 
	 53 
show a significant change between the Gal4 cells and HDAC3-Gal4 cells, nor between the FKBP-Gal4 
+/- CEM23 cells (Supplementary Figure S4a,b). This is not surprising, as regions this close to the 
TSS are typically largely devoid of nucleosomes. The results of H3K27ac levels in the four cell lines at 
-169, 489, 738, and 1199 bp from the TSS are summarized in Figure 4d. These data support our 
hypothesis that our CEM-mediated gene repression occurs through endogenous HDAC recruitment. 
   
 To confirm and further characterize the observed changes in histone tail acetylation, FKBP-Gal4 
cells treated with 100nM of CEM23 for 48 hours were separated into positive and negative populations 
by FACS. We expected that the decreased acetylation levels observed in the CEM23-treated cells were 
contributed by the cells with decreased GFP expression (as observed by flow cytometry and 
microscopy). We measured the H3K27ac levels in the GFP(+) and GFP(-) population from three 
separate sorting experiments. We compared H3K27ac enrichment levels between the GFP(+) and 
GFP(-) populations. As expected, H3K27ac levels in the GFP(+) population were significantly higher 
than the GFP-negative population. Additionally, H3K27ac levels in the untreated FKBP-Gal4 cells were 
not significantly different from the FKBP-Gal4 + CEM23 positively sorted cells. And, H3K27ac levels in 
the FKBP-Gal4 CEM23-treated cells were not significantly different from the FKBP-Gal4 + CEM23 
negatively sorted cells (Supplementary Figure S4c). It should be expected that the sorted GFP(+) 
population has acetylation levels similar to the unsorted FKBP-Gal4 control cells, and that the sorted 
GFP(-) population has acetylation levels similar to the unsorted FKBP-Gal4 CEM23 treated cells. For 
all ChIP reactions, qPCR was done with primer pairs along the Oct4 locus (Supplementary Figure 
S4d). H3K27ac enrichment levels were normalized to primers recognizing an intergenic region (IGR). 
These data confirm what we expected and show that within the CEM23-treated cells, the GFP(-) cells 




 CEM compounds cause specific, targeted gene suppression by modifying the local chromatin. 
The mechanism of action for these compounds is direct recruitment of HDAC-containing corepressor 
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complexes to the FKBP-Gal4 transcription factor. Evidence supporting this claim is: the known ability 
of similar HDAC inhibitors to bind HDAC-containing corepressor complexes,23 the reduction of 
transcription and H3K27 acetylation at the target gene, and the recapitulation of the drug-induced 
phenotype by a Gal4-HDAC3 fusion protein.  
 
 Suberanilohydroxamic acid (SAHA) derivatives like CEM23 and CEM42 are known to bind to 
multiple corepressor complexes, and have particularly high affinity towards CoREST, Sin3, and the 
HDAC3-containing nuclear receptor corepressor complex (NCOR).23,33 HDAC3 does not need to be 
catalytically active to cause gene repression in cells, and represses transcription independent of direct 
deacetylation, dependent on association with NCOR.34 When a CEM recruits HDAC3/NCOR to a gene, 
HDAC3/NCOR can suppress transcription even while HDAC3’s catalytic activity is blocked. HDAC3 is 
the only HDAC enzyme known to reside in the NCOR complex,35 so it is unclear how deacetylation 
takes place while the NCOR HDAC3 enzyme is engaged by an inhibitor. Because we observe the 
associated deacetylation in proximity to our FKBP-Gal4 DNA anchor, we are likely recruiting uninhibited 
HDACs to the gene locus. This could be happening through indirect recruitment of inhibited HDACs 
that our CEMs are recruiting, through direct recruitment whereby the reversible HDAC-CEMs 
interaction is allowing for previously inhibited HDACs to be active, or a mixture of both conditions. We 
hypothesize that we generate a cloud of HDACs in the proximity of the gene that are actively 
deacetylating and altering the chromatin environment in a chemically-dependent manner.  
 
 Less selective, hydroxamic acid-containing HDAC inhibitors like CEM23 were most effective in 
our assays. Slow dissociating benzamide compounds like CEM36 were not as effective, perhaps 
because these compounds have less affinity for the enzyme.15,16 Future medicinal chemistry campaigns 
will more exhaustively explore alternative chromatin modification pathways by changing the chromatin 
activity portion of the bifunctional CEMs to include chemical probes that bind other complexes, for 
example polycomb repressive complex factors or heterochromatin pathway proteins, since the direct 
tethering of either pathway has been linked to gene repression.27,36  
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 The CEM compounds could be used in other cell lines that contain Gal4 binding arrays at a 
gene of interest, or could be adapted for use with other genetic engineering systems. dCas9-CRISPR 
is currently the most programmable system for epigenome editing, and we are working to adapt dCas9 
to work with the CEMs. Because the dose of small molecules can be precisely controlled, the CEMs 
could have value as part of a CRISPR-directed epigenome editing platform. 
 
 Drugs that target the addition, removal, or recognition of histone modifications, such as HDAC 
inhibitors, do this across the genome. The HDAC inhibitors SAHA and depsipeptide have been shown 
to change the expression of up to 22% of genes.26 HDAC inhibitors also modulate acetylation of many 
non-histone proteins.37 This lack of selectivity causes side effects, and thus, most of these drugs are 
reserved for use in cancers for which there aren’t many other therapeutic options.38 By tethering 
epigenetic modulator drugs to a DNA-targeting group, the pharmacology of these drugs is constrained 
to the target locus, providing a robust effect at the target gene with minimal off-target effects.  
 
 The success of this work, and other results,11 raises the possibility that purely small molecule 
epigenome editing is possible. An HDAC inhibitor could be tethered to a glucocorticoid or androgen 
receptor (AR) ligand, and be used to repress genes bound by these receptors. An AR receptor ligand 
– HDAC inhibitor conjugate could be a therapy for androgen-independent prostate cancer, where the 
AR inappropriately activates target genes with changes to the epigenome.39 Because of the difficulties 
in delivering proteins or genes in vivo, bivalent small molecules may be the easiest way to achieve 




Cell lines and infection:  
The CiA mouse embryonic stem cells, previously described in Hathaway et al., 2012, were grown on 
0.1% gelatin coated tissue culture dishes in high-glucose DMEM (Corning, 10-013-CV) supplemented 
with FBS serum (Gibo, 26140-079), 10mM HEPES (Corning, 25-060-Cl), NEAA (Gibco, 11140-050), 
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Pen/Strep, 55μM 2-Mercaptoethanol, and 1:500 LIF conditioned media produced from LIF-1Cα (COS) 
cells. Low passage (22-30) mESC were used. Cells were typically passaged at a density of 3-4 x 106 
cells per 10 cm plate, fed every day, and split every 2-3 days. Lentivirus production of mESC infection 
was done using 293T LentiX cells (Clontech). Low passage cells were plated onto 15 cm cells such 
that they were 80% confluent 24 hours later. Each plate was transfected with 18μg of the plasmid of 
interest, 13.5μg of the Gag-Pol expressing plasmid, and 4.5μg of the VSV-G envelope expressing 
plasmid. PEI transfection was done and 60 hours after transfection, virus was spun down at 20,000 
RPM for 2 ½ hours and then added to the mESCs in combination with 5 μg/mL Polybrene (Santa Cruz, 
sc-134220). Selection of lentiviral constructs was done with either puromycin (1.5μg/mL) or blasticidin 
(7.5μg/mL).  CEM and FK506 were diluted in DMSO (Sigma D2650) and kept at -20oC added to the 
cells during cell passaging and the cells were given fresh media and compound daily.  
 
Construct Design:  
The plasmids expressing the Gal4-DBD control and FKBP-Gal4 were previously constructed and can 
be found on Addgene (44176 and 44245, respectively). HDAC3-Gal4 was constructed by stitching 
PCR. The HDAC3 was amplified from mESC cDNA and the Gal4 was amplified from Addgene #44176. 
Both pieces were stitched into a lentivirus backbone with EF1-α promoter driving HDAC3-Gal4 and a 
PGK promoter driving a resistance gene. The primers for the stitching pcr are as follows: forward primer 
(AC044) tgaggatccgcggccgcgccaccatggccaagaccgtggcg ; middle forward primer (AC045) 
cgacaaggaaagtgatgtggagattatgaagctactgtcttctatcgaac ; middle reverse primer (AC046) 




Flow cytometry and FACS: 
Flow cytometry analysis and fluorescence activated cell sorting were done with the University of North 
Carolina Flow Facility. The cells were washed, trypsinized, and plated into a 96 well format (at a density 
of about 2,000 cells/μL) for analysis in the Intellicyt iQue screener PLUS. UNC Flow Core Staff 
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conducted the FACS with the FACSAria II. 107 cells were harvested for ChIP immediately after the 
sorted populations were acquired.  
 
Image acquisition and quantification:  
The images taken for quantification were taken with the GE IN Cell Analyzer 2200 24 hours and 48 
hours after compound exposure. Ten images, randomly dispersed throughout the well were taken per 
cell line. For each cell line treatment condition, 147-213 colonies were counted and characterized as 
GFP On, GFP Off, or GFP Variegated. The percentage of each category was determined. This was 
done in duplicate with freshly infected and selected cell lines. Percentages for each category were 
averaged. The brightness/contrast of the brightfield images was uniformly adjusted in ImageJ FIJI. 
Background artifact in the GPF-fluorescent images was uniformly removed in FIJI with a sliding 
paraboloid with a rolling ball radius of 10 pixels.  
Confirmatory images were taken of the cells 24 and 48 hours after compound exposure with the Leica 
Olympus IX71. Phase images were not edited. Fluorescent images were edited in FIJI with a sliding 
paraboloid with a rolling ball radius of 20 pixels. 5 images were taken per replicate per condition, and 
representative images are shown.  
 
ChIP-qPCR:  
For each sample, cells were trypsinized for 8-10 minutes, trypsin was quenched with 10mL of ES media, 
and 107 cells were obtained. Cells were spun down, washed with 10mL PBS, fixed for 12 minutes in a 
mix of formaldehyde (to a final concentration of 1%) and Fix Buffer (50mM HEPES pH 8.0, 1mM EDTA, 
0.5mM EGTA, 100mM NaCl), and then quenched by glycine (final concentration of 0.125M). Cells were 
incubated on ice, spun down at 1000xg for 5 minutes. Nuclei were prepared by consecutive washes 
with Rinse 1 Buffer (50mM HEPES pH 8.0, 140mM NaCl, 1mM EDTA, 10% glycerol, 0.5% NP40, 0.25% 
Triton X100), Rinse 2 Buffer (10mM Tris pH 8.0, 1mM EDTA, 0.5mM EGTA, 200mM NaCl) and 
Shearing Buffer (0.1% SDS, 1mM EDTA, 10mM Tris HCl pH 8). After a final spin down, cells were 
resuspended in 100μL Shearing Buffer and 1 x protease inhibitor cocktail (Calbiochem), nanodroplets 
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(generous gift from Samantha Pattenden40, and sonicated in an E110 Covaris Sonicator for 4 minutes 
or until DNA was sheared to between 70-500bp (as confirmed by agarose gel).  
After sonication, the rest of the protocol was performed with a ChIP-IT High Sensitivity Kit (Active Motif, 
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Figure 1. Design and structure of chemical epigenetic modifiers (CEMs). (a) A Gal4-FKBP fusion binds 
to a 5X Gal4 binding array at the promoter of the CiA:Oct4 locus. A bivalent FK506-HDAC inhibitor 







Figure 2. CEM23 reversibly and specifically represses GFP expression. (a) Flow cytometry data for 
ES cells expressing either Gal4 or Gal4-HDAC3. (b) ES cells expressing Gal4 were treated with 
either 0 or 100 nM CEM23 for 48 hours. (c) ES cells expressing Gal4-FKBP were treated with CEM23 
over 72 hours. (d) ES cells treated with 100nM CEM23 were sorted to keep only GFP(-) cells. These 
cells were treated with either 0 or 100nM CEM23 for 5 additional days, and analyzed on days 5 or 7. 
(e) CEM23 treated, GFP(-) sorted cells were washed out for five days, treated with either 0 or 100nM 





Figure 3. Fluorescent microscopy images and colony categorization for CEM-treated cells. 
Fluorescence images were taken of ES cells and colonies were characterized as being GFP On, GFP 





Figure 4. H3K27Ac chromatin immunoprecipitation at the Cia:Oct4 locus. Quantitative RT-PCR was 
performed at four sites at the nucGFP locus. Quantitative RT-PCR compared Gal4 to HDAC3-Gal4 cell lines 
(b) and Gal4-FKBP cells to Gal4-FKBP with 100nM CEM23 (c) using an H3K27ac antibody. Results at all 
four regions are summarized (d). Significance was calculated using Student’s t test with n = 4 for B and n = 





Supplemental Figure S1. (a) Overlays of histograms of dose response for CEM23 (0, 10, 50, 100, 
1000, 10000nM) with legend showing colors for each dose. (b) Overlays of histograms of CEM42 +/- 
compound for Gal4 and Gal4-FKBP cell lines. (c) Overlays of histograms of CEM36 +/- compound for 





Supplemental Figure S1d. Overlays of histograms for the Gal4 cell line and FKBP-Gal4 cell line with 100nM 





Supplemental Figure S1e. Overlays of histograms for the FKBP-Gal4 cell line with FK506 or 










Supplemental Figure S2a.The gating of FKBP-Gal4 + 100nM CEM23 cells and gating of 





Supplemental Figure S2b.The gating of FKBP-Gal4 + 100nM CEM23 cells and gating of 






Supplemental Figure S2c.The gating of FKBP-Gal4 + 100nM CEM23 cells and gating of 






















Supplemental Figure S3b. The raw data of colony characterization into GFP-Off, GFP-On, GFP-





Supplemental Figure S3c. Representative images of Phase and GFP Fluorescence for Gal4 and 





Supplemental Figure S4. Quantitative RT-PCR comparing Gal4 to HDAC3-Gal4 cell lines (a) and 
Gal4-FKBP cells to Gal4-FKBP with 100nM CEM23 (b) using an H3K27ac antibody and qPCR 
primers 169 basepairs upstream of the transcriptional start site. Quantitative RT-PCR compared 
Gal4-FKBP cells, Gal4-FKBP with 100nM CEM23, and Gal4-FKBP with 100nM CEM23 sorted into 
positive and negative populations, using an H3K27ac antibody and qPCR primers 738 basepairs 
downstream of the transcriptional start site (c). Primer sequences used for qPCR in Figure 4 and 
Supplemental Figure 4A-C (d). 
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Supplemental Text 1. Chemistry General Procedures. FK506 was purchased from Selleck. All 
other chemicals were purchased from Sigma-Aldrich or Fisher Scientific. HPLC spectra for all 
compounds were acquired using an Agilent 1200 Series system with DAD detector. Analytical HPLC 
chromatography was performed on a 2.1×150 mm Zorbax 300SB-C18 5 μm column with water 
containing 0.1% formic acid as solvent A and acetonitrile containing 0.1% formic acid as solvent B at 
a flow rate of 0.4 mL/min. The gradient program was as follows: 1% B (0−1 min), 1−99% B (1−4 min), 
and 99% B (4−8 min). High resolution mass spectra (HRMS) data were acquired in positive ion mode 
using an Agilent G1969A API-TOF with an electrospray ionization (ESI) source. Flash column 
chromatography was performed on a Teledyne ISCO CombiFlash Rf system equipped with a variable 
wavelength UV detector and a fraction collector using RediSep Rf normal phase silica columns. 
Microwave reactions were performed using a Discover SP CEM. Nuclear Magnetic Resonance 
(NMR) spectra were acquired on a Bruker DRX-600 spectrometer with 600 MHz for proton (1H NMR) 
and 150 MHz for carbon (13C NMR); chemical shifts are reported in ppm (δ). Preparative HPLC was 
performed on Agilent Prep 1200 series with UV detector set to 254 nm. Samples were injected onto a 
Phenomenex Luna 75 x 30 mm, 5 μm, C18 column at room temperature. The flow rate was 30 
mL/min. A linear gradient was used with 10% (or 50%) of MeOH (A) in H2O (with 0.1 % TFA) (B) to 
100% of MeOH (A). HPLC was used to establish the purity of target compounds. All final compounds 
had > 95% purity using the HPLC methods described above. NMR integration marked as n.d. 
indicates that integration could not be determined due to large numbers of protons overlapping with 





Supplemental Figure 5. Synthesis of compounds 1-3. (2) FK506-mercaptopropanamide 
propylazide: FK506-mercaptopropionic acid (Compound 1) was prepared as described.1 Compound 1 
(182 mg, 0.2 mmol) in DMF (1 ml) was treated sequentially with EDCI-HCl (25 mg, 0.25 mmol), 
HOAT (41 mg, 0.3 mmol), 3-Azido-1-propanamine (25 mg, 0.25 mmol), and DIPEA (70 ul, 0.4 mmol). 
This was stirred for 24 h and purified by HPLC. Yield: 82 mg, 41%. TOF-HRMS (m/z) found (calcd.) 
for [C50H81N5O13S + H]+: 992.5634 (992.5630). 1H NMR (600 MHz, Chloroform-d) δ 6.09 (s, 1H), 5.37 
(s, 1H), 5.14 - 4.95 (m, 2H), 4.63 (m, 1H), 4.44 (d, J = 13.7 Hz, 1H), 3.94 (d, J = 10.3 Hz, 1H), 3.70 (d, 
J = 9.6 Hz, 1H), 3.65 - 3.54 (m, 1H), 3.46 - 3.25 (m, 17H), 3.07 - 2.97 (m, 2H), 2.86 - 2.73 (m, 3H), 
2.54 (dt, J = 12.5, 7.0 Hz, 3H), 2.49 - 2.22 (m, 7H), 2.22 - 1.85 (m, 11H), 1.85 - 1.74 (m, 6H), 1.74 - 
1.23 (m, 20H), 1.16 - 0.81 (m, 13H). (3) Compound 1 (200 mg, 0.27 mmol), 11-Azido-3,6,9-
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trioxaundecan-1-amine (51 ul, 0.26 mmol), EDCI-HCl (53 mg, 0.28 mmol), DIPEA (0.094 ml, 0.54 
mmol), and HOAT (51 mg, 0.33 mmol) were stirred in 2 ml DCM for 24 h. The product was purified by 
HPLC. Yield: 143 mg, 48%. TOF-HRMS (m/z) found (calcd.) for [C55H91N5O16S + H]+: 1110.6260 
(1110.6260). 1H NMR (600 MHz, Chloroform-d) δ 6.43 (d, J = 15.8 Hz, 1H), 5.36 (s, 1H), 5.26 - 4.91 
(m, 3H), 4.61 (s, 1H), 4.44 (d, J = 13.8 Hz, 1H), 4.04 - 3.84 (m, 1H), 3.71 - 3.57 (m, 12H), 3.48 - 3.29 
(m, 14H), 3.02 (d, J = 11.7 Hz, 2H), 2.81 (t, J = 7.3 Hz, 2H), 2.75 (d, J = 15.9 Hz, 1H), 2.54 (s, 2H), 





Supplemental Figure 6. Synthesis of compounds 4, CEM23, CEM42. (4) N1-(3-Ethynylphenyl)-N8-
hydroxyoctanediamide: Methyl 8-((3-ethynylphenyl)amino)-8-oxooctanoate2 (250 mg, 0.87 mmol) was 
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dissolved in 3 ml of MeOH and 3 ml of THF, then treated with KOH (97 mg, 1.74 mmol, dissolved in a 
minimal amount of water) and NH2OH (50% aqueous solution, 0.57 ml, 8.7 mmol), and stirred 24 h. 
The reaction was neutralized with 1M HCl and the product was extracted with DCM. Purification by 
HPLC gave the product. Yield: 43 mg, 17%. TOF-HRMS (m/z) found (calcd.) for  [C16H20N2O3 + H]+: 
289.1655 (289.1552). 1H NMR (600 MHz, DMSO-d6) δ 10.34 (s, 1H), 9.98 (s, 1H), 8.67 (s, 1H), 7.79 
(s, 1H), 7.55 (d, J = 8.2 Hz, 1H), 7.30 (t, J = 7.9 Hz, 1H), 7.13 (d, J = 7.6 Hz, 1H), 4.17 (s, 1H), 2.29 (t, 
J = 7.5 Hz, 2H), 1.94 (t, J = 7.4 Hz, 2H), 1.57 (t, J = 7.4 Hz, 2H), 1.52 - 1.45 (m, 2H), 1.27 (s, 4H). 13C 
NMR (151 MHz, DMSO-d6) δ 171.93, 169.49, 139.92, 129.56, 126.58, 122.34, 122.20, 119.97, 83.84, 
80.89, 40.44, 36.78, 32.64, 28.80, 25.43, 25.33. General procedure for click reactions with 
FK506-azides: The azide (1 equiv, 0.02 mmol) and the alkyne (1 equiv) were dissolved in 1 ml 
tBuOH. This was treated sequentially with TBTA (2 mg), copper sulfate pentahydrate (0.05 equiv of a 
0.1M solution in water), and sodium ascorbate (0.2 equiv of a 0.1M solution in water). The reaction 
was stirred for 24 h then purified by HPLC. (CEM23) The product was prepared from 10 and 3 by the 
general procedure for click reactions. Yield: 13 mg, 56%. TOF-HRMS (m/z) found (calcd.) for  
[C66H101N7O16S + H]+: 1280.7011 (1280.7104). 1H NMR (600 MHz, Methanol-d4) δ 8.36 (s, 1H), 8.03 
(s, 1H), 7.58 (dd, J = 16.2, 7.9 Hz, 2H), 7.40 (t, J = 7.9 Hz, 1H), 5.29 - 5.09 (m, 2H), 4.54 (m, 2H), 
4.36 (d, J = 13.5 Hz, 1H), 3.97 (m, 1H), 3.79  - 3.68 (m, 1H), 3.63 (m, 3H), 3.50 - 3.39 (m, 6H), 3.36 
(m, 3H), 3.02 (m, 2H), 2.89 - 2.65 (m, 4H), 2.55 (m, 2H), 2.52 - 2.25 (m, 7H), 2.25 - 1.98 (m, 10H), 
1.94 (m, 3H), 1.88 - 1.71 (m, 9H), 1.71 - 1.18 (m, 23H), 1.18 - 1.06 (m, 1H), 1.06 - 0.80 (m, 10H). 
HPLC Purity: >95%, tR = 4.78 min. (CEM42) The product was prepared from 4 and 3 by the general 
procedure for click reactions. Yield: 13 mg, 56%. TOF-HRMS (m/z) found (calcd.) for  [C71H111N7O19S 
+ H]+: 1398.7731 (1398.7734). 1H NMR (600 MHz, Methanol-d4) δ 8.37 (s, 1H), 8.06 (s, 1H), 7.57 (d, 
J = 7.8 Hz, 2H), 7.41 (t, J = 7.9 Hz, 1H), 5.27 - 5.19 (m, 2H), 4.69 - 4.61 (m, 2H), 3.97 (t, J = 5.0 Hz, 
2H), 3.78 - 3.71 (m, 1H), 3.69 - 3.51 (m, 9H), 3.49 - 3.39 (m, 7H), 3.39 - 3.34 (m, overlaps with 
solvent), 3.04 (s, 1H), 2.73 (t, J = 7.2 Hz, 2H), 2.55 - 2.25 (m, 9H), 2.23 - 1.86 (m, 10H), 1.82 - 1.03 







Supplemental Figure 7. Synthesis of compounds 5, 6, CEM36. (5) Methyl 6-(4-
ethynylbenzamido)hexanoate: 4-Ethynylbenzoic acid (500 mg, 3.42 mmol), methyl 6-aminohexanoate 
HCl salt (743 mg, 4.11 mmol), EDCI-HCl (795 mg, 5.13 mmol), HOAT (697 mg, 5.13 mmol), and 
DIPEA (1.49 ml, 8.55 mmol) were stirred in 12 ml of a 1:3 mixture of DMF: DCM. Aqueous workup 
followed by silica gel purification (20 to 100% gradient of EtOAc in hexane) gave the product. Yield: 
487 mg, 52%. TOF-HRMS (m/z) found (calcd.) for [C16H19NO3 + H]+: 274.2439 (274.1443). 1H NMR 
(600 MHz, Chloroform-d) δ 7.75 (d, J = 8.0 Hz, 2H), 7.57 (d, J = 8.0 Hz, 2H), 6.24 (s, 1H), 3.69 (s, 
3H), 3.49 (q, J = 6.7 Hz, 2H), 3.21 (s, 1H), 2.36 (t, J = 7.3 Hz, 2H), 1.71 - 1.65 (m, 4H), 1.44 (t, J = 7.8 
Hz, 2H). (6) N-(6-((2-Aminophenyl)amino)-6-oxohexyl)-4-ethynylbenzamide: Compound 4 (340 mg, 
1.25 mmol) was dissolved in THF (20 ml). To this was added aqueous LiOH (355 mg LiOH dissolved 
in 20 ml H2O), and the mixture was stirred 24 h. The mixture was acidified with 2N HCl and the 
product was extracted with EtOAc. The EtOAc extracts were concentrated to give 6-(4-
ethynylbenzamido)hexanoic acid. Yield: 93%, 301 mg. TOF-HRMS (m/z) found (calcd.) for 
C15H17NO3 (M): [M+H]+, 260.1286 (260.1287). 6-(4-ethynylbenzamido)hexanoic acid (100 mg, 0.38 
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mmol), o-phenylenediamine (206 mg, 1.90 mmol), EDCI (66 mg, 0.42 mmol), and HOAT (58 mg, 0.42 
mmol) were stirred in 8 ml of a 1:3 mixture of DMF:DCM for 24 h. The reaction was taken up in sat. 
aq. NaHCO3 and the product was extracted with EtOAc. The product was purified by silica gel 
chromatography (eluting first with a gradient of 50 to 100% EtOAc in hexane, followed by 0 to 20% 
MeOH in DCM). Yield: 50 mg, 38% for final step. TOF-HRMS (m/z) found (calcd.) for  [C21H23N3O2 + 
H]+: 350.1954 (350.1869). 1H NMR (600 MHz, Chloroform-d) δ 7.74 (d, J = 8.4 , 2H), 7.47 (m, 2H), 
7.21 (d, 1H), 7.04 (q, J = 8.0 Hz, 1H), 6.88 - 6.77 (m, 2H), 3.50 - 3.44 (m, 2H), 3.20 (s, 1H), 2.45 (t, J 
= 7.1 Hz, 2H), 1.78 (p, J = 7.2 Hz, 2H), 1.66 (m, 2H), 1.48 (m, J = 7.8 Hz, 2H). 13C NMR (151 MHz, 
DMSO-d6) δ 171.49, 165.64, 142.31, 135.15, 132.01, 127.84, 126.10, 125.71, 124.62, 123.94, 
116.55, 116.27, 83.33, 83.13, 40.45, 36.12, 29.30, 26.59, 25.49. (CEM36) The product was prepared 
from 2 and 5 by the general procedure for click reactions, except that the product was purified by 
silica gel chromatography (gradient of 0 to 20% MeOH in DCM) rather than by HPLC. Exposure to 
acid used in HPLC buffer causes the product to decompose. Yield: 41 mg, 78%. TOF-HRMS (m/z) 
found (calcd.) for [C76H114N8O18S + H]+: 1459.8060 (1459.8050). HPLC Purity: >95%, tR = 4.88 min. 
1H NMR (600 MHz, Methanol-d4) δ 8.51 - 8.46 (m, 1H), 7.93 (q, J = 8.0 Hz, 4H), 7.11 - 7.06 (m, 1H), 
7.05 - 7.00 (m, 1H), 6.85 (s, 1H), 6.73 - 6.67 (m, 1H), 5.22 (s, 2H), 4.65 (dd, J = 26.9, 5.5 Hz, 3H), 
4.36 (d, J = 13.7 Hz, 1H), 4.00 - 3.94 (m, 3H), 3.68 - 3.50 (m, 13H), 3.48 - 3.28 (m, n.d.), 3.02 (d, J = 
17.0 Hz, 2H), 2.72 (t, J = 7.2 Hz, 3H), 2.47 (ddd, J = 28.7, 14.1, 6.8 Hz, 7H), 2.41 - 1.89 (m, 13H), 








Supplemental Figure 8. 1H NMR spectra of CEM23.
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CHAPTER 3: REPRESSING GENE TRANSCRIPTION BY REDIRECTING CELLULAR 
MACHINERY WITH CHEMICAL EPIGENETIC MODIFIERS2 
 
Introduction: 
Chromatin consists of DNA wrapped around histone octamer proteins that form the core 
nucleosome particle. Regulation of chromatin compaction is an essential mechanism for proper DNA 
repair, replication, and expression1,2,3. One way in which cells control the level of compaction is through 
the addition or removal of various post-translational histone tail modifications. Two such modifications 
include (1) lysine acetylation, which is most commonly associated with gene activation, and (2) lysine 
methylation, which can be associated with either gene activation or repression, depending on the amino 
acid context. The addition of the acetylation and methylation marks is catalyzed by histone 
acetyltransferases (HATs) and histone methyltransferases (HMTs), respectively, whereas the removal 
of the mark is done by histone deacetylases (HDACs) and histone demethylases (HDMs), 
respectively4,5. Although the existence of these proteins has been known for decades, many 
mechanisms of how chromatin-modifying machinery works to properly regulate gene expression remain 
to be defined. Since chromatin regulatory processes are dysregulated in many human diseases, new 
mechanistic insights could lead to future therapeutic applications. 
 
The chromatin in vivo assay (CiA) is a recently described technique that uses a chemical 
inducer of proximity (CIP) to control chromatin- modifying machinery recruitment to a specific locus6. 
This technology has been used to study an expanding list of chromatin dynamics, including histone-
modifying proteins, chromatin remodelers, and transcription factors6,7,8,9. CIP-based chromatin 
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tethering of exogenously expressed proteins has also been extended past CiA to modulate non-
modified genetic loci by use with a deactivated Clustered Regularly Interspaced Short Palindromic 
Repeats (CRISPR)-associated protein (dCas9)10,11. In the CiA system, mESCs have been modified to 
express a GFP reporter gene at the Oct4 locus, a highly expressed and strictly regulated area of the 
mESC genome. Previously, this system has been applied to describe the dose-dependent and 
reversible recruitment of exogenously expressed heterochromatin protein 1 (HP1), an enzyme that 
binds H3K9me3 and propagates repressive marks (e.g., H3K9me3) and DNA methylation6. To 
accomplish this type of recruitment strategy, the mESCs are infected with a plasmid that expresses an 
FK506-binding protein (FKBP) linked to a Gal4, which is a DNA-protein anchor that binds to a Gal4-
binding array upstream of the GFP reporter. The cells are also infected with an FKBP-rapamycin-
binding domain (FRB) connected to HP1. When the mESCs are exposed to low nanomolar 
concentrations of the CIP, rapamycin, both FRB and FKBP, are brought together at the target locus. 
Within days of rapamycin treatment, expression of the target gene is repressed, as evidenced by 
fluorescence microscopy and flow cytometry, and histone acetylation is decreased, shown by ChIP and 
bisulfite sequencing. While the development and validation of this approach have been significant 
advances in the field of chromatin research and regulation, one drawback is the required exogenous 
expression of chromatin- modifying machinery. 
 
To make the technology based on recruitment of only endogenous physiologically-relevant 
enzymes and make a more modular system, we designed and characterized novel bifunctional 
molecules, termed CEMs (Figure 1)12. One component of the CEMs includes FK506 which, similar to 
rapamycin, binds tightly and specifically to FKBP. Thus, the CEMs will still be recruited to the Oct4 
locus in the CiA mESCs. The other component of the CEMs is a moiety that binds endogenous 
chromatin-modifying machinery. In a pilot study, we tested CEMs that contain HDAC inhibitors. While 
the concept of using an inhibitor to recruit HDACs seems counter-intuitive, the inhibitor is nonetheless 
able to recruit HDAC activity to the gene of interest. This is accomplished by (1) redirecting the HDAC 
to the locus, releasing the enzyme, and increasing the density of un-inhibited HDACs in the area and 
(2) maintaining HDAC inhibition at the locus, but recruiting repressive complexes that bind to the 
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inhibited HDACs, or (3) a combination of both. In a previous study, we showed that the CEMs were 
able to successfully repress the GFP reporter in a dose- and time-dependent manner, as well as in a 
manner that was rapidly reversible (i.e., within 24 hours)12. We characterized the ability of the CEM 
technology presented here to control gene expression using fluorescence microscopy, flow cytometry, 
and the ability to control the chromatin environment using ChIP-qPCR6. Here, we describe a method 
for using and characterizing the CEMs, which will facilitate the adaptation of this system to answer 
additional questions related to chromatin biology. 
 
Protocol:  
1) Cell Line Culture for Producing Lentivirus 
 
1. Grow fresh, low-passage (less than passage 30) 293T human embryonic kidney (HEK) cells 
in high-glucose Dulbecco's modified Eagle's medium (DMEM) base media supplemented with 
10% fetal bovine serum (FBS), 10 mM HEPES, 1x non-essential amino acids (NEAA), Pen/ 
Strep, 2-mercaptoenthanol in a 37 °C incubator with 5% CO2. Split the cells every 3 - 5 d and 
before they become > 95% confluent. 
 
2. Passage 293T HEK cells with 18 x 106 per 15-cm plate (one 15-cm plate for each virus 
produced). 
 
1. For a 15-cm format, aspirate the old media, add 10 mL of 1x phosphate-buffered 
saline (PBS), aspirate the PBS, and add 3 mL of 0.05% trypsin. Incubate the cells in 
trypsin for 8 min at 37 °C, rocking and tapping the cells halfway through the incubation. 
  
NOTE: The goal of this step is to get the cells into a single-cell suspension. 
 
3. When the cells have reached 60% - 80% confluency the following day, perform a 
polyethylenimine (PEI) transfection with 13.5 µg of the psPAX2 plasmid, 4.5 µg of the pMD2.G 
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plasmid, 18 µg of lentiviral-compatible delivery vector with the gene of interest (i.e., FKBP-
Gal4), 108 µL of PEI, and 1.8 mL of transfection media. 
 
1. Gently mix the DNA, PEI, and transfection media in a 15-mL conical tube, incubate 
the sample at room temperature for 15 min, and add it dropwise to the 15-cm plate. 
 
NOTE: Please use appropriate safety measures and follow all institutional and 
laboratory safety procedures after this step, as all reagents will contain a live virus. 
 
4. After 16 h of transfection and incubation in a 37 °C incubator with 5% CO2, aspirate the 
media and gently add fresh 293 HEK media (prewarmed in a 37 °C water bath) to the 15-cm 
plates. Incubate the cells in a 37 °C incubator with 5% CO2 for 48 h after the media change. 
The virus is then ready to be harvested. 
 
2) Infection of Mouse Embryonic Stem Cells (mESC) with Lentivirus 
 
1. Grow low-passage (less than passage 35), feeder-free adapted CiA mESCs in high-glucose 
DMEM base media supplemented with 20% ESC-grade FBS, 10 mM HEPES, 1x NEAA, 
Pen/Strep, 2-mercaptoenthanol, and 1:500 leukemia inhibitor factor (LIF) in a 37 °C incubator 
with 5% CO2. 
 
NOTE: The LIF is obtained from the supernatant of COS LIF-producing cells, which are 
collected in batch and frozen at -80 °C. 
 
1. Grow cells on plates that have been preincubated for 1 - 3 h with 0.1% gelatin in 1x 
PBS, and subsequently washed with 1x PBS. Feed the cells daily and split them every 
2 - 3 d, depending on their density. 
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NOTE: Morphologically, embryonic stem cell (ES) colonies should be small, round, and 
distinct from each other. 
 
2. Passage mESC into a 12-well plate format (100,000 cells/well) 1 d prior to infection. 
 
1. Count the cells with a hemocytometer. For cells grown in a 10-cm format, aspirate 
the old media, add 5 mL of 1x PBS, aspirate the PBS, and add 1 mL of 0.25% trypsin. 
Incubate the cells in trypsin for 8 min at 37 °C, rocking and tapping the cells halfway 
through the incubation. The goal of this step is to get the cells into a single-cell 
suspension. 
 
3. 48 h after changing the media from the 293T15-cm viral packaging cells from step 1.4, 
remove and transfer the supernatant to a 50-mL conical tube. 
 
4. Centrifuge the supernatant at 300 x g for 5 min to pellet cell debris. 
 
5. Filter the supernatant through a 0.45-µm membrane. 
 
NOTE: Make sure to use surfactant-free cellulose acetate (SFCA) membranes, as some other 
materials can retain virus and significantly reduce yields. 
 
6. Concentrate the virus with ultracentrifugation, using a centrifuge with an SW32 rotor, and 
spin it at 20,000 rpm (~72,000 x g) for 2.5 h at 4 °C. 
 
7. While the virus concentrates under ultracentrifugation, treat the CiA mESCs in the 12-well 
plate with fresh ES media containing 5 µg/mL of polybrene. 
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8. When the virus concentration has finished, carefully aspirate the supernatant and suspend 
the virus pellet in 100 µL of 1x PBS (avoid excess bubbles). 
 
9. Add the virus and 1x PBS to a 1.5-mL microfuge tube. Vortex/shake the tube at 300 x g (or 
at the lowest setting) to fully suspend the virus. Spin down the tube in a mini-tabletop centrifuge 
for 5 - 10 s to remove bubbles. 
 
10. Add 30 µL of the virus to each well of a 12-well plate. Swirl the plate and then centrifuge 
the plate at 1,000 x g for 20 min.  
 
NOTE: The amount of virus added can be varied depending on the viral titer, which is inversely 
related to delivery construct size. 
 
1. Alternatively, flash freeze the virus with liquid nitrogen and store it at -80 °C. 
However, freezing the virus will lower the viral titer. 
 
11. Place the 12-well plate back in the 37 °C incubator and change the media the following 
morning (~16 h later) with fresh ES media (as described in step 2.1). 
 
12. After 48 h of infection, select for cells that integrated the viral plasmid by adding the 
appropriate antibiotic (i.e., 1.5 µg/mL of puromycin, 10 µg/mL of blasticidin, etc.). Change the 
media daily and wash the cells with 1x PBS if a majority of the cells are floating/dead. Keep the 
selection media on the cells for 72 - 96 h in a 37 °C incubator with 5% CO2. 
 
3) Chemical Epigenetic Modifiers (CEM)s Preparation and Treatment 
 
1. Suspend the powdered CEM into dimethyl sulfoxide (DMSO) to a stock concentration of 1 
mM and a working concentration of 100 µM. 
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2. After the cells have undergone the selection for 72 - 96 h, split the mESCs into a 12-well 
format with 100,000 cells/well. Incubate the cells in a 37 °C incubator with 5% CO2 for 24 h. 
Afterward, prepare a media solution of 100 nM CEM with ES media. Use this media to feed the 
CiA mESC with 1 mL/well. To serve as a control, keep a well of cells without any added CEMs. 
 
1. Change the media by aspirating old media and adding 1 mL/well of freshly prepared 
CEM-containing or CEM-free ES media every 24 h for the duration of an experiment. 
 
4) Analysis of the Expression by Microscopy and Flow Cytometry 
 
1. After 48 hours of CEM treatment, image the cells without CEM treatment and the cells treated 
with 100 nM CEM using a fluorescence microscope. Take representative images using phase 
or brightfield to record the mESC morphology at 20X magnification; the cells should have 
formed round colonies, with a few differentiated cells. Under the FITC fluorescence channel, 
image both cell conditions. 
 
2. Isolate the control and CEM-treated cells for flow cytometry by aspirating the media, washing 
the cells with 1 mL of 1x PBS, aspirating the PBS, and adding 0.25 mL of 0.25% trypsin with 
EDTA for 8 - 10 min. 
 
3. Confirm that the cells are no longer in large clumps by looking in the microscope. Use a 20X 
magnification. If the cells do not appear to be in a single-cell suspension, gently pipette up and 
down with a P1000 pipette to fully trypsinize the cells. 
 
4. Quench the trypsin with 1 mL of fresh media and resuspend the cells at high speed with a 




5. Spin down the cells at 300 x g for 5 min. Aspirate the supernatant. Wash with 1x PBS and 
recentrifuge the cells. Aspirate the PBS supernatant. 
 
6. Resuspend the cell pellet in 200 mL of FACS buffer (1 mM ethylenediaminetetraacetic acid 
[EDTA], 1x PBS, and 0.2% bovine serum albumin [BSA]). 
 
1. The total volume of FACS buffer will be dependent on how many cells are present, 
but the concentration should be 1,000 - 3,000 cells/ µL. Count the number of cells in 3 
samples and average the concentration of cells. Add more FACS buffer if needed. 
 
7. Perform flow cytometry on > 50,000 cells with the suspended cells, keeping the cells on ice 
when they are not being analyzed. Use a 530/40 filter (FITC, AF488, GFP, etc.) for recording 
the changes in expression. Determine the appropriate fluorescent voltage using an untreated 
control cell sample and set the voltage to have the fluorescent peak be in the middle of the 
recorded intensity spectrum. Run the samples at a sheath speed of around 5,000 cells/s. 
 
8. Export the data and analyze the FCS files on a flow cytometry program (i.e., FlowJo) by 
gating first on forward scatter vs. side scatter for live cells and then on forward scatter height 
vs. area for singlets. Then, visualize GFP channel data on a histogram to determine the relative 
GFP expression in the targeted and control populations. 
 
5) Analysis of Chromatin by Chromatin Immunoprecipitation (ChIP) Followed by qPCR 
 
1. Split the mESCs into a 10-cm plate with 3 million cells and 10 mL of ES media (one 10-cm 
plate for each experimental or control condition). The following day, add 10 mL of CEM-
containing or CEM-free media. After 48 hours of CEM treatment, aspirate the old media. Wash 
and aspirate the cells with 5 mL of 1x PBS. Next, dissociate the cells with 0.25% trypsin, and 
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quench the trypsin with 10 mL of ES media. Count and isolate a sample of 10 million cells per 
condition. 
 
2. Spin down each of the 10 million cell samples at 300 x g for 5 min. 
 
3. Resuspend each pellet in 10 mL of 1x PBS and recentrifuge the cells at 300 x g for 5 min. 
 
4. Resuspend each pellet in 10 mL of CiA Fix buffer (50 mM pH 8, 1 mM EDTA pH 8, 0.5 mM 
ethylene glycol-bis[ß-aminoethyl ether]-N,N,N',N'- tetraacetic acid [EGTA] pH 8, and 100 mM 
sodium chloride [NaCl]). Add 1 mL of 11% formaldehyde solution and immediately invert the 
samples 5x - 10x. Incubate the sample at room temperature for 10 min. 
 
5. Add 0.5 mL of 2.5 M glycine. Invert the samples immediately and incubate the sample on 
ice for 5 min. 
 
6. Centrifuge the sample at 1,200 x g for 5 min at 4 °C. Aspirate the supernatant. 
 
7. Resuspend the pellet in 10 mL of CiA Rinse 1 (50 mM HEPES pH 8, 140 mM NaCl, 1 mM 
EDTA pH 8, 10% glycerol, 0.5% Nonidet P-40 [NP40], and 0.25% Triton X100). Incubate the 
sample on ice for 10 min. Centrifuge it at 1,200 x g for 5 min at 4 °C. 
 
8. Resuspend the pellet in 10 mL of CiA Rinse 2 (10 mM tris[hydroxymethyl]aminomethane 
[Tris] pH 8, 1 mM EDTA pH 8, 0.5 mM EGTA pH 8, and 200 mM NaCl). Centrifuge the sample 
at 1,200 x g for 5 min at 4 °C. 
 
9. Gently add 5 mL of CiA shearing buffer (0.1% SDS, 1 mM EDTA, and 10 mM Tris pH 8) 
along the sides of the conical tube to wash off any salt without disrupting the pellet. Centrifuge 
the sample at 1,200 x g for 3 min at 4 °C. Repeat the wash step. 
	 96 
 
10. Resuspend the pellet in 90 µL of CiA shearing buffer and fresh protease inhibitors (use a 
mixture of leupeptin, chymostatin, and pepstatin A dissolved together at 10mg/mL each in 
DMSO to make a 1,000x stock solution, making a final concentration of 10 µg/mL). Add 10 µL 
of sonication-enhancing nanodroplets while keeping everything on ice13,14. 
 
11. Transfer 100 µL of the solution to a glass tube and cap the tube. 
 
12. Sonicate the samples for 3.5 min (determined based on the cell line and number of cells). 
To avoid overheating the samples, process the samples in 2-min-maximum cycle times if the 
total sonication time exceeds 2 min. 
 
Note: The focused ultrasonicator used here functions at a high frequency (500 kHz). Run the 
machine at an acoustic power of 55 W. The sonication duration should be predetermined by 
each individual lab. 
 
13. Transfer each sonicated chromatin sample to a new 1.5-mL microcentrifuge tube. Spin the 
tubes at 8,000 x g for 2 min at 4 °C. 
 
14. To analyze the shearing efficiency and to quantify the relative amount of chromatin, follow 
the ChIP kit manufacturer's protocol. 
 
NOTE: Determine the DNA concentration spectrophotometrically (e.g., using a DNA nanodrop 
instrument), and run ~200 ng of DNA on a 1% agarose gel to verify that the chromatin is 
sonicated to roughly 200 - 500 basepairs (bp) in size. 
 




NOTE: For the immunoprecipitation of samples with higher DNA concentrations, warm the 
elution buffer at 37 °C and elute the samples 2x with 30 µL of elution buffer (spinning for 1 min 
each time). 
 
16. To perform qPCR, load the reagents into a 384-well plate. Add 5 µL of 2x asymmetrical 
cyanine dye master mix, 2.5 µM of each primer, water, and 0.1 - 10 ng of DNA for each reaction. 
 
1. Design primers to amplify 50 - 100 bp amplicons, and CT values are normalized to 
a house-keeping gene, intracisternal A-type particles (IAP). 
 
NOTE: For further qPCR methods, see the kit manufacturer's protocol. The primer set 
used to target the Oct4 locus was: 
(F) CACATGAAGCAGCACGACTT; (R) CCTTGAAGAAGATGGTGCGC. The control 
primer set used to target IAP was: (F) ATTTCGCCTAGGACGTGTCA; (R) 
ACTCCATGTGCTCTGCCTTC. 
 
2. Based on the primers and the desired product, run the qPCR with 40 cycles of an 
annealing temperature of 60 °C for 1 min. 
 
NOTE: The resulting data was quantitated using the delta-delta Ct comparisons 
between samples, with CiA:Oct4 normalized over IAP. The final analysis results are 
displayed as averages of triplicate experimental samples, with the error represented 
as the standard deviation from the mean. 
  
17. Gently add 5 mL of CiA shearing buffer (0.1% SDS, 1 mM EDTA, and 10 mM Tris pH 8) 
along the sides of the conical tube to wash off any salt without disrupting the pellet. Centrifuge 
the sample at 1,200 x g for 3 min at 4 °C. Repeat the wash step. 
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18. Resuspend the pellet in 90 µL of CiA shearing buffer and fresh protease inhibitors (use a 
mixture of leupeptin, chymostatin, and pepstatin A dissolved together at 10mg/mL each in 
DMSO to make a 1,000x stock solution, making a final concentration of 10 µg/mL). Add 10 µL 
of sonication-enhancing nanodroplets while keeping everything on ice13,14. 
 
19. Transfer 100 µL of the solution to a glass tube and cap the tube. 
 
20. Sonicate the samples for 3.5 min (determined based on the cell line and number of cells). 
To avoid overheating the samples, process the samples in 2-min-maximum cycle times if the 
total sonication time exceeds 2 min. 
 
Note: The focused ultrasonicator used here functions at a high frequency (500 kHz). Run the 
machine at an acoustic power of 55 W. The sonication duration should be predetermined by 
each individual lab. 
 
21. Transfer each sonicated chromatin sample to a new 1.5-mL microcentrifuge tube. Spin the 
tubes at 8,000 x g for 2 min at 4 °C. 
 
22. To analyze the shearing efficiency and to quantify the relative amount of chromatin, follow 
the ChIP kit manufacturer's protocol. 
 
NOTE: Determine the DNA concentration spectrophotometrically (e.g., using a DNA nanodrop 
instrument), and run ~200 ng of DNA on a 1% agarose gel to verify that the chromatin is 
sonicated to roughly 200 - 500 basepairs (bp) in size. 
 




NOTE: For the immunoprecipitation of samples with higher DNA concentrations, warm the 
elution buffer at 37 °C and elute the samples 2x with 30 µL of elution buffer (spinning for 1 min 
each time). 
 
24. To perform qPCR, load the reagents into a 384-well plate. Add 5 µL of 2x asymmetrical 
cyanine dye master mix, 2.5 µM of each primer, water, and 0.1 - 10 ng of DNA for each reaction. 
 
1. Design primers to amplify 50 - 100 bp amplicons, and CT values are normalized to 
a house-keeping gene, intracisternal A-type particles (IAP). 
 
NOTE: For further qPCR methods, see the kit manufacturer's protocol. The primer set 
used to target the Oct4 locus was: 
(F) CACATGAAGCAGCACGACTT; (R) CCTTGAAGAAGATGGTGCGC. The control 
primer set used to target IAP was: (F) ATTTCGCCTAGGACGTGTCA; (R) 
ACTCCATGTGCTCTGCCTTC. 
 
2. Based on the primers and the desired product, run the qPCR with 40 cycles of an 
annealing temperature of 60 °C for 1 min. 
 
NOTE: The resulting data was quantitated using the delta-delta Ct comparisons 
between samples, with CiA:Oct4 normalized over IAP. The final analysis results are 
displayed as averages of triplicate experimental samples, with the error represented 
as the standard deviation from the mean. 
 
Representative Results:  
We recently developed CEMs and demonstrated that this technology can be applied to regulate gene 
expression and the chromatin environment at a reporter locus in a dose-dependent and reversible 
	 100 
manner. In Figure 1, a model of the lead CEM, CEM23, is shown. HDAC machinery is recruited to the 
reporter locus by the HDAC inhibitor which, in this case, is the GFP reporter inserted at the Oct4 locus. 
 
We sought to characterize the CEM system at the Oct4 locus in CiA mESCs. Because the cells express 
GFP, it was possible to quickly visualize the expression of the reporter with fluorescence microscopy. 
The cells were imaged after 48 hours of treatment with 100 nM of CEM23, along with untreated cells. 
The phase images show healthy mESCs, which is important because unhealthy or differentiated 
mESCs would indicate a non-specific GFP repression. The fluorescence images show a bright GFP 
expression in the control cells and a reduced GFP expression in mESCs treated with CEM23. 
Representative images are displayed in Figure 2. 
 
To quantify the changes in the GFP expression, flow cytometry was used. Again, the CiA mESCs were 
treated with 100 nM of CEM23 for 48 hours. Experimental cells treated with CEM23 and control cells 
were prepared for flow cytometry, using > 100,000 cells per sample. Consistently, we observed a > 
30% decrease in GFP-expressing cells among those treated with CEMs. A representative histogram is 
shown in Figure 3. 
 
Once evidence of CEM-induced GFP gene expression decrease was shown, we tested for changes in 
the chromatin environment using ChIP. One important factor for preparing samples for ChIP is the 
extent of chromatin sonication. To have the samples as consistent and properly sheared as possible, 
10 million cells were sonicated for 3.5 minutes to obtain chromatin between 200 and 500 bp in size 
(Figure 4). Because we hypothesized that the repressive CEMs were binding to and recruiting HDAC 
proteins and repressive complexes to the reporter, we tested for changes in histone tail acetylation. 
Histone 3 Lysine 27 acetylation (H3K27ac) is commonly found along the transcriptional start site (TSS) 
of genes. We performed ChIP with an antibody for H3K27ac and then performed a qPCR with primer 
sets upstream and downstream of the TSS. The results show that a 48-hour treatment with 100 nM of 
CEM23 decreased the level of H3K27ac at the target locus when compared to control cells not treated 




Here, we described the recently developed CEM system being applied to regulate gene expression 
and chromatin environment at a specific gene in a dose-dependent manner. We provide an accurate 
method to study the dynamics involved in regulating gene expression through the selective recruitment 
of specific endogenous chromatin regulatory proteins. This is a highly modular technology that can be 
applied to investigate how different protein- and chromatin-modifying complexes work in concert to 
properly regulate the chromatin environment, as well as to study how these processes are 
dysregulated, with the benefit of achieving gene specificity. 
 
Here, three ways were demonstrated to visualize changes in the chromatin structure and gene 
expression with new technology. After perturbation of specific targeted loci with CEMs, real-time 
changes to gene expression could be analyzed by fluorescence microscopy. Then, changes in gene 
expression levels could be measured more quantitatively with flow cytometry at defined endpoints. 
Finally, changes to posttranslational epigenetic marks on chromatin were examined by ChIP; 
specifically, in this case, H3K27ac. We did not test HDAC recruitment with ChIP-qPCR because of the 
diversity of HDACs that act in concert at a single locus. It is likely that a heterogenous population of 
HDAC enzymes was recruited and it would, therefore, be technically difficult to test them all by ChIP. 
In a previously published work, we have demonstrated that the direct recruitment of HDAC3 by a GAL4 
fusion caused similar activity on gene expression and chromatin modification by ChIP12. If a non-
fluorescent reporter is being modulated, changes in gene expression can also be measured by (1) an 
RNA expression analysis with reverse transcriptase qPCR or (2) protein expression with western 
blotting, or imaging and conducting flow cytometry with fluorescent secondary antibodies. 
 
In relation to current CIP-based techniques like the CiA system12, this CEM technology has the 
advantage of recruiting endogenous epigenetic modulators to the target gene. Redirecting the cell's 
own machinery creates a more physiologically relevant means of modulating expression. Exogenously 
	 102 
expressing master enzymes, like HATs and transcription factors, might result in side effects from their 
increased expression, especially while not being actively recruited to the gene locus. 
 
While this article shows the functionality of this novel system with CEMs composed of HDAC inhibitors, 
several other inhibitors or protein recruiters can be synthesized in place of the HDAC inhibitor. To 
achieve gene activation, HAT inhibitor- or HDMT inhibitor-based CEMs can be synthesized. To repress 
and then overexpress the same gene, it is possible to treat the cells with a repressive CEM, wash them 
with regular media, and then add an activating CEM. This would allow for a clean system to study the 
dynamics of recruiting repressive and activating complexes to the same genomic region. When 
designing future CEMs, several characteristics need to be considered, including cell permeability, 
inhibitor potency, structure, and inhibitory kinetics. The linker length between FK506 and the recruiter 
moiety will influence the permeability of the CEMs, as well as the position of the recruited protein. When 
comparing two CEMs that differed only in linker length, the CEM with the shorter linker was more 
effective12. While it has not been tested directly here, the higher effectiveness is a result of greater cell 
permeability. Choosing inhibitors with chemical structures amenable to modification without disrupting 
the portion that binds the active site of the target is also important. 
 
The potency and specificity were also considered by selecting inhibitors with a high potency and 
specificity for a given class of proteins. The kinetics of inhibition may influence the effectiveness of the 
CEMs. CEMs comprised of inhibitors with slow on-off rates tend to be less effective. 
 
One constraint of the current CEM technology is the requirement of a Gal4-binding array at the target 
gene locus. To recruit CEMs to a region other than the Oct4 CiA locus, any of the hundreds of 
engineered Gal4 upstream activation sequence (UAS) lines available to the scientific community can 
be used. One way the system will be made more modular is by incorporating a deactivated Cas9 
(dCas9) with chemical epigenetic enzyme recruitment10,11,15. This nuclease-dead protein from the 
CRISPR-Cas9 system will still be recruited to any region of the genome to which a guide RNA (gRNA) 
is designed, but it will not cut the DNA. Using a dCas9-FKBP fusion, the FKBP component will recruit 
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the CEMs where the dCas9 is recruited, greatly increasing the ease and flexibility of potential target 
genes. Imagine using this technology to target disease-relevant genes as a potential therapeutic or a 
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Figure 1: CEMs bind to the CiA:Oct4 locus through recruitment to the FKBP and tether 
endogenous epigenetic machinery. The model of the CEM system shows Gal4-FKBP as the protein-
to-DNA anchor. The FK506 portion of the CEM binds to FKBP and the HDAC inhibitor recruits 




Figure 2: Fluorescence images of mouse embryonic stem cells (mESCs) with a CiA:Oct4-GFP 
reporter. Fluorescence microscopy images show a decrease in GFP expression upon CEM treatment. 
The top panel shows phase and fluorescent images of mESCs grown with untreated media. The bottom 
panel shows phase and fluorescent of the mESCs treated with 100 nM of CEM23 for 48 hours. The 





Figure 3: Flow cytometry analysis quantitates a decreased expression of GFP in mESCs upon 
CEM23 treatment. mESCs without CEM23 (blue) were compared with mESCs treated with 100 nM of 




Figure 4: Sonication of chromatin is uniform, and a smear is visible between 200 and 500 bp. To 
perform ChIP-qPCR, the chromatin from mESCs was sonicated. Each sample consisted of 
approximately 10 million cells, which were sonicated for 3.5 minutes, to produce similarly- sheared 




Figure 5: CEM23 treatment causes a decrease in H3K27ac at the CiA locus. ChIP-qPCR was 
performed to test for changes in the chromatin environment. After a 48-hour treatment with 100 nM of 
CEM23, a decrease in H3K27ac was observed at CiA:Oct4 (**p < 0.01, two-tailed Student's t-test with 
three biological replicates. The error bars represent the standard deviation). 
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CHAPTER 4: GENE SPECIFIC ACTIVATION DRIVEN BY SMALL MOLECULES 
   
Introduction:  
The eukaryotic genome is organized and packaged into chromatin with varying degrees of 
compaction, which contributes to the regulation of gene expression. A complex network of protein-
protein and DNA-protein interactions ensures the proper levels of gene expression. Disruptions to this 
regulatory network drives many human diseases including cancer1,2. An important contributing factor 
that sculpts the chromatin landscape is post-translational histone tail modifications. Lysine acetylation 
is one such modification that has both biophysical and indirect protein-recruitment effects. Protein 
families of writers (histone acetyl transferases, HATs), erasers (histone deacetylases, HDACs), and 
reader proteins control the deposition, removal, and down-stream gene expression changes associated 
with this mark3,4.  
Several labs have previously demonstrated the power of recruiting exogenous chromatin 
modifying machinery as a way to control expression levels in a gene-specific manner5–11. With major 
advances in the CRISPR associated protein 9 (Cas9) and deactivated Cas9 (dCas9) technology, the 
ability to precisely induce changes in expression has rapidly evolved. We were inspired by these studies 
and sought to incorporate recent advances in the fields of chemical biology to redirect endogenous 
chromatin modifying machinery in a dose-dependent and chemically-dependent manner.  
We previously demonstrated the power of Chemical Epigenetic Modifiers (CEM) and their 
ability to control the chromatin landscape and repress genes in a specific and reversible manner12. In 
this study, we report for the first time CEM activating (CEMa) molecules which recruit activating 
chromatin modifying machinery. Our CEMa family includes CEM87, CEM88, and CEM114 that bind to 
activating chromatin modifying enzymes with various binding efficiencies. The warhead portion of the 
CEM used to recruit chromatin modifying machinery was previously published inhibitors of HATs or 
lysine reader proteins (Figure 1A.) CEM87 was created with iBet762, shown to inhibit BRD2, BRD3, 
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 and BRD413 (Figure 1B, Supplementary Figure 1A, B). CEM88 was created with a 1,3-dimethyl 
benzimidazolone, previously shown to inhibit the BRPF1 bromodomain (Figure 1C, Supplementary 
Figure 1A, C)14. Lastly, CEM114 was created with “compound 33”, previously shown to inhibit CBP 
(Figure 1D, Supplementary Figure 1A, D)15. We retained the FKBP-interacting moiety (FK506) and the 
peg-linker in the bifunctional molecule, as they have functioned successfully in other previously 
synthesized CEMs to interact with the FK506 Binding Protein (FKBP). We also show for the first time 
the coupling of this new synthetic technique to be compatible with dCas9-FKBP-based systems, 
allowing us to direct the CEMs to virtually any gene of interest. By recruiting endogenous cellular 
machinery associated with euchromatin and increased gene expression, we hypothesized that the 
CEMs would increase transcriptional activity in a dose- and chemically-dependent manner.  
 
Results:  
To test for changes in gene expression, we transfected Human Embryonic Kidney (HEK) 293T 
cells with a BFP reporter gene downstream of a tre3g promoter and performed flow cytometry on at 
least 100,000 cells after co-expressing the gRNA and dCas9 machinery9. As a benchmark control for 
gene activation, we used a dCas9-p300 fusion protein known to increase expression11. Using a gRNA 
that targets the tre3g promoter at six interspaced sites, the dCas9-p300 increased BFP expression 14-
fold compared to the non-targeting (NT) control gRNA (Figure 2A, p< 0.05). We then tested activating 
the reporter gene with a plasmid expressing dCas9 (N-terminus) –FKBPx2 (C-terminus) and tested 
three of our predicted activating CEMs. After 48 hours of exposure to 200nM of CEM87, CEM88 and 
CEM114, BFP expression significantly increased 7.5, 1.8, 1.6- fold, respectively, compared to untreated 
cells (Figure 2B, p< 0.005, 0.000001, 0.05, respectively). 
Optimization of the dCas9-CEMa system was done by testing gRNAs targeted to areas along 
the span of the promoter and increasing the density of recruitment, as this has been previously shown 
to have a great impact on dCas9 efficiency16–18. Cells were transfected with plasmids expressing the 
BFP reporter, one or multiple gRNA, and dCas9, and were either treated with 200nM of CEM87 for 48 
hours or given regular media. Compared to the untreated control cells, the CEM-treated cells 
expressing the 6x-tre3g gRNA showed a 5-fold increase in BFP expression (Supplemental Figure S2, 
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p< 0.0005). The cells expressing a gRNA designed at a single site, further into the gene body showed 
a 2-fold increase (Supplemental Figure S2, p< 0.00000005). We also tested a multiplexing gRNA 
plasmid, whereby the cells would express the 6x-tre3g gRNA and the single site gRNA19. This multiplex 
gRNA led to an activation of 4-fold (Supplemental Figure S2, p< 0.0005). It is possible that the less-
effective single-site gRNA led the chromatin modifying machinery away from the promoter and drove 
down the overall effectiveness of the system. For future optimization experiments, we exclusively used 
the 6x-tre3g gRNA plasmid. To serve a positive control, we also transfected cells with dCas9-HA and 
the targeting 6x-tre3g gRNA. As expected, the addition of CEM87 at 200 nM did not significantly affect 
the BFP expression (Supplemental Figure S3) 
Next, we sought to increase the number of FKBP molecules being recruited to the gene of 
interest with the idea that increased CEM-recruitment would yield a more effective and highly dose-
able system. We adapted the dCas9 “SunTag” system to be compatible with the CEMa technology20,21. 
A dCas9-SunTagx10 plasmid was used that expresses an array of 10 yeast-specific GCN4 (gene 
control protein 4) peptides from the C-terminus of the dCas9. We co-transfected with a single chain 
variable fragment (scFv), made to be GCN4-specific) fused to FKBP. Theoretically, as many as 10 
FKBP molecules per dCas9 would be recruited to our gene of interest, increasing the CEMa recruitment 
power. With the adapted SunTag method and the tre3g x6 gRNA, 48 hours of 200 nM CEM87 exposure 
increased expression 16-fold compared to untreated cells (Supplemental Figure S4, p< 0.001). 
Equimolar CEM88 and CEM114 increased expression 2-fold (Supplemental Figure S4, p< 0.005 and 
p< 0.05, respectively). 
Another protein-engineering approach that we used to optimize the dCas9-CEMa system was 
incorporating ms2-compatible gRNAs. The ms2-gRNAs have a modified stem-loop, capable of 
recruiting both a dCas9-fusion as well as a bacteriophage MS2 coat protein (MCP)-fusion7,22. By using 
an MCP-FKBP fusion, we increase the number of FKBPs by 2-fold (as two MCP fusions can bind one 
stem loop) and physically increase the proximity of recruited CEMa to the chromatin. Compared to the 
untreated cells, CEM87 increased BFP expression 18-fold (p< 0.0000005). With our most efficient 
system (comprised of the dCas9-FKBPx2; ms2-FKBP; and the tre3g x6 gRNA), we re-tested the other 
CEMa compounds to determine whether their activating efficiency also improved. Equivalent 
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concentrations of CEM88 increased expression 5-fold (p< 0.0005), and CEM114 increased expression 
6-fold (p< 0.001) compared to cells expressing the NT gRNA (Figure 2C).  
With the optimized dCas9 system and the most efficient CEMa, CEM87, we performed a dose-
curve and determined the ideal concentration for maximum expression to be 200nM (Figure 2D). Since 
activity is governed by amount of small molecule ligand added, with this technique we can intricately 
control gene expression obtaining 2-fold activation at 10 nM, p< 0.05 and 8-fold activation at 50 nM, p< 
0.001. At concentrations of 500 nM and above, the cells appeared less healthy as assessed by cell 
density and morphology (data not shown). Thus, dCas9-CEMa platform does not only have control of 
gene activity but by varying compound dose between 0 and 200nM the level of gene expression can 
be differentially modulated. This could be very useful for target validation studies, which is an area of 
the drug development pipeline in desperate need of new tools if clinical success rates are to be 
improved23,24.  
We also asked what would happen with a dual compound exposure of (1) the gene-specific 
system of activation with CEM87 and (2) a globally effective HDACi. Upon treatment 2.5 µM of 
entinostat, a previously characterized HDAC inhibitor, and 200 nM of CEM87 with the dCas9-FKBPx2, 
ms2-FKBP recruitment system, we observed 34-fold gene activation compared to untreated cells 
(Supplemental Figure S5, p< 0.0005)25. While the purpose of the CEMs system is to target 
transcriptional activity at a gene-specific level, these data to suggest a synergistic effect with 
complimentary chromatin-regulatory pathways.  
We next sought to adapt our plasmid-optimized dCas9-CEMa system to target endogenous 
mammalian genes. Because we were targeting an endogenous gene, rather than hundreds of 
transiently expressing reporter plasmids, we chose to infect the dCas9 machinery (dCas9-p300, dCas9-
FKBPx2 and/or MCP-FKBP) into HEK 293T cells. After the cells have been stably selected for 
integration of the dCas9- and MCP- expressing plasmids, we transfect the gRNAs for the desired gene 
target. To determine the time point at which we observe more efficient dCas9 regulation by this method, 
we transfected cells expressing dCas9-p300 with gRNAs for myogenic differentiation (MYOD1), 
extracted the RNA and performed qRT-PCR after 24, 48 and 72 hours post transfection. MYOD1 was 
an ideal initial target for this question because it has been previously shown to be capable of modulation 
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by transiently expressed dCas9-p30011. With dCas9-p300 infected and the gRNAs transfected, we 
found that dCas9-mediated gene regulation was most efficient after 48 hours (Supplemental Figure 
S6). To test the ability of CEM87 to activate endogenous genes, we transfected cells expressing dCas9-
FKBPx2 and ms2-FKBP with gRNA plasmids targeting MYOD1 (or NT gRNA for the control). After 48 
hours of CEM87 exposure, mRNA levels increased 13-fold compared to untreated cells (Figure 3A, p< 
0.01), whereas the cells expressing the NT gRNAs showed no significant changes in expression upon 
CEM treatment (Figure 3A, p> 0.05).   
To determine the versatility of the dCas9-CEMa system, we tested a second endogenous gene, 
C-X-C chemokine receptor type 4 (CXCR4), that has also been previously regulated by other labs using 
a dCas9 technology5,7,26,27. After 48 hours of CEM87 exposure, expression increased 10-fold compared 
to untreated cells (Figure 3B, p< 0.005), where-as the cells expressing the NT gRNA had a less than 
2-fold change in CXCR4 expression (Figure 3B, p< 0.05). Lastly, we targeted endogenous Achaete-
Scute family BHLH Transcription factor 1 (ASCL1) with previously tested and optimized gRNAs7,21,22.  
Upon 48 hours of CEM87-treatment, mRNA levels of ASCL1 increased 22-fold compared to untreated 
cells (Figure 3C, p< 0.00005), compared to a less than 4-fold increase observed in the NT samples 
(Figure 3C, p< 0.05).  
 
Conclusions: 
In summary, we have designed, synthesized, and optimized the use of novel bifunctional CEMs 
capable of robustly activating endogenous genes in a dose-dependent, gene-specific manner. By 
adapting the CEMa technology to dCas9 targeting constructs, we can theoretically target any gene in 
the genome by strategic gRNA designing. We have demonstrated the ability to control the chromatin 
landscape and induce changes in the expression of endogenous mammalian genes in a direct, 
biologically-relevant manner. This dCas9-CEMa technology paves the way for us and others to target 
disease relevant genes to ask specific, targeted questions about disease mechanisms of action. Since 
our gene activation platform is chemically activated in a dose dependent manner, it will be useful in 
target validation work for visualization of trends between phenotype and gene dosage over a wide 
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range of target gene concentrations. Additionally, we hope to develop the dCas9-CEMa platform as a 
novel therapeutic approach to changing gene expression levels driving human disease. 
 
Methods: 
Chemical Synthesis: See supplemental Figure 1A-D. CEMa compounds were diluted in DMSO 
(Sigma D2650) and kept dry at −20 °C. 
 
Plasmid design: To construct dCas9-FKBPx1 and -FKBPx2, we digested Addgene #61425 at the 
BamHI and BsrG1 sites. To insert the FKBPx1 (from Addgene #44245) and FKBPx2 (from N160) 
fusion, we used In-Fusion (#639650) with the following primers: FKBPx1- Forward (5’ 
GGCGGCCGCTGGATCCGGCGTGCAGGTGGAGACTAT) Reverse (5’ 
CTCCACTGCCTGTACATTCCAGTTTTAGAAGCTCCACATC) ; FKBPx2- Forward (5’ 
CTCCACTGCCTGTACATTCCAGTTTTAGAAGCTCCACATC) Reverse (5’ 
GGCGGCCGCTGGATCCGGGGTCCAAGTTGAAACCATTA). To create a dCas9-SunTagx10 
construct with a BFP fusion, we used Addgene #60903, digested with Not1 and Sbf1 restriction 
enzymes, and re-inserted the WPRE and NLS domains from the original plasmid using In-Fusion and 
primers: Forward (5’ GGTCCGATGGATCTACAGCGGCCGGGTGGAGGTCCAAAAAAGAAAAGG) 
Reverse (5’ CAGTGATCGATCCCTGCAGGGCGGGGAGGCGGCCCAA). To create a multiplex 
parent plasmid capable of expression the tre3g x6 gRNA and the BFP x1 gRNA from a single 
plasmid, we used Addgene #52963 and digested with Not1 and PspX1 restriction enzymes. We CIP 
treated the backbone (NEB, M0290S) and PNK annealed (NEB, M0201S) the following oligos (oligo 
1: 5’ GGCCACTAGTCTCTGGAGACGAAACGTCTCTCTAGCCC ; oligo 2: 5’ 
TCGAGGGCTAGAGAGACGTTTCGTCTCCAGAGACTAGT). After cleaning the reactions, we ligated 
(NEB, M020S) the annealed insert and the CIP-treated backbone. For the multiplexing system, the 
insert plasmids were created and digested as previously described19 and the multiplex parent 2_3 
plasmid was digested with BsmB1, CIP treated, then ligated together.  
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Cell culture: Low passage (p30-40) HEK 293T cells were cultured with high-glucose DMEM (Corning, 
10-013-CV) supplemented with 10% FBS serum (Atlantic Biologicals, S11550), 10 mM HEPES 
(Corning, 25-060-Cl), NEAA (Gibco, 11140-050), Pen/Strep, and 55 μM 2-Mercaptoethanol. Cells were 
passaged every 2 - 5 days and maintained at 10-90% confluency in an incubator at 37 °C and 5% CO2.  
 
Cell Transfection: For Figure 2 and supplemental data, HEK 293T cells were split into 12-well plates 
with 100,000 cells per well. The next day, PEI (polyethlenimine, Polysciences #23966-1) transfection 
was done with 1 µg of DNA, 3 µL of PEI, and 100 µL of Optimem (Gibco, 31985070). For Figures 2A, 
2B, S2, and S3 we transfected with 0.1 µg BFP reporter; 0.7 µg dCas9-X; 0.2 µg gRNA. For Figures 
1C, 1D, S4, and S5 we transfected with 0.1 µg BFP reporter; 0.5 µg dCas9-X; 0.2 µg scFv-FKBP or 
ms2-FKBP; 0.2 µg gRNA. Media was change 16 hours after transfection with fresh media, with or 
without CEMa addition. After 48 hours of CEMa exposure, cells were isolated for flow cytometry 
analysis. For Figure 3 and supplemental data, HEK 293T cells were split into 6-well plates with 200,000 
cells per well. The next day, PIE transfection was done with 3 µg of DNA, 9 µL of PEI, and 200 µL of 
Optimem. For Figures 3A-C and S6, 3 µg of gRNA was added in equal ratio (if applicable). Media was 
change 16 hours after transfection with fresh media, with or without CEMa addition. After 48 hours of 
CEMa exposure, cells were isolate for RNA extraction.  
 
Flow cytometry: Flow cytometry was performed with the Attune Nxt as previously described28. The 
data presented represents three separate transfections and significance was determined with the two-
tailed student’s t-test. Confidence interval is 95%. Variance between two conditions being compared 
was calculated, and equal or unequal variance was considered. The degrees of freedom were 
calculated to be sample size (N) - 1. Error bars represent standard deviation. A representative gating 
strategy is shown in Supplemental Figure S7.  
 
Lentiviral infection: Lentivirus production for HEK 293T infection was done using LentiX 293T cells 
(Clontech). Low passage cells (8-20) were plated onto 15 cm cells such that they were 70% confluent 
24 hours later. Each plate was transfected with 18 μg of the plasmid of interest (dCas9-X), 13.5 μg of 
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the Gag-Pol expressing plasmid (Addgene #12260), and 4.5 μg of the VSV-G envelope expressing 
plasmid (Addgene #12259). PEI transfection was done and 60 hours after transfection, the virus was 
spun down at 20, 000 rpm for 2 1/2 hours at 4°C and then added to the HEK 293Ts in combination 
with 10 μg/mL Polybrene (Santa Cruz, sc-134220). The selection of lentiviral constructs was done 
with either hygromycin (200 μg/mL) or blasticidin (12 μg/mL). 
 
RNA extraction: For Figures 3 and Supplemental Figure S6, cells from the 6-well plates were isolated. 
Cells were washed with 1X PBS, disassociated with 0.05% trypsin, quenched with media, centrifuged 
and washed with 1X PBS.  RNA extraction was performed with a RNeasy Plus Mini Kit (Qiagen, 74134) 
and the relative enrichment of mRNA was quantified with the RNA-to-CTTM 1-step kit (Thermo Fisher 
Scientific, 4389986). Three biological replicates were performed for RNA extraction. The qRT-PCR 
results represent two technical replicates for each of the three biological replicates. Quartile analysis 
was done to exclude outliers and significance was determined with the two-tailed student’s t-test. 
Confidence interval is 95%. Variance between two conditions being compared was calculated, and 
equal or unequal variance was considered. The degrees of freedom were calculated to be sample size 
(N) - 1. Error bars represent standard deviation.  
 
 Table of primers for qRT-PCR and source: 
Target Forward (5’-3’) Reverse (5’-3’) Source 




















Table of gRNAs and source: 
Target: Protospacer Sequence (5’-3’) Source 
Tre3g x6 TACGTTCTCTATCACTGATA doi: 10.1038/nmeth.4042 
BFP x1 TACAAACTTGGGTCGAATT This study 
Myod1 gRNA #1 CCTGGGCTCCGGGGCGTTT doi:  10.1038/nmeth.2600 
Myod1 gRNA #2 GGCCCCTGCGGCCACCCCG  doi:  10.1038/nmeth.2600 
Myod1 gRNA #3 CTCCCTCCCTGCCCGGT AG  doi:  10.1038/nmeth.2600 
Myod1 gRNA #4 AGGTTTGGAAAGGGCGTGC  doi:  10.1038/nmeth.2600 
CXCR4 gRNA #1 GCAGACGCGAGGAAGGAGGGCGC doi:  10.1038/s41467-017-00644-y 
CXCR4 gRNA #2 CCGACCACCCGCAAACAGCA doi:  10.1038/s41467-017-00644-y 
CXCR4 gRNA #3 GCCTCTGGGAGGTCCTGTCCGGCTC doi:  10.1038/s41467-017-00644-y 
ASCL1 gRNA #1 CGGGAGAAAGGAACGGGAGG doi:  10.1038/s41467-017-00644-y 
ASCL1 gRNA #2 TCCAATTTCTAGGGTCACCG doi:  10.1038/s41467-017-00644-y 
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Figure 1. dCas9 CEMa system recrutis endogenous chromatin modifying machinery to regulate 
transcriptional activity. (A) Overall dCas9-CEMa strategy showing gRNAs that are designed to target a 
specific gene-of-interest using HEK 293T cells as a model system. Changes in transcriptional activity 
are evident by increases in fluorescent protein levels and relative mRNA quantification. dCas9-FKBP 
is introduced by transfection, or by infection of lentiviral delivery units. The CEMa molecules are brought 
to the gene-of-interest through interaction of the FK506 moiety with FKBP. Blue lines represent mRNA. 
A chemical linker combines this recruitment event with an interchangeable warhead, specific activating 





Figure 2. Protein engineering and synthetic chemistry explored to optimize dCas9–CEMa system. 
HEK 293T cells were transfected with a reporter plasmid that carried a BFP gene (driven by a Tre3G 
promoter that has low expression) along with a sgRNA targeting the Tre3G promoter and the dCas9. 
All samples were measured by flow cytometry 48-hrs after treatment. (A) As a positive control, dCas9-
p300 was transfected, and showed a ~14-fold increase in BFP expression. (B) dCas9-FKBPx1 was 
transfected and was combined with 3 different CEMa compounds that were formulated with different 
chemical warheads. (CEM87= binds Brd -2,-3,-4; CEM88= binds BRPF1 which recruits MOZ/MORF 
histone acetyltrransferases, CEM114= binds CBP/p300). The most effective compound was CEM87, 
which demonstrated ~7-fold increased expression. (C) dCas9 with tandem FKBP repeats and additional 
FKBP recruited to MS2 RNA-binding-sites introduced into the sgRNA, and added with the same CEMa 
set. Again, CEM87 was the most active with ~18-fold increased expression. (D) Using the optimized 
	 123 
dCas9-CEMa system and the most effective to-date CEMa, CEM87, a dose curve was performed. 
These data demonstrate that transcriptional activity, as measured by mean fluorescence, can be tightly 




Figure 3. Optimized dCas9–CEMa effectively reactivates three diverse mammalian genes. Overall 
optimized strategy in HEK 293T cell lines with stably expressing dCas9-FKBPx2 and ms2-FKBP 
machinery. We transfected gRNAs that were designed to target endogenous mammalian genes. After 
48 hours of treatment with 200 nM CEM87, RNA was extracted, qRT-qPCR was performed and results 
were normalized to Gapdh. (A) dCas9-CEMa causes ~13-fold activation of MYOD1. (B) dCas9-CEMa 




Supplemental Figure S1A. Chemistry General Procedures. FK506 was purchased from 
Selleckchem. All other chemicals were purchased from Sigma-Aldrich or Fisher Scientific. HPLC 
spectra for all compounds were acquired using an Agilent 1200 Series system with DAD detector. 
Analytical HPLC chromatography was performed on a 2.1×150 mm Zorbax 300SB-C18 5 μm column 
with water containing 0.1% formic acid as solvent A and acetonitrile containing 0.1% formic acid as 
solvent B at a flow rate of 0.4 mL/min. The gradient program was as follows: 1% B (0−1 min), 1−99% 
B (1−4 min), and 99% B (4−8 min). High resolution mass spectra (HRMS) data were acquired in positive 
ion mode using an Agilent G1969A API-TOF with an electrospray ionization (ESI) source. Flash column 
chromatography was performed on a Teledyne ISCO CombiFlash Rf system equipped with a variable 
wavelength UV detector and a fraction collector using RediSep Rf normal phase silica columns. 
Microwave reactions were performed using a Discover SP CEM. Nuclear Magnetic Resonance (NMR) 
spectra were acquired on a Bruker DRX-600 spectrometer with 600 MHz for proton (1H NMR) and 150 
MHz for carbon (13C NMR); chemical shifts are reported in ppm (δ). Preparative HPLC was performed 
on Agilent Prep 1200 series with UV detector set to 254 nm. Samples were injected onto a Phenomenex 
Luna 75 x 30 mm, 5 μm, C18 column at room temperature. The flow rate was 30 mL/min. A linear 
gradient was used with 10% (or 50%) of MeOH (A) in H2O (with 0.1 % TFA) (B) to 100% of MeOH (A). 
HPLC was used to establish the purity of target compounds. All final compounds had > 95% purity 











Supplemental Figure S1B. (S)-2-(6-(4-Chlorophenyl)-8-methoxy-1-methyl-4H-
benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)-N-(prop-2-yn-1-yl)acetamide: 
(S)-2-(6-(4-Chlorophenyl)-8-methoxy-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-
yl)acetic acid (purchased from a commercial vendor) (35 mg, 0.09 mmol), propargylamine (23 µL, 0.36 
mmol), EDCI-HCl (21 mg, 0.13 mmol), HOBT (25 mg, 0.18 mmol), and DIPEA 31 µL, 0.18 mmol) were 
all added to 4 mL dichloromethane (DCM) and stirred 24 h. The product was purified by HPLC. Yield: 
35 mg, 90%. 1H NMR (600 MHz, Chloroform-d) δ 7.52 (d, J = 8.3 Hz, 2H), 7.43 (d, J = 8.9 Hz, 1H), 
7.35 (d, J = 8.2 Hz, 2H), 7.26 - 7.23 (m, 1H), 6.90 (d, J = 2.8 Hz, 1H), 4.67 (t, J = 7.0 Hz, 1H), 4.23 - 
3.98 (m, 2H), 3.83 (s, 3H), 3.52 - 3.39 (m, 2H), 2.70 (s, 3H). TOF-HRMS (m/z) [M+H]+ for C23H21ClN5O2+ 


























4-yl)-N-(prop-2-yn-1-yl)acetamide (15 mg, 0.035 mmol), compound A (shown above, synthesized as 
previously described1) (39 mg, 0.035 mmol), were dissolved in 1 mL tert-butanol. TBTA (2 mg), copper 
sulfate pentahydrate (0.05 equiv of a 0.1M solution in water), and sodium ascorbate (0.2 equiv of a 
0.1M solution in water) were added to the solution. The reaction was stirred for 24 h then purified by 
HPLC. Yield: 8 mg, 15%. 1H NMR (600 MHz, Methanol-d4) δ 7.99 (s, 1H), 7.75 (d, J = 8.9 Hz, 1H), 7.51 
(d, J = 8.3 Hz, 2H), 7.48-7.25 (m, 3H), 6.94 (s, 1H), 5.23 (m, 2H), 4.73-4.48 (m, 5H), 3.90 (m, 2H), 3.86 
(m, 2H), 3.78-3.38 (m, n.d. - integration obscured by solvent peak), 3.04 (m, 3H), 2.72 (t, J = 7.2 Hz, 
2H), 2.67 (s, 3H), 2.51 (s, 2H), 2.44 (t, J = 7.3 Hz, 2H), 2.36 (s, 2H), 2.18 (m, 5H), 2.04 (m, 2H), 1.94 
(m, 3H), 1.83 - 1.58 (m, 11H), 1.32 (m, 17H), 0.92 (m, 11H). TOF-HRMS (m/z) [M+H]+ for 








































































Supplemental Figure S1C. 3-(prop-2-yn-1-yloxy)benzoic acid:  To the solution of methyl 3-
hydroxybenzoate (760 mg, 5 mmol) in DMF (10 mL) was added K2CO3 (1.38 g, 10 mmol). Then, 3-
bromoprop-1-yne (1.49 mL, 10 mmol) was added, and the reaction was stirred at room temperature for 
2 days. Water and ethyl acetate (EtOAc) were added, and the aqueous phase was extracted with EtOAc 
(3 x 20 mL). The combined organic layers were washed with water, brine, and dried over Na2SO4. The 
solvent was removed and dried under vacuum. The crude product (950 mg, 5 mmol), which was used 
for next step without further purification, was dissolved in THF / H2O (25 mL / 25 mL). Then, LiOH (1.0 
g, 43 mmol) was added, and the reaction was stirred at room temperature overnight. The reaction 
mixture was then treated with 4 N HCl until pH = 1, and extracted with EtOAc (3 x 30 mL), dried over 
Na2SO4. The solvent was removed under reduced pressure to obtained the title compound (801 mg, 
yield 91% over two steps). 1H NMR (600 MHz, Chloroform-d) δ 7.79 (dt, J = 7.7, 1.2 Hz, 1H), 7.73 (dd, 
J = 2.9, 1.5 Hz, 1H), 7.44 (t, J = 7.9 Hz, 1H), 7.30 – 7.20 (m, 1H), 4.78 (d, J = 2.4 Hz, 2H), 2.58 (t, J = 
















   LiOH






yloxy)benzamide: 3-(prop-2-yn-1-yloxy)benzoic acid (200 mg, 1.13 mmol) was dissolved in excess 
SOCl2, and the reaction was heated to reflux for 2 h. Then, the mixture was cooled and concentrated 
to generate 3-(prop-2-yn-1-yloxy)benzoyl chloride for the next step without purification. To a solution of 
5-amino-1,3-dimethyl-6-(piperidin-1-yl)-1H-benzo[d]imidazole-2(3H)-one (shown above, synthesized 
as previously described2) (323 mg, 1.24 mmol) in CH2Cl2 (10 mL) was added pyridine (0.114 mL, 1.41 
mmol) at room temperature. Then, 3-(prop-2-yn-1-yloxy)benzoyl chloride (220 mg, 1.13 mmol) was 
added and the reaction mixture was stirred for 1 h at this temperature. The reaction was diluted with 
DCM and washed by saturated NaHCO3 solution, and the aqueous phase was extracted with DCM. 
The combined organics were washed with water, dried over Na2SO4. The solvent was removed under 
reduced pressure and the residue was purified by flash chromatography on silica gel (50%-100% of 
EtOAc in Hexanes), and to obtain the product as white solid (294 mg, yield 62%). 1H NMR (600 MHz, 
Methanol-d4) δ 8.19 (s, 1H), 7.57 – 7.45 (m, 3H), 7.29 – 7.22 (m, 1H), 7.16 (s, 1H), 4.84 (d, J = 2.4 Hz, 
2H), 3.41 (d, J = 4.8 Hz, 6H), 3.01 (t, J = 2.4 Hz, 1H), 2.88 (t, J = 5.2 Hz, 4H), 1.79 (p, J = 5.7 Hz, 4H), 



















Supplemental Figure S1C. CEM88: Compound A1 (39 mg, 0.035 mmol) and N-(1,3-dimethyl-2-oxo-
6-(piperidin-1-yl)-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-3-(prop-2-yn-1-yloxy)benzamide (15 mg, 
0.035 mmol) were dissolved in tert-Butanol (1 mL). TBTA (2 mg, 10 mol %), copper sulfate pentahydrate 
(0.035 mL, 10 mol %, 0.1 M), and sodium ascorbate (0.17 mL, 0.2 equiv.) were added, and the reaction 
was stirred at room temperature for 24 h. The reaction mixture was purified by preparative HPLC (10%-
100% methanol / 0.1% TFA in H2O) to afford CEM88 as white solid in TFA salt form (38 mg, yield 71%).  
1H NMR (600 MHz, Methanol-d4) δ 8.19 (s, 1H), 7.83–7.57 (m, 2H), 7.55–7.44 (m, 2H), 7.36–7.30 (m, 
2H), 5.30 (s, 2H), 5.24–5.08 (m, 2H), 4.63–4.58 (m, 3H), 4.33 (d, J = 13.6 Hz, 1H), 4.06–3.87 (m, 3H), 
3.74–3.67 (m, 1H), 3.63–3.53 (m, 11H), 3.55–3.36 (m, 19H), 3.07–2.92 (m, 2H), 2.79 (dd, J = 14.4, 5.8 
Hz, 1H), 2.68 (t, J = 7.2 Hz, 2H), 2.46 (s, 2H), 2.40 (t, J = 7.3 Hz, 2H), 2.37–2.23 (m, 2H), 2.21–2.07 
(m, 3H), 2.06–1.68 (m, 18H), 1.67–1.56 (m, 8H), 1.56–1.26 (m, 10H), 1.25–1.16 (m, 1H), 1.09 (q, J = 
12.9, 12.4 Hz, 1H), 0.99–0.79 (m, 11H). HRMS (m/z) [M+H]+ for C79H118N9O19S+ calculated 1528.8259, 




















































Supplemental Figure S1D. 3-(3-fluoro-4-(prop-2-yn-1-yloxy)phenyl)propanoic acid: To a solution 
of 3-fluoro-4-hydroxybenzaldehyde (1.40 g, 10 mmol) in dimethyl formamide (DMF) (20 mL) was added 
benzyl chloride (1.39 mL, 12 mmol), K2CO3 (2.04 g, 15 mmol), and DMAP (10 mg). The reaction was 
stirred overnight at room temperature. Water and EtOAc were added, and the aqueous phase was 
extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with water, brine, and 
dried over Na2SO4. The solvent was removed under reduced pressure, and the residue was purified by 
flash chromatography on silica gel (0%-10% of EtOAc in Hexane). The product 4-(benzyloxy)-3-
fluorobenzaldehyde was obtained as white solid (1.33 g, yield 58%). 4-(benzyloxy)-3-
fluorobenzaldehyde (1.33 g, 5.8 mmol) and methyl (triphenylphosphoranylidene) acetate (2.12 g, 6.4 
mmol) were dissolved in DCM (20 mL). The resulting mixture was stirred at room temperature for 3 
days. The solvent was removed and purified by flash chromatography on silica gel (0%-25% of EtOAc 
in Hexane). Methyl 3-(4-(benzyloxy)-3-fluorophenyl)acrylate was obtained as white solid (1.55 g, yield 
93%) and dissolved in EtOAc (50 mL). Pd/C (200 mg) was added and the reaction was stirred under 
H2 for 18 h. The Pd/C was filtered through Celite, and the filtrate was concentrated. The crude product 
was dissolved in DMF (20 mL). Then, 3-bromoprop-1-yne (0.72 mL, 6.5 mmol) and K2CO3 (1.1 g, 8.1 
mmol) were added. The reaction was stirred at 60 oC overnight. Water and EtOAc were added, and the 
aqueous phase was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with 
water, brine, and dried over Na2SO4. The solvent was removed and purified by flash chromatography 
on silica gel (0%-50% of EtOAc in Hexane). Methyl 3-(3-fluoro-4-(prop-2-yn-1-yloxy)phenyl)propanoate 
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yloxy)phenyl)propanoate (850 mg, 3.6 mmol) was dissolved in THF/H2O (8 mL/8 mL). LiOH (432 mg, 
18 mmol) was added, and the reaction was stirred at room temperature overnight. The reaction was 
treated with 2 N HCl until pH = 1, extracted with EtOAc (3 x 30 mL), dried over Na2SO4. The solvent 
was removed to get the title product (754 mg, yield 94%). 1H NMR (600 MHz, Methanol-d4) δ 7.10 (t, J 
= 8.5 Hz, 1H), 7.00 (dd, J = 25.3, 10.2 Hz, 2H), 4.77 (q, J = 3.5 Hz, 2H), 3.02 – 2.92 (m, 1H), 2.87 (d, 























Supplemental Figure S1D. 4-(2-(5-(3,5-dimethylisoxazol-4-yl)-2-(3-fluoro-4-(prop-2-yn-1-
yloxy)phenethyl)-1H-benzo[d]imidazol-1-yl)ethyl)morpholine: 3-(3-fluoro-4-(prop-2-yn-1-
yloxy)phenyl)propanoic acid (53 mg, 0.24 mmol) and 4-(3,5-dimethylisoxazol-4-yl)-N1-(2-
morpholinoethyl)benzene-1,2-diamine (shown above, synthesized as previously described3) (63 mg, 
0.2 mmol) were dissolved in EtOAc (0.7 mL). T3P (0.578 mL, 1 mmol) and DIPEA (0.041 mL, 0.24 
mmol) were added, then, the reaction was heated to 150 oC for 10 minutes in microwave reactor (MW). 
Water was added to quench the reaction, and the aqueous phase was extracted with EtOAc (3 x 5 mL), 
dried over Na2SO4. Solvent was removed and the resulting mixture was purified by preparative HPLC 
(10%-100% methanol / 0.1% TFA in H2O) to afford title compound as white solid in TFA salt form (41 
mg, yield 41%). 1H NMR (600 MHz, Methanol-d4) δ 8.04 (d, J = 8.6 Hz, 1H), 7.74 (d, J = 1.4 Hz, 1H), 
7.60 (dd, J = 8.6, 1.5 Hz, 1H), 7.19 – 7.11 (m, 2H), 7.03 (d, J = 8.3 Hz, 1H), 4.78 (d, J = 2.4 Hz, 2H), 
3.94 (s, 4H), 3.58 (t, J = 7.8 Hz, 2H), 3.54 – 3.48 (m, 2H), 3.35 (d, J = 9.1 Hz, 4H), 3.31 (p, J = 1.6 Hz, 
4H), 2.98 (t, J = 2.5 Hz, 1H), 2.44 (s, 3H), 2.27 (s, 3H). HRMS (m/z) [M + H]+ for C29H32FN4O3+ calculated 
503.2453, found 503.2442.  
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Supplemental Figure S1D. CEM114: CEM114 was synthesized following the standard procedures for 
preparing CEM88 from Compound A1 (36 mg, 0.032 mmol) and 4-(2-(5-(3,5-dimethylisoxazol-4-yl)-2-
(3-fluoro-4-(prop-2-yn-1-yloxy)phenethyl)-1H-benzo[d]imidazol-1-yl)ethyl)morpholine (20 mg, 0.032 
mmol), TBTA (1 mg, 10 mol %), copper sulfate pentahydrate (0.032 mL, 10 mol %, 0.1 M), and sodium 
ascorbate (0.16 mL, 0.2 equiv) in tert-Butanol (1 mL). The reaction mixture was purified by preparative 
HPLC (10%-100% methanol / 0.1% TFA in H2O) to afford CEM114 as white solid in TFA salt form (23 
mg, yield 45%).  1H NMR (600 MHz, Methanol-d4) δ 8.16 (d, J = 2.8 Hz, 1H), 7.98 (dd, J = 8.6, 3.2 Hz, 
1H), 7.72 (s, 1H), 7.58 (dd, J = 8.6, 1.5 Hz, 1H), 7.19 (td, J = 8.5, 5.3 Hz, 1H), 7.15 – 7.10 (m, 1H), 7.01 
(t, J = 8.6 Hz, 1H), 5.24 – 5.12 (m, 4H), 4.66 – 4.57 (m, 3H), 4.28 (d, J = 13.4 Hz, 1H), 4.06 – 3.94 (m, 
1H), 3.89 (dd, J = 12.9, 7.8 Hz, 7H), 3.75 – 3.66 (m, 1H), 3.63 – 3.51 (m, 13H), 3.48 (t, J = 5.5 Hz, 3H), 
3.43 – 3.36 (m, 8H), 3.26 – 3.11 (m, 7H), 3.01 (ddd, J = 15.0, 9.6, 4.1 Hz, 1H), 2.92 (t, J = 12.4 Hz, 
1H), 2.80 (dd, J = 14.3, 5.3 Hz, 1H), 2.70 (t, J = 7.2 Hz, 2H), 2.51 – 2.40 (m, 8H), 2.28 (s, 5H), 2.23 – 
1.97 (m, 6H), 1.95 – 1.68 (m, 9H), 1.68 – 1.30 (m, 17H), 1.24 – 1.14 (m, 1H), 1.13 – 1.04 (m, 1H), 1.00 
– 0.77 (m, 11H). HRMS (m/z) [M+H]+ for C84H123N9O19S+ calculated 1612.8634, found 1612.8475. 


























































Supplemental Figure S2. dCas9-CEMa gRNA optimization. HEK 293T cells were transfected with 
dCas9-FKBPx2, a BFP reporter, and one of 3 gRNAs sets as indicated. Treated cells were exposed to 
media with 200 nM of CEM87 for 48 hours at which point flow cytometry was used to quantify changes 
in BFP gene expression. Upon CEMa exposure, the tre3g x6 gRNA increased expression 5-fold, the 
BFP x1 gRNA increased expression 2-fold, and the multiplexing plasmid that co-expressed both gRNAs 





Supplemental Figure S3. dCas9-HA control. To serve as a control for CEMa exposure upon dCas9 
and gRNA recruitment, HEK 293T cells were transfected with dCas9-HA (with no FKBP recruitment 
site), tre3g x6 gRNA, and the BFP reporter. Treated cells were exposed to 200 nM of CEM87 for 48 







Supplemental Figure S4. A dCas9-SunTag approach adapted to the dCas9-CEMa system. To 
optimize the dCas9-CEMa system and explore other recruitment strategies, we tested the efficiency of 
the dCas9-SunTagx10 approach. HEK 293T cells were transfected with dCas9-SunTag10, a scFv 
(GCN4) - FKBP, tre3g x6 gRNA, and a BFP reporter. Cells were treated with one of three CEMa 
compounds as indicated at 200 nM. After 48 hours of treatment, flow cytometry was performed to 
measure BFP expression. CEM87 induced a 16-fold increase in expression compared to untreated 






Supplemental Figure S5. CEMa in combination with an HDACi. Using the optimized the dCas9-
CEMa system (dCas9-FKBPx2, ms2-FKBP, tre3g x6 gRNA, BFP reporter), the effects of a global 
epigenetic inhibitor in combination with a gene-specific approach was tested. After the cells were 
transfected, they were treated with 200 nM of CEM87 and 2.5 μM of Entinostat. BFP expression 





Supplemental Figure S6. dCas9-p300 time course at MYOD1. To determine the optimal timepoint 
post transfection, RNA extraction and qRT-PCR was performed on HEK 293T cells infected with 
dCas9-p300, and transfected MYOD1-targeting or control gRNA as indicated. Compared to the NT-
gRNA cells, dCas9-p300 increased MYOD1 expression 15-fold 24 hours after transfection (p < 0.01), 
















Supplemental Figure S7. The above histograms represent the gating scheme that is performed on all 
flow cytometry-based experiments. (A) The FSC-area (A) and SSC-A gate is used to select live, round 
cells. (B) The SSC-A and SS-height (H) gate is used to select single cells. 
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CHAPTER 5: CAVITATION ENHANCEMENT INCREASES THE EFFICIENCY AND 





Investigating DNA-protein interactions is essential for the study of cellular processes including 
gene regulation, DNA replication, DNA repair, and nucleosomal organization.  Chromatin 
immunoprecipitation (ChIP) is a key method used to determine the genomic location of specific proteins 
or posttranslational marks at individual loci or genome-wide1, 2. A typical workflow incorporating ChIP 
is as follows: (1) fixation of cells with formaldehyde, which crosslinks chromatin-bound proteins to DNA; 
(2) isolation of the crosslinked chromatin from cell nuclei; (3) nuclei lysis and fragmentation of chromatin 
into 200-500 base pair (bp) fragments by sonication; (4) enrichment of the protein target and its 
associated DNA sequences from the sheared lysates using antibody immunoprecipitation; (5) reversal 
of crosslinks and isolation of DNA; and (6) downstream quantitative analysis of enriched DNA 
sequences by quantitative PCR (qPCR) or next-generation sequencing. 
 Random, unbiased fragmentation of chromatin is an important step in protocols incorporating 
ChIP analysis1, 3. Since ChIP followed by qPCR or next-generation sequencing determines protein 
localization to specific regions of the genome, chromatin must be fragmented to 200-500 bp segments2, 
4, 5. If the fragments are too small or degraded, the DNA sequence will be lost from downstream 
analyses. If the fragments are too large, it is impossible to map protein occupancy to a narrow region 
of the genome. Therefore, variability in the fragmentation technique between samples can bias data  
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analyses6. 
Despite the importance of sonication to the success of the ChIP-based assays, chromatin 
fragmentation remains an inefficient and inconsistent process, with few recent innovations in the 
development of chromatin fragmentation technology6-8. Proper chromatin fragmentation is a bottleneck 
in current protocols, often adding a day to processing times when handling large sample sets. To 
address this issue, we applied a novel cavitation enhancement reagent to improve fragmentation of 
chromatin from fixed cell nuclei. These biologically inert nanodroplets are composed of a liquid 
perfluorocarbon stabilized with a phospholipid monolayer shell9, 10. The droplets have an average 
diameter of 250 nanometers (nm).  Once exposed to ultrasound energy, they vaporize into 
microbubbles of ~1–5 microns (µm) in diameter resulting in an intense, prolonged cavitation and release 
of mechanical energy that can be transferred to chromatin causing greater fragmentation than 
sonication alone10-12. 
To assess the performance of nanodroplet reagent in the sonication step of a typical protocol 
using ChIP, we use the Chromatin in vivo Assay (CiA)13. We chose this assay as it was a previously 
characterized robust method that can generate significant changes to enrichment of posttranslational 
marks at a well-defined genomic locus in mammalian cells. This system allows us to recruit chromatin 
modifying proteins to DNA binding elements inserted in the promoter of a specific gene and then to 
determine changes in the chromatin environment. Here, we recruited a fragment of heterochromatin 
protein 1 alpha (HP1) which stimulates heterochromatin formation and performed ChIP of histone 
posttranslational modifications followed by the quantitative polymerase chain reaction (ChIP-qPCR). 
We show that nanodroplets increase efficiency of chromatin fragmentation time by roughly 16-fold, 
while maintaining chromatin quality for downstream analysis by ChIP-qPCR. In practice, this method 
can reduce processing time for mouse embryonic stem cells from >38 minutes to <3 minutes, 








Cell culture and infection 
The CiA mouse embryonic stem cells were cultured and infected as previously described13. 
Rapamycin was diluted in molecular grade ethanol and stored at -20°C. HEK 293T cells were cultured 
as previously described14. 
 
Fluorescent microscopy and image analysis 
Representative images of the CiA mouse embryonic stem cells were imaged using a 
fluorescence microscope prior to flow cytometry analysis and ChIP-qPCR. The brightness/contrast of 
the brightfield images was uniformly adjusted in ImageJ FIJI. The background artifact in the GPF- 
fluorescent images was uniformly removed in FIJI with a sliding paraboloid with a rolling ball radius of 
10 pixels. 
 
Flow cytometry  
 Flow cytometry was performed at the University of North Carolina Flow Facility. The cells were 
washed in 1XPBS, trypsinized, and resuspended in FACS buffer (1X PBS, 0.2% BSA, 1 millimolar (mM) 
EDTA). For each replicate > 100,000 cells were analyzed and gated as shown in Figure S1. 
 
Preparation of fixed cell nuclei 
The optimal sonication time for the ChIP-qPCR protocol was determined through titration over 
a series of sonication time points. For consistency purposes, a fixed number of cells were treated with 
formaldehyde, nuclei were isolated, prepped for sonication, and analyzed using a standard protocol. 
The mESCs were prepared by trypsinization on 15 centimeter (cm) plates containing ~40 
million cells (mESCs). Cells were transferred to a 15 milliliter (mL) conical tube and pelleted at 300 x g 
for 5 minutes followed by resuspension in 15 mL of 1x phosphate buffered saline (PBS). Cells were 
centrifuged at 300 x g for 5 minutes and the pellet was resuspended in 10 mL fixation buffer (50 mM 
HEPES (pH 8.0), 1 mM EDTA (pH 8.0), 0.5 mM EGTA (pH 8.0), 100 mM NaCl). Crosslinking was 
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performed with the addition of 1 mL of 11% formaldehyde (final concentration 1%) followed by rotation 
for 10 minutes at room temperature. To quench the formaldehyde crosslinking, 0.5 mL of 2.5 molar (M) 
glycine (125 mM final concentration) was added and rapidly mixed by inversion.  
For the HEK 293T cells, formaldehyde was added to the media of a 15 cm plate containing ~2 
million cells to a final concentration of 1%. Plates were then placed on a plate shaker for 10 minutes at 
room temperature. To quench the formaldehyde crosslinking, glycine was added to a final concentration 
of 125 mM, followed by a 5 minute incubation at room temperature with agitation. Cells were scraped 
from the plate using a rubber policeman and transferred to a 50 mL conical tube on ice.  Cells were 
pelleted by centrifugation at 300 x g for 5 minutes and the supernatant was discarded. 
The pellets from both cell types were place on ice for the remaining preparation steps. Cells 
were pelleted by centrifugation at 4°C and 1,200 x g for 5 minutes, the pellet was washed in 10 mL of 
1x PBS and re-centrifuged under the same conditions. The cell pellets (without supernatant) were flash 
frozen in liquid nitrogen and stored at -80°C. Nuclei were isolated from the cell pellet by resuspension 
in 10 mL of Rinse Buffer #1 (50 mM HEPES (pH 8.0), 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% 
NP40, and 0.25% Triton X 100), incubation on ice for 10 minutes, and followed by centrifugation at 
1,200 x g at 4°C for 5 minutes. The pellet was resuspended in 10 mL of Rinse Buffer #2 (10 mM Tris 
(pH 8.0), 1 mM EDTA, 0.5 mM EGTA, 200 mM NaCl) and centrifuged at 1,200 x g and 4°C for 5 
minutes. To wash residual salts from the side of the 15 mL conical tube, 5 mL of Shearing Buffer [0.1% 
SDS, 1 mM EDTA (pH 8.0), 10 mM Tris-HCl (pH 8.0)] was carefully added without disturbing the pellet. 
The samples were spun at 1,200 x g at 4°C for 3 minutes, the supernatant was discarded, and the 
wash step was repeated.  
 
Sonication of fixed nuclei 
  Sonication was performed in a Covaris E110 instrument with a customized holder designed 
to hold glass tubes (Fisher C4008-632R) that were crimp sealed with caps (Fisher C4008-2A).  Isolated 
cell nuclei were resuspended in 90 microliters (µl) of Shearing Buffer (supplemented with 1x protease 
inhibitor) per 10 million mESCs and 500,000 HEK 293T cells. The resuspended cells were carefully 
mixed by pipetting and transferred to the glass sonication tubes on ice. 
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The nanodroplet cavitation reagent (MegaShear™, Triangle Biotechnology) was stored at -
20°C and was prepared by defrosting on wet ice prior to use.  Briefly, this reagent is formulated by the 
encapsulation of liquid decafluorobutane in a lipid shell in a buffer of phosphate buffered saline, 
glycerine (15% v/v), and propylene glycol (5% v/v).  The encapsulation lipid was composed of 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC) (Avanti Polar Lipids, Alabaster, AL, USA) stabilized by 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy (polyethylene-glycol)-2000 (DSPE-
PEG2000) (Avanti Polar Lipids, Alabaster, AL, USA) in a 9 to 1 molar ratio.   Further details of the 
formulation process are provided by Kasoji et al9.   
Ten µl of nanodroplets or 10 µl of Shearing Buffer (traditional) was added to the appropriate 
tubes, the tubes were inverted to mix, followed by a brief centrifugation to remove liquid from the sides 
of the tube.  Samples were sonicated at 4°C for 5 minutes followed by at least 5 minutes of rest for the 
total designated time using the settings 20% duty cycle, intensity = 8, and 200 cycles per burst.  
 
Extraction and quantitation of total DNA for determination of fragmentation efficiency 
Following sonication, the cell lysate containing chromatin was transferred to a 1.5 mL microfuge 
tube and centrifuged full speed (>18,000 x g) at 4°C for 5 minutes. The supernatant was transferred to 
a 0.2 mL PCR tube, and the pellet was resuspended in 100 μL Shearing buffer and transferred to 
another PCR tube. Next, 2 μL 10 µg/µL RNase (Qiagen) was added to each pellet and supernatant 
sample, followed by incubation at 37°C for 30 minutes. Protein was removed by addition of 2 μL of 20 
mg/mL proteinase K (Worthington), samples were mixed by inversion and briefly centrifuged. Samples 
were incubated at 55°C for 30 minutes followed by 65°C overnight to reverse the formaldehyde 
crosslinks (~14 hours). DNA was extracted from both pellet and supernatant samples using silica matrix 
columns (Zymo Research ChIP DNA clean and concentrate kit, D5201) according to manufacturer’s 
instructions and eluted in a 25 µL volume of 10 mM Tris, pH 8.0.  The concentration of DNA in the pellet 
and supernatant samples was determined using fluorometry (Qubit® dsDNA High Sensitivity Assay Kit, 
Invitrogen). To visualize the DNA and determine fragmentation efficiency, electrophoresis was 
performed on 9 μL (36% of total volume) of eluted supernatant DNA per lane loaded on a 1.2% agarose 
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gel.  Average peak fragment size was determined using the Agilent TapeStation 2200 HS D1000 and 
D5000 kits according to manufacturer’s instructions.   
 
ChIP assay 
ChIP-qPCR was performed using the ChIP-IT High Sensitivityâ kit (Active Motif #53040) 
according to the manufacturer’s instructions, except that inputs were purified using a clean and 
concentrate column (Zymo Research #D5205), and the ChIP samples were eluted twice with 30 µL 
each for a total of 60 µL of elution buffer for the H3K4me3 and H3K9me3 ChIP assays. For each ChIP 
assay, the equivalent of 5 million cells was used for mESCs and 1 million cells for HEK293T cells.  
These samples were analyzed by qPCR using primers and methods as previously described (Table 
S1)15. The following antibodies were used: G9a (Abcam #40542), H3K4me3 (Active Motif #39915), and 
H3K9me3 (Active Motif #39161). 
 
Results and Discussion: 
 
The Chromatin in vivo Assay as a system for testing the quality of chromatin fragmented in the 
presence of nanodroplets 
The Chromatin in vivo Assay (CiA) is designed to control the chromatin environment at a 
specific gene locus (Figure 1A)13. This platform is ideal for testing the quality of nanodroplet-
fragmented chromatin because it uses well defined methods to induce enrichment of posttranslational 
marks at the CiA:Oct4 locus in mouse embryonic stem cells (mESCs). In this system HP1a is rapidly 
tethered using the chemical inducer of proximity (CIP) rapamycin13. When HP1a is recruited to the 
CiA:Oct4 promoter region it induces histone methyltransferases (HMT) to catalyze tri-methylation on 
histone H3 lysine-9 (H3K9me3)16-19. This posttranslational mark then will recruit endogenous HP1 
enzymes to propagate heterochromatin formation mostly symmetrically across the promoter and gene 
body of the targeted allele20. These domains lead to chromatin compaction and gene repression21. 
ChIP-qPCR can be used to quantify the extent of H3K9me313. In our system CIP-rapamycin mediated 
recruitment of HP1a for 5-days results in a complete heterochromatin domain formed at the CiA:Oct4 
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target locus marked by H3K9me313. In this report, we used this well-characterized system to investigate 
the quality of chromatin fragmented using nanodroplets. 
 Our experimental system compares enrichment by ChIP-qPCR of H3K9me3 at the CiA:Oct4 
locus between two conditions, euchromatin (no CIP-HP1a) and heterochromatin (CIP-HP1a 
recruitment for 5 days). To confirm that recruitment of HP1a results in the expected gene repression, 
the cells were exposed to 3nM of CIP-rapamycin for 5 days and GFP expression was quantified and 
imaged. Flow cytometry results revealed a decrease in GFP positive cells in CIP-HP1a treated samples 
from 99.8% to 19.4% (Figure 1B, Figure S1). Cells were also imaged with fluorescent microscopy, 
which confirms the flow cytometry data (Figure 1C). Taken together these results show that recruitment 
of HP1a causes gene repression at the CiA:Oct4 locus, as previously described13. 
 
Determining efficiency of nanodroplet-mediated chromatin fragmentation using fixed mouse 
embryonic stem cells and human embryonic kidney (HEK) 293T cells 
 To determine if cavitation enhancement could alleviate the sonication bottleneck in sample 
processing for ChIP, we measured chromatin fragmentation efficiency in the presence or absence of 
nanodroplets in two different cell lines. Cell nuclei were prepared from formaldehyde crosslinked 
mESCs or HEK293T cells, sonicated in the presence (nanodroplets) or absence (traditional) of the 
nanodroplet reagent, followed by purification of total soluble DNA, which was used to measure 
chromatin fragmentation efficiency (Figure 2A, Experimental Procedures). DNA was visualized on 
an agarose gel (Figure S2), and peak average fragment size was quantitated using an Agilent 
TapeStation (Figure 2B-C). Agarose gel electrophoresis demonstrated that samples sonicated in the 
presence of nanodroplets reached the desired ChIP fragment size distribution of 200-500 bp in less 
time than traditional sonication for both cell lines (Figure S2). Quantitation of DNA size by TapeStation 
revealed that samples sonicated with nanodroplets reached a mean peak fragment size of 318 ± 34.7 
bp after just 2.3 minutes sonication time for mESCs (Figure 2B, Figure S3-5) and 239 ± 39.4 bp after 
3 minutes sonication time for HEK 293T cells (Figures 2C, Figure S6-8). In contrast, traditional 
samples did not achieve the targeted 200-500 bp range until 38.4 minutes sonication time (mean peak 
fragment size of 301 ± 27.2 bp) for mESCs (Figure 2B), and 48 minutes sonication time (347 ± 152.3 
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bp) for HEK 293T cells (Figure 2C). Therefore, the addition of nanodroplets to the sonication mixture 
decreases chromatin fragmentation time from formaldehyde crosslinked cells by 16.7-fold for mESCs, 
and 16-fold for HEK 293T cells, both of which represent a similarly significant reduction in sample 
processing time. 
 
ChIP of G9a lysine methyltransferase can be successfully performed on chromatin fragmented 
from HEK 293T cells in the presence of nanodroplets.  
After determining optimal times for chromatin fragmentation using either traditional or 
nanodroplet-mediated sonication, we tested HEK 293T cell chromatin quality by performing ChIP-qPCR 
for lysine methyltransferase protein G9a, and a IgG control. The qPCR amplification regions were 
selected from previously published G9a ChIP-next generation sequencing (ChIP-seq) data (Figure 3A-
B)14. Chromatin preparation and sonication steps were performed as described (Experimental 
Procedures). To minimize variability, the post-sonication ChIP protocol was performed using a 
commercially available kit (Experimental Procedures). We determined that sonication for 3 minutes with 
nanodroplets and 48 minutes without nanodroplets (Figures 2C) was appropriate to fragment HEK 
293T cell chromatin to a range of 200-500 bp. We used these conditions to prepare chromatin for ChIP 
and confirmed fragmentation by subjecting ChIP input samples to agarose gel electrophoresis (Figure 
S9A), and Agilent TapeStation (Figure 3C). Despite 48 minutes sonication, we were unable to fragment 
all of the traditionally sonicated inputs within the desired 200-500 bp range.  Nanodroplet-mediated 
sonication produced a lower average peak bp size distribution (243 ± 86 bp) compared to the traditional 
method (482 ± 180 bp) with a similar coefficient of variation (CV) for both methods (nanodroplet CV = 
35%; traditional CV = 37%).  ChIP-qPCR was performed for G9a or IgG (background) at the G9a 
positive PGSF1 locus (Figure 3A) and the BC006361 G9a negative locus (Figure 3B) as determined 
from published G9a ChIP-seq data14. The large variation in input fragment size coupled with the long, 
48-minute sonication time resulted in poor G9a ChIP signal over background for the traditional samples 
and no significant difference in G9a occupancy between positive and negative control regions (Figure 
3D). In contrast, samples sonicated for only 3 minutes in the presence of nanodroplets resulted in a 
more robust G9a ChIP signal over background with a 6-fold difference between G9a occupancy at the 
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positive and negative regions (p = 0.03). Therefore, the addition of nanodroplets to the sonication of 
fixed HEK 293T cells results in a 16-fold decrease in sonication time compared to the traditional method 
and produces chromatin of sufficient quality to perform G9a ChIP-qPCR with a significant signal over 
background.   
 
Chromatin fragmented using nanodroplets faithfully recapitulates ChIP-qPCR data for analysis 
of histone tail modifications in the CiA system.  
Following confirmation that we could perform ChIP from HEK 293T chromatin fragmented in 
the presence of nanodroplets, we further tested chromatin quality from mESCs by performing ChIP-
qPCR for histone posttranslational modifications that undergo a dynamic change following 
heterochromatin formation in the CiA:Oct4 system13. Chromatin was prepared as described 
(Experimental Procedures) and sonicated for 2.3 minutes when nanodroplets were used, and 38.4 
minutes for the traditional method (Figure 2B). To confirm fragment size, the ChIP input samples were 
subjected to agarose gel electrophoresis where they appeared to be fragmented within the desired 
range (Figure S9B). When fragmentation of these input samples was quantified by TapeStation, 
however, nanodroplet-mediated sonication produced an overall 2.7-fold reduction in variance of DNA 
size distribution (coefficient of variation (CV) = 27%) compared to the traditional method (CV = 72%) 
(Figure 4A). The CV values were calculated using 6 data points for nanodroplet reagent samples and 
5 data points for the traditional method since one traditional sonication data point produced a peak DNA 
fragment size >1,500 bp, which is outside of the linear range of the high sensitivity TapeStation assay. 
Average peak fragment sizes for traditional sonication were: 614 ± 511 control and 927 ± 346 with 
rapamycin, and for sonication with nanodroplets average peak fragment sizes were: 277 ± 83 control 
and 275 ± 48 with rapamycin.  There was no significant change in average peak fragment size after 
rapamycin treatment.  Overall, in addition to decreasing sonication time, nanodroplets also increased 
fragmentation consistency by 2.7-fold between input samples in mESCs.  
The ChIP assay was performed as described for HEK 293T cells. ChIP antibodies for H3K4me3 
were used as a marker of active gene transcription, whereas antibodies for H3K9me3 were used to 
mark transcriptional repression as previously described13. ChIP was performed using three biological 
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replicates in the presence or absence of nanodroplets, and qPCR experiments had two technical 
replicates for each of the three biological replicate samples using three primer sets spanning the 
CiA:Oct4 locus (Figure 4B). Following recruitment of HP1a by treatment of cells with rapamycin, 
H3K4me3 enrichment was significantly decreased at all CiA:Oct4 locus regions tested. As expected, 
the opposite trend was observed for H3K9me3 levels following HP1a recruitment (Figure 4C). Unlike 
the ChIP-qPCR results for HEK 293T cells (Figure 3D), the ChIP-qPCR results for our mESC CiA:Oct4 
system13 recapitulated previous findings equally well for samples treated with or without nanodroplets. 
Overall, our results indicate that the addition of a nanodroplet cavitation enhancing reagent to the 
sonication mixture does not alter the conclusions of previously-published data in HEK 293T cells or the 
mESC CiA:Oct4 system13, but does allow for a 16-fold increase in chromatin fragmentation efficiency, 
and a 2.7-fold reduction in chromatin fragmentation variance in the inducible mESC CiA:Oct4 system. 
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Figure 1. Establishment of the CiA system as a tool assessing chromatin changes. Mouse ES cells 
were infected with constructs expressing FKBP-Gal4 and FRB-HP1. Rapamycin (a chemical inducer 
of proximity) brings together FKBP and FRB at the Gal4 domain upstream of eGFP (A) as shown in 
cartoon form. (B) Flow cytometry results of infected cells treated with 3nM of rapamycin. (C) 




Figure 2. Efficiency of chromatin fragmentation in the presence and absence of nanodroplets. (A) 
Nanodroplets increase the number of cavitation events when exposed to ultrasound during the 
sonication phase of the chromatin isolation protocol. (B-C) Peak DNA fragment size (bp) after 
sonication was determined by Agilent TapeStation 2200 analysis for mESC (B) and HEK 293T (C) 
cells. Data from each replicate in base pairs (bp) size at each DNA fragment peak without (–) or with 
(+) nanodroplets is shown as a heat map. The mean value of all three replicates is also indicated. 
The peak bp size for each sample was also plotted as a function of time without (blue dots) or with 
(red dots) nanodroplets.  The mean peak bp size for each condition is indicated by a horizontal line.  
Error bars represent the standard deviation of 3 biological replicates except HEK 293T cells 





Figure 3. G9a ChIP from HEK 293T cells. ChIP-qPCR regions were selected from Simon et al.,14 to 
include a G9a positive region (A) and a G9a negative region (B). Amplicons are indicated by a grey 
vertical bar. (C) The peak base pair (bp) size of each input sample without (Traditional, red dots; 
mean = 482 ± 180 bp; CV = 37%) or with (Nanodroplets, purple dots mean = 243 ± 86 bp; CV = 
35%) nanodroplets was measured by Agilent TapeStation.  The mean peak bp size for each 
condition is indicated by a horizontal black line. Error bars represent the average of 3 biological 
replicates. (D) G9a ChIP-qPCR showing the fold change of G9a signal over IgG signal with 







Figure 4. ChIP-qPCR results using traditional sonication compared to using nanodroplets. Control 
(dots) and rapamycin-treated (triangles) cells were sonicated with and without nanodroplets (n=3). 
(A) The peak base pair (bp) size of each input sample without (Traditional, red, CV = 72%) or with 
(Nanodroplets, purple, CV = 27%) nanodroplets was measured by Agilent TapeStation.  The mean 
peak bp size for each condition is indicated by a horizontal black line.  (B) ChIP-qPCR was 
performed using primers positioned along the reporter gene locus as indicated. (C) Rapamycin 
treated cells were compared to control cells with the traditional and nanodroplet sonication methods 





Supplemental Figure 1. ES cells were gated to select for a healthy, single-cell population. 
The same gating scheme was applied to all samples.  
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Supplemental Figure 2. Nanodroplets decrease sonication times for HEK 293T and mouse 
embryonic stem cells. DNA fragment distribution following sonication of (A) HEK 293T cells and (B) 
mouse embryonic stem cells was determined by agarose gel electrophoresis. These gels are 
representative of three biological replicates. Base pair size of the DNA ladder is indicated to the left 










Supplemental Figures 3-5. Agilent TapeStation data showing DNA fragment size distribution 
for mESCs represented in Figure 2B for each of 3 biological replicates.  Sonication time 
(minutes) is indicated on the left for both Traditional and Nanodroplet methods.  Peak 
fragment size called by the TapeStation software is indicated by a vertical blue line with the 







Supplemental Figures 6-8. Agilent TapeStation data showing DNA fragment size distribution 
for HEK 293T cells represented in Figure 2C for each of 3 biological replicates.  Sonication 
time (minutes) is indicated on the left for both Traditional and Nanodroplet methods.  Peak 
fragment size called by the TapeStation software is indicated by a vertical blue line with the 
base pair value listed above. 
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Supplemental Figure 9. DNA fragment distribution of ChIP input samples for (A) HEK 293T cells 
(n=3 for each condition) and (B) mESCs (n=6 for each sonication condition) was determined by 
agarose gel electrophoresis. Samples treated with rapamycin are indicated. Replicate number and 
sonication time (minutes) is indicated for each condition. Base pair size of the 1 Kilobase DNA ladder 
is indicated to the left of the image. 
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Table S1.  
Primer Name Forward  Reverse 
PGSF1 CTTCAGCACGAGGGACAGCT CTGTCCGGATATTTGGTGCT 
BC006361 TTCTCCAACTTTGGAAGCCCAGGA TGTCTCCTTCTAGGCCCTCACAAT 
-169 CTAGAGGATCCGAGGACCAATTG ACCTTCAAGGTCCTCTCACC 
738 CACATGGTCCTGCTGGAGTT ATCTAGAGTCGCGGCCGG 
1199 GTGATGGGTCAGCAGGGCT TCCGATTCCAGGCCCACCT 
IAP ATTTCGCCTAGGACGTGTCA ACTCCATGTGCTCTGCCTTC 
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Chapter 6: Discussion 
 
Conclusions: 
 Since the 1970’s, the concept of chromatin and DNA having a highly ordered structure has 
been known, with the first microscopic observation of chromatin appearing as “beads on a string”1–3.  
With advancements in technology, the structure of chromatin has become increasingly clear4. Thanks 
to leaders in the field of chromatin biology, the mechanistic consequences of various chromatin are 
beginning to be understood5. Much of the early work on chromatin regulation and gene expression has 
been done by associating observations of the chromatin environment with upstream or downstream 
observations. For example, labs have mutated or deleted a known histone tail writer or erasers and 
then tested for transcriptional changes. One drawback of this approach is that many histone tail writers 
and erasers have non-histone substrates, so the downstream effects could be an indirect effect of a 
non-chromatin based changed. Technology enabling directly recruit endogenous chromatin readers, 
writers, and erasers with temporal precision will allow researchers to investigate (1) how the chromatin 
modifying machinery is directly effecting the chromatin environment and what histone tail modifications 
are increasing or decreasing (2) what other transcriptional or chromatin machinery are being recruited 
as a consequence (3) if there is a change in the transcriptional activity of the gene of interest (4) what 
cell-wide consequences results from the up- or down- regulation of this one gene in its native genomic 
location. 
To create a system capable of redirecting endogenous chromatin regulatory machinery to a 
specific gene, we began combining the fields of chromatin biology, synthetic biology, and synthetic 
chemistry. Chemical Epigenetic Modifiers (CEMs) are able to be recruited in a gene-specific manner 
by incorporating FK506, a small molecule with low nanomolar binding and specificity to a protein 
domain, FKBP6. By fusing FKBP to a DNA binding domain, we are able to target to CEMs to a specific 
gene or subset of genes. The original gene-specific recruitment was achieved using a Gal4-FKBP 
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fusion and inserting a Gal4 binding array in proximity to the transcriptional start site (TSS) of our gene 
of interest7. While this system was found to be very efficient, we sought to make the technology more 
modular and be able to target mammalian genes of interest without the requirement of gene editing (to 
insert the Gal4 array). To accomplish this, we incorporated CRISPR/Cas9 technology. A deactivated 
version of Cas9 (dCas9) is capable of being recruited to virtually any region of the genome to which a 
guide RNA (gRNA) is designed, but will not cut the DNA8.  Using a dCas9-FKBP fusions, among other 
dCas9-related fusions (ms2-FKBP, scFv-FKBP), we demonstrate functionality with our CEMs. 
The other portion of the bifunctional CEM is the component capable of binding specific 
chromatin regulatory machinery. To demonstrate the proof of principle for these novel compounds we 
focused on recruiting machinery related to histone tail acetylation. After synthesizing and testing over 
20 CEMs, we found three activating CEMs (CEMa) and three repressing CEMs (CEMr). The CEMa 
molecules were synthesized with derivatives shown to bind histone acetyl transferases (HAT) and 
lysine acetylation reader proteins (hypothesized to recruit downstream writers or transcriptional 
activators). CEMr molecules were synthesized with derivatives of histone deacetylase (HDAC) 
inhibitors, most of which were hypothesized to recruit Class I HDACs.  
 With these novel CEMs, we demonstrated the ability to control gene expression in a specific, 
dose-responsive, reversible manner. Following our proof-of-principle study, we created a video protocol 
so that other labs could incorporate this new CEMs technology into their own research. We also 
demonstrated the ability to enact changes in the chromatin environment, with our lead CEMr decreasing 
levels of H3K27ac7. In order to efficiently and accurately investigate what CEM-induced changes were 
occurring in the chromatin environment, we also developed an optimized ChIP protocol. This new 
protocol can now be used by anyone in the field interested in studying chromatin. Because we 
completed years of research to invent, thoroughly trouble-shoot, optimize, and characterize the CEMs 
system, there are a lot of directions that this work may now take. The initial platform for investigation 
and control of chromatin regulatory processes is complete, yet changes can still be made including the 
(1) genes-of-interest (2) cellular context of investigation (3) gene-targeting CRISPR machinery (4) 




The CEMr and CEMa systems have evolved into a highly modular platform that can be 
repurposed to target virtually any gene or regulatory element. We have begun working to target genes 
with disease significance. For example, our CEMr set of compounds allows us to target genes that are 
driving human cancer such as oncogenes. We hypothesize that if we target such genes with CEMr, we 
can decrease expression of the gene and induce death in the cancer cells at a greater efficiency than 
non-cancerous cells. We have started by targeting the MYC1 gene in human malingancies. c-Myc is a 
well-studied oncogene that is mutated or overexpressed in most human tumor types. It has been 
implicated in affecting tumor cell DNA replication and transcription, growth, cellular metabolism, stem-
like characteristics, and tumor microenvironment9–11. Furthermore, it has also been suggested that 
MYC1 is, in part, regulated by histone acetylation levels. Bromodomain inhibitors, iBet-762 and JQ1, 
reduced MYC expression and caused an anti-tumor effect in Myc-dependent cancers12,13. This data 
makes MYC1 an ideal target for our targeted CEM-based therapy. By using gRNAs previously 
optimized and tested for MYC114, we will treat MYC-addicted cancer models with CEMr. We 
hypothesize that this will recruit HDACs to the loci, decrease MYC1 expression, and induce cell death 
in a targeted and specific manner. We will begin by optimizing MYC repression in 293T HEK cells, a 
non-disease setting so as to not confound optimization results with induction of cell death. Once we 
have compared the different dCas9-based recruitment systems, and performed time-course and dose-
curve experiments with our set of CEMr, we will begin repressing MYC in disease models of Burkitt’s 
lymphoma (Daudi cells), acute promyelocytic leukemia (HL60 cells), and prostate cancer (LnCaps) 
which are models of cancers with driven by increased c-Myc activity15–17. We will next characterize cell 
death at different doses of CEMr and correspond that with decreasing levels of MYC1 expression. We 
will also investigate the direct downstream effects of CEM-mediated HDAC recruitment on the 
chromatin environment of the MYC locus (including changes in histone marks and recruitment of 
transcriptional/chromatin machinery). We will then test any effects on cell viability and global gene 
expression profiles. If successful, we will begin transferring our studies to mouse models of MYC-driven 
cancers in order to move a step closer to a new therapeutic. 
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Another way that we will improve and continually evolve the CEM platform is by modifying the 
CRISPR-based gene targeting system that we use to anchor epigenetic activity. By expanding our 
CEM-compatible gene-targeting machinery we will be able to explore using different gene delivery 
platforms, as well as regulating multiple genes orthogonally. Adeno-associated virus (AAV) is a gene-
delivery system with many characteristics that make it ideal for use in the clinic, including little to no 
toxicity in small and large animal models and some level of organ-specific targeting18. One drawback 
of this delivery system is that the DNA being delivered needs to be less than 5kb, which can be very 
limiting considering the Streptococcus pyogenes (Sp) dCas9 that has been used for the CEM system 
is 4.2 kb. With the addition of FKBPx2 (642 bp) and the promoter (221 bp), the construct exceeds the 
payload limit. This size limit also prevents the ability to co-express an antibiotic selection (for isolating 
cells that are expressing the Cas9 machinery), the gRNA(s) (which in many cases is several), or the 
ms2- or scFv-fusions for increased CEM recruitment. Recently, a series of domain deletions of 
CRISPR-related proteins were created and tested. A mini-version of the Sp-dCas9 (3.5 kb) was shown 
to be roughly 50% functional, and a mini-version of the Staphylococcus aureus (Sa) dCas9 (2 kb) was 
about 40% functional19. These experiments were done with a VPR activating domain, and it is possible 
that the “mini” dCas9-FKBP maintains close to 100% functionality with CEMs relative to the regular-
sized version. This is something that we are very eager to test, because with a 2 kb version of Cas9 
we could co-express several other recruitment components simultaneously with an AAV delivery 
method. In addition, by incorporating the CEMs system with Sa-dCas9 we will be able to target multiple 
genes orthogonally. An orthogonal system was previously demonstrate using the Sa-dCas9 and Sp-
dCas9 to target and activate one gene, while simultaneously targeting and repressing another gene20. 
With our current system, we would need to control the expression of gRNA (Sa vs Sp-compatible) 
based on the chemical with which we are treating the cell, or we could employ another chemical 
recruitment system (i.e. rapamycin or ABA),21 to recruit different regulatory machinery to different 
genes. For example, we could use the CEMa system to activate one gene, and the ABA system to 
repress a different gene.  
 The bifunctional CEMs can be modified to control a diverse range of cellular proceses. The 
linker between FK506 and the chromatin machinery recruiter is a polyethylene glycol (PEG) linker. In 
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terms of delivery, the size and length of the PEG linker can influence chemical stability and 
permeability22,23. For the specific purposes of the CEMs, the length may play a major role in the steric 
characteristics and influence how well the recruited chromatin modifying machinery is able to exert an 
effect on the chromatin environment of the gene locus of interest. In the future, changing the size and 
composition of the linker will need to be explored in relation to its permeability and CEM-related 
function. For example, CEM23 and CEM42 are both comprised of FK506 and the HDAC inhibitor SAHA, 
yet CEM23, which has a shorter linker is more effective7. We are currently unsure of whether this is 
due to the changes in CEM permeability, or specific to the recruited HDACs and how they are being 
redirected. 
 The endogenous protein recruiter portion of the CEMs (i.e. SAHA derivative, iBet-762 
derivative) can be substituted. Frequently, there are new chemical probes discovered which we could 
design and synthesize a CEM24–27. Our current series of CEMs mainly focuses on proteins that 
recognize and/or regulate histone tail acetylation, but designing CEMs capable of redirecting histone 
methylation or DNA methylation readers, writers, and erasers could greatly benefit and expand the 
scope of what CEM technology can study. Thus, novel CEMs can be used to exert a specific and 
predictable effect on the chromatin environment of a gene-of-interest, or they could be used to study 
the effect that previously uncharacterized proteins have on chromatin.  
 Lastly, the DNA recruiting portion of the CEMs, FK506, can be substituted. For example, the 
recently published dTAG chemical system uses a molecule that binds to a mutated FKBP domain 
(FKBP F36V), but not the endogenous FKBP domain28. By replacing our current FK506 with the portion 
of dTAG that binds FKBP F36V, we can prevent any off-targeting binding that is occurring with our 
current CEMs. If the CEMs are more-specifically being recruited to the dCas9-related FKBP fusions, 
the CEMs may exhibit higher efficiency. In addition, replacing the FK506 with a trimethoprim (TMP) we 
can design CEMs that bind to DHFR, rather than FKBP. A set of CEM function with FKBP fusions and 
a second set functional with DHFR would allow for dual activities in the Sa-dCas9 and Sp-dCas9 
orthogonal systems (i.e. Sa-dCas9-FKBP and Sp-dCas9-DHFR). DHFR is a bacterial specific domain 
that binds TMP. It has also bene shown that a photocage can be added to TMP to prevent TMP-DHFR 
interaction and effectively control recruitment with light29. This would add an extra layer of control to our 
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CEMs system. For example, by exposing an organ or set of tumorigenic cells to light at the specified 
wavelength, we can have time and localization control of the CEM-mediated activity.   
 As we learn more about chromatin dysregulation in clinical settings our need for improved 
technology to ask complex and directed questions increases. The fields of synthetic biology and 
chemical biology have exponentially expanded over the past several decades. We believe the 
technological advances we have made will aid us in our continued investigation of chromatin biology. 
Hopefully, combined with other’s work in this emerging field we can contribute to progression of these 
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